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Background: Cancer patients are at risk of developing multiple primary cancers (MPCs). 
MPCs and non-cancer events compete with first cancers as the cause of death. This thesis 
aims to investigate temporal trends in the risk of MPCs and competing mortality due to 
MPCs and non-cancer events among adult-onset cancer patients in Tasmania.  
Methods: A systematic review of temporal trends in the risk of MPCs was performed. 
Original data were extracted from the population-based Tasmanian Cancer Registry in 
Australia. Patients with a first cancer registered between 1980-2009 were followed for 
incident second cancers to 2013 and for deaths to 2014. For non-cancer mortality, patients 
with a first cancer registered between 2006-2013 were followed up to 2015. MPC risks were 
quantified and trends in MPC risk were assessed in multivariable Poisson models. Mortality 
due to MPCs and non-cancer events were assessed in competing risk models.  
Results: The systematic review indicated an increasing trend in the risk of MPCs from the 
1980s to 2000 in studies from Australia and the USA. In Tasmania, there was an increasing 
trend in the risk of any second cancer from 1980-2013. The competing mortality due to 
MPCs increased from the 1980s to a peak for first cancers diagnosed in 1995-1999. From 
2006-2015, the competing mortality due to cardiovascular events increased significantly with 
age at first cancer diagnosis and exceeded other competing events at age 65 years or older.  
Conclusions: In Tasmania, the risk of MPCs has increased with periods of first cancer 
diagnosis from 1980-2009. The competing mortality due to MPCs increased for first cancers 
diagnosed in the 1990s possibly indicating overdiagnosis of non-fatal first cancers in the 
1990s. Cardiovascular events were the leading cause of competing mortality among 
Abstract 
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Tasmanian patients diagnosed with a first cancer from 2006-2013 suggesting potential 




I would like to express my deepest appreciation to all those individuals who provided me 
with the supports to complete my PhD. First, I would like to thank my loving family, who 
support me not only through this PhD but also through my whole life. In particular, I would 
like to thank my Dad Shiwei Ye and Mom Qinglian Shen, who always encourage me to 
pursue my dreams and give me emotional and financial support throughout my many years as 
a medical and PhD student. I owe all of my achievements to you and the sacrifices you have 
made in my life. I love you with all my heart. 
I am extremely fortunate to have had the opportunity to work with Professor Alison Venn as 
my primary supervisor. Her high standards of supervision and mentoring have significantly 
enriched my research experience as a PhD candidate. She encouraged my own independent 
thinking and provided me with invaluable guidance and encouragement to navigate through 
all the challenges encountered during my PhD. The way of thinking and skills I have learnt 
under her supervision are enormous and will be beneficial throughout my research career. My 
academic writing skill has improved significantly under my co-supervisor Dr Amanda Neil, 
and I am very grateful for her continued patience and guidance. I would also like to express 
my thanks to my co-supervisor Dr Karen Wills, for her fantastic statistical support and 
guidance. 
I would like to express my deepest appreciation to Petr Otahal. Petr is a very smart and 
brilliant statistician who helped me solve the most difficult statistical problem in each of my 
study. I would also like to express my sincere thanks to Dr Raoul Reulen, for his fantastic 
statistical help in the second study of my PhD project. I am also very grateful to Brian Stokes, 
manager of the Tasmanian Cancer Registry (TCR), for his patience and kind help on the data 
Acknowledgements 
XI 
management and interpretation of specific records in the TCR. Many thanks to the past and 
current TCR staff for making my PhD study possible. I am also grateful to the administrative 
staff of the Menzies Institute for Medical Research for their assistance throughout my PhD 
candidature. 
I would like to express special thanks to Dr Saliu Balogun. Saliu is my neighbour in Menzies 
and all the “short chats” with him were very encouraging. I would like to express my 
gratitude to Professor Changhai Ding and other PhD fellows in Menzies for their support and 
friendship, with a special mention to Dr Jing Tian, Dr Feitong Wu, Dr Feng Pan, Dr Yuan 
Zhou, Hoang Phan, Yan Zhang, Xiaoqing Peng, Brooklyn Fraser, Larissa Bartlett and Dean 
Picone. I am also very grateful to the University of Tasmania, the Menzies Institute for 
Medical Research and Anhui Medical University for providing me with the Tasmanian 
Graduate Research Scholarship to study for my PhD. 
Publications Arising from the Thesis 
XII 
Publications Arising from the Thesis 
Chapter 3: Ye Y, Neil AL, Wills KE, Venn AJ. Temporal trends in the risk of developing 
multiple primary cancers: a systematic review. BMC Cancer. 2016;16(1): 849. 
Chapter 4: Ye Y, Otahal P, Wills KE, Neil AL, Venn AJ. Temporal trends in the risk of 
second primary cancers among survivors of adult-onset cancers, 1980 through 2013: An 
Australian population-based study. Cancer. 2018;124(8): 1808-1818. 
Chapter 5: Ye Y, Otahal P, Wills KE, Neil AL, Venn AJ. Temporal trends in competing 
mortality from second and subsequent primary cancers, 1980-2014: An Australian 
population-based study. Cancer Epidemiology. 2018;55: 61-67. 
Chapter 6: Ye Y, Otahal P, Marwick TH., Wills KE, Neil AL, Venn AJ. Cardiovascular and 
other competing causes of death among cancer patients, 2006-2015: An Australian 
population-based study. Cancer. 2018. doi:10.1002/cncr.31806. 
Publication during candidature, but external to thesis material: 
Correspondence: Ye Y, Fonseca R. Overestimation of cardiovascular outcome incidence. 
The Lancet. 2017;390: 2546-2547.
Scientific Presentations Arising from the Thesis 
XIII 
Scientific Presentations Arising from the Thesis 
October, 2018 European Society for Medical Oncology (ESMO) 2018 Congress 
Munich, Germany – 19 Oct - 23 Oct 2018 
“Cardiovascular and other competing causes of death among cancer 
patients, 2006-2015: An Australian population-based study”  
(Poster presentation) 
September, 2017 European Society for Medical Oncology (ESMO) 2017 Congress 
Madrid, Spain – 08 Sep - 12 Sep 2017 
“Risk of second primary cancers and competing mortality in 
survivors of adult-onset cancer: changing pattern over three decades” 
(Poster presentation) 
July, 2017 Haematology/Oncology/Palliative Care Meeting 
Royal Hobart Hospital, Australia – 18 Jul 2017 
“Cause-specific mortality among cancer patients: changing patterns 
over three decades” 
(Oral presentation) 
September, 2016 2016 Australasian Epidemiological Association (AEA) 23rd Annual 
Scientific Meeting, Canberra, Australia – 14 Sep - 16 Sep 2016 
“Changing Trends in the Risk of Second Primary Cancers among 
Survivors of Adult-onset Cancer in Tasmania, 1980-2013: A 
Population-based Study” 
(Oral presentation) 
July, 2016 Haematology/Oncology/Palliative Care Meeting 
Royal Hobart Hospital, Australia – 26 Jul 2016 
Scientific Presentations Arising from the Thesis 
XIV 
“Increasing Trends in the Risk of Second Primary Cancers in 
Tasmania, 1980-2013: A Population-based Study” 
(Oral presentation) 
November, 2015 2015 Clinical Oncology Society of Australia (COSA) 42nd Annual 
Scientific Meeting, Hobart, Australia – 17 Nov - 19 Nov 2015 
“Temporal Trends in the Risk of Developing Multiple Primary 
Cancers: A Systematic Review” 
(Poster presentation) 
November, 2015 2015 5th Australia-China Biomedical Research Conference 
(ACBRC), Hobart Satellite Meeting 
Hobart, Australia – 02 Nov 2015 
“Temporal Trends in the Risk of Developing Multiple Primary 
Cancers: A Systematic Review” 
(Poster presentation) 
September, 2015 Haematology/Oncology/Palliative Care Meeting 
Royal Hobart Hospital, Australia – 29 Sep 2015 
“Temporal Change in the Risk of Developing Multiple Primary 
Cancers” 
(Oral presentation) 
September, 2015 2015 Graduate Research Conference 
Hobart, Australia – 03 Sep - 04 Sep 2015 
“Temporal Trends in the Risk of Developing Multiple Primary 
Cancers: A Systematic Review” 
(Poster presentation) 
 
Awards Resulting from the Thesis 
XV 
Awards Resulting from the Thesis 
October, 2018 European Society for Medical Oncology (ESMO) 2018 Congress 
Merit Award (AUD ≈ $3000) 
September, 2017 European Society for Medical Oncology (ESMO) 2017 Congress 
Travel Award (AUD ≈ $3000) 
September, 2017 University of Tasmania Conference and Research Travel Funding 
(AUD ≈ $1600) 
September, 2016 Australasian Epidemiology Association (AEA) Student Award 
(AUD = $500) 
November, 2015 Best Poster Award- First place   5th Australia-China Biomedical 
Research Conference (ACBRC), Hobart Satellite Meeting 
(AUD = $250) 
September, 2014 Tasmanian Graduate Research Scholarship, 2014 
List of Abbreviations 
XVI 
List of Abbreviations 
ABS Australian Bureau of Statistics  
ACD Australian Cancer Database  
ACR Australian Coordinating Registry  
AER Absolute Excess Risk  
AIHW Australian Institute of Health and Welfare 
AML Acute Myeloid Leukaemia  
ASR Age–Standardised incidence Rates  
BCC Basal Cell Carcinoma 
CHR Hazard Ratio derived from Cox model  
CI Confidence Interval 
CIF Cumulative Incidence Function  
CLL Chronic Lymphocytic Leukaemia 
CML Chronic Myeloid Leukaemia 
COD-URF Cause of Death Unit Record File  
COPD Chronic Obstructive Pulmonary Disease  
CR Competing Risk  
CT Computed Tomography  
CVD Cardiovascular Disease  
HPV Human Papillomavirus 
HR Hazard Ratio 
IACR International Association of Cancer Registries 
List of Abbreviations 
XVII 
IARC International Agency for Research on Cancer 
ICD-10 International Classification of Diseases, Version 10  
ICD-O3 International Classification of Diseases for Oncology, Third Edition  
IQR Interquartile Range 
KM Kaplan-Meier  
MCC Merkel Cell Carcinoma 
MM Multiple Myeloma 
MPC Multiple Primary Cancer 
NHL Non-Hodgkin Lymphoma  
NMSC Non-melanoma Skin Cancer 
PET/CT Positron Emission Tomography - Computed Tomography 
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
PSA Prostate Specific Antigen  
PYR Person-Years at Risk  
RBDM Registry of Births, Deaths and Marriages  
RR Relative Risk 
SCC Squamous Cell Carcinoma 
SEER Surveillance, Epidemiology, and End Results  
SHR Subdistribution Hazard Ratio 
SIR Standardised Incidence Ratio  
SMR Standardised Mortality Ratio  
SPC Second Primary Cancer (Chapter 4)  
Subsequent Primary Cancer (Chapters 5 and 6) 
List of Abbreviations 
XVIII 
STROBE STrengthening the Reporting of OBservational studies in Epidemiology 
TCR Tasmanian Cancer Registry  
USA United States of America 
List of Tables 
XIX 
List of Tables 
Table 3.1: Search strategy for Medline and Embase (1 March 2015) ..................................... 69 
Table 3.2: MPCs following a first primary cancer at any site or a specific site ...................... 79 
Table 4.1: Characteristics of the study population................................................................. 109 
Table 4.2: Number of second primary cancers, by type of first and second cancer .............. 110 
Table 4.3: Temporal trends of standardized incidence ratios (SIRs) for all second primary 
cancers in Tasmania, 1980-2009.................................................................................... 114 
Table 4.4: Multivariable Poisson regression for Ratio of SIRs for all SPCs and specific SPC 
types ............................................................................................................................... 116 
Table 4.5: Standardized incidence ratios (SIRs) for specific first cancer types by calendar 
year of first cancer diagnosis, 1980-2013 ...................................................................... 118 
Table 4.6: Standardized incidence ratios (SIRs) for specific second cancer types by calendar 
year of first cancer diagnosis, 1980-2013. ..................................................................... 119 
Table 4.7: Standardized incidence ratios (SIRs) and absolute excess risks (AERs) for selected 
second cancer types, by first cancer types and periods of first cancer diagnosis, 1980-
1989, 1990-1999 and 2000-2009. .................................................................................. 120 
Table 4.8: Temporal trends of standardized incidence ratios (SIRs) for second discordant 
primary cancers (excluding SPCs occurring in the same site as a first cancer) in 
Tasmania, 1980-2009. .................................................................................................... 124 
Table 5.1: Characteristics of the study population................................................................. 137 
Table 5.2: Cumulative incidence of cause-specific deaths (%) at 5-, 10-, 15- and 20-years 
after first cancer diagnosis, by periods of first cancer diagnosis, with follow-up to 
December 2014 .............................................................................................................. 141 
List of Tables 
XX 
Table 5.3: Kaplan-Meier (KM) estimates and Cumulative Incidence Function (CIF) for 
cumulative incidence of cause-specific deaths by periods of first cancer diagnosis, with 
follow-up to December 2014 ......................................................................................... 143 
Table 5.4: The hazard ratios (HRs) of cause-specific deaths by periods of first cancer 
diagnosis, with adjustment on sex (not for female breast cancer and prostate cancer) and 
age at first cancer diagnosis ........................................................................................... 148 
Table 5.5: The hazard ratios (HRs) of cause-specific deaths by periods of first cancer 
diagnosis, with follow-up restricted to 5 years .............................................................. 150 
Table 6.1: Characteristics of the patients ............................................................................... 166 
Table 6.2: Characteristics of non-cancer deaths among cancer patients during 2006-2015 .. 167 
Table 6.3: Cumulative incidence (%) of death due to non-cancer events, by sex, age at first 
cancer diagnosis and first cancer sites ........................................................................... 171 
Table 6.4: Standardized mortality ratios (SMRs) and absolute excess risks (AERs) for 
specific non-cancer disease by sex, age at first cancer diagnosis, follow-up intervals and 
first cancer sites ............................................................................................................. 176 
Table 6.5: Number of CVD deaths among cancer patients with all first cancer sites combined, 
by age at first cancer diagnosis ...................................................................................... 184 
Table 6.6: Number of respiratory deaths among lung cancer patients .................................. 186 
List of Figures 
XXI 
List of Figures 
Figure 1.1 Trends in age standardised incidence and mortality of all cancers (excluding non-
melanoma skin cancers) in Tasmania (1980-2013) (Source: Reproduced from Cancer in 
Tasmania: Incidence and Mortality 2013. Tasmanian Cancer Registry, 2015) 3 ............ 30 
Figure 1.2 Trends in relative survival by periods of diagnosis for all cancers (excluding non-
melanoma skin cancers) in Tasmania (1984-2008) (Source: Reproduced from Cancer 
survival and prevalence in Tasmania 1978-2008. Tasmanian Cancer Registry, 2012) 8 31 
Figure 1.3 Factors associated with ascertainment of multiple primary cancers ...................... 33 
Figure 1.4 Annual Medicare (Australia’s publicly funded universal health care system) 
outlays on diagnostic imaging in Australia ($ millions) (Source: Reproduced from 
Review of Funding for Diagnostic Imaging Services: Final Report. Medical Benefits 
Reviews Task Group, Diagnostic Imaging Review Team, Department of Health and 
Ageing, Australia 2011) 26 ............................................................................................... 35 
Figure 1.5 Prostate cancer incidence among males in Australia 1982-2009 (ASR was 
standardised to the Australian 2001 population) (Source: Reproduced from Prostate 
cancer in Australia. Australian Institute of Health and Welfare 2013) 52 ........................ 37 
Figure 1.6 Four types of cancer progression (Source: Reproduced from Overdiagnosis in 
cancer. Journal of the National Cancer Institute 2010) 32 ................................................ 38 
Figure 2.1: Example illustrating the calculation of person-years at risk (PYR) ...................... 58 
Figure 3.1: Flow diagram of study selection ........................................................................... 78 
Figure 4.1: Ratio of SIRs for all SPCs and specific SPC types after any first cancer by 
calendar periods of first cancer diagnosis. ..................................................................... 115 
Figure 5.1: Proportion of cause-specific deaths in each calendar year .................................. 136 
Figure 5.2: Cumulative incidence of cause-specific deaths for all cancer types and five 
specific cancer types for the whole study period, 1980-2014 ........................................ 140 
List of Figures 
XXII 
Figure 6.1: Cumulative incidence function curves for deaths due to subsequent primary 
cancers (SPCs) and non-cancer events by sex. .............................................................. 169 
Figure 6.2: Cumulative incidence function curves for deaths due to subsequent primary 
cancers (SPCs) and non-cancer events by age at first cancer diagnosis. ....................... 170 
Figure 6.3: Cumulative incidence function curves for cause-specific deaths. ....................... 173 
Table of Contents 
XXIII 
Table of Contents 
Statement of Originality ......................................................................................................... II 
Statement of Authority of Access and Regarding Published Work ................................. III 
Statement of Co-Authorship ................................................................................................ IV 
Statement of Ethical Conduct ............................................................................................. VII 
Abstract ............................................................................................................................... VIII 
Acknowledgements ................................................................................................................. X 
Publications Arising from the Thesis ................................................................................. XII 
Scientific Presentations Arising from the Thesis ............................................................ XIII 
Awards Resulting from the Thesis ..................................................................................... XV 
List of Abbreviations ......................................................................................................... XVI 
List of Tables ...................................................................................................................... XIX 
List of Figures ..................................................................................................................... XXI 
Table of Contents ............................................................................................................ XXIII 
Chapter 1: Introduction .................................................................................................... 29 
1.1 The rationale for studying multiple primary cancers ............................................... 29 
1.1.1 Increased cancer incidence .................................................................................. 29 
1.1.2 Improved cancer survivorship.............................................................................. 30 
1.2 Definition of multiple primary cancers (MPCs) ...................................................... 32 
1.2.1 History.................................................................................................................. 32 
1.2.2 Current coding rules for MPCs ............................................................................ 32 
1.3 Factors associated with trends in the development of MPCs .................................. 33 
Table of Contents 
XXIV 
1.3.1 Medical investigations ......................................................................................... 34 
1.3.1.1 Medical imaging .......................................................................................... 34 
1.3.1.2 Cancer screening ......................................................................................... 36 
1.3.1.3 Overdiagnosis in cancer .............................................................................. 37 
1.3.2 Cancer treatment .................................................................................................. 39 
1.3.3 Lifestyle or environmental factors ....................................................................... 40 
1.4 Mortality from MPCs and the presence of competing risks .................................... 41 
1.5 Non-cancer events as a competing cause of death ................................................... 42 
1.6 Summary .................................................................................................................. 43 
1.7 Research aims .......................................................................................................... 44 
1.8 References ................................................................................................................ 45 
Chapter 2: Methods ........................................................................................................... 55 
2.1 Data sources ............................................................................................................. 55 
2.1.1 Tasmanian Cancer Registry (TCR) ...................................................................... 55 
2.1.2 Cause of Death Unit Record File (COD-URF) .................................................... 57 
2.2 MPC incidence risk .................................................................................................. 58 
2.2.1 Person-years at risk (PYR)................................................................................... 58 
2.2.2 Outcome measures ............................................................................................... 59 
2.2.2.1 Standardised incidence ratio (SIR) .............................................................. 59 
2.2.2.2 Absolute excess risk (AER) .......................................................................... 60 
2.3 MPC mortality risk .................................................................................................. 60 
2.3.1 Competing risk analysis ....................................................................................... 60 
2.3.2 Outcome measures ............................................................................................... 61 
2.4 Non-cancer mortality among cancer patients .......................................................... 61 
2.5 Statistical analysis .................................................................................................... 62 
Table of Contents 
XXV 
2.6 References ................................................................................................................ 63 
Chapter 3: Temporal trends in the risk of developing multiple primary cancers: A 
systematic review ................................................................................................................... 64 
3.1 Abstract .................................................................................................................... 64 
3.2 Introduction .............................................................................................................. 66 
3.3 Methods.................................................................................................................... 67 
3.3.1 Scope of the review .............................................................................................. 67 
3.3.2 Search strategy and selection criteria ................................................................... 67 
3.3.3 Data extraction and analysis ................................................................................ 71 
3.4 Results ...................................................................................................................... 72 
3.4.1 Literature search................................................................................................... 72 
3.4.2 Study characteristics ............................................................................................ 72 
3.4.3 Study quality ........................................................................................................ 73 
3.4.4 Risk of MPCs following first primary cancer with all sites combined ................ 73 
3.4.5 Risk of MPCs following first primary cancers at specific sites ........................... 74 
3.4.5.1 MPCs following leukaemia, lymphoma and myeloma ................................. 74 
3.4.5.2 MPCs following breast and ovarian cancer ................................................ 75 
3.4.5.3 MPCs following thyroid cancer ................................................................... 76 
3.4.5.4 MPCs following prostate cancer ................................................................. 76 
3.4.5.5 MPCs following first cancers at other sites ................................................. 76 
3.5 Discussion ................................................................................................................ 90 
3.5.1 Increased detection............................................................................................... 90 
3.5.2 Increased radiation exposure during the follow-up after a first cancer diagnosis 91 
3.5.3 Changed cancer treatments .................................................................................. 92 
3.5.4 Other factors to be considered ............................................................................. 93 
Table of Contents 
XXVI 
3.5.5 Limitations ........................................................................................................... 93 
3.5.6 Conclusion ........................................................................................................... 94 
3.6 References ................................................................................................................ 96 
Chapter 4: Temporal trends in the risk of second primary cancers among survivors 
of adult-onset cancers, 1980-2013: An Australian population-based study ................... 102 
4.1 Abstract .................................................................................................................. 102 
4.2 Introduction ............................................................................................................ 104 
4.3 Methods.................................................................................................................. 105 
4.3.1 Study population ................................................................................................ 105 
4.3.2 Ascertainment of SPCs ...................................................................................... 105 
4.3.3 Statistical analysis .............................................................................................. 106 
4.3.3.1 Comparisons with the general population ................................................. 106 
4.3.3.2 Internal comparisons within the study cohort ........................................... 107 
4.4 Results .................................................................................................................... 108 
4.4.1 Characteristics of the study population .............................................................. 108 
4.4.2 SPCs at any site .................................................................................................. 111 
4.4.3 SPCs at specific sites ......................................................................................... 112 
4.5 Discussion .............................................................................................................. 121 
4.6 References .............................................................................................................. 126 
Chapter 5: Temporal trends in competing mortality from second and subsequent 
primary cancers, 1980-2014: An Australian population-based study............................. 129 
5.1 Abstract .................................................................................................................. 129 
5.2 Introduction ............................................................................................................ 131 
5.3 Methods.................................................................................................................. 132 
Table of Contents 
XXVII 
5.3.1 Study population ................................................................................................ 132 
5.3.2 Ascertainment of SPC and deaths ...................................................................... 132 
5.3.3 Measures of Outcomes ....................................................................................... 133 
5.3.4 Statistical analysis .............................................................................................. 133 
5.3.4.1 Cumulative incidence of cause-specific deaths.......................................... 133 
5.3.4.2 Mortality risk ............................................................................................. 134 
5.4 Results .................................................................................................................... 135 
5.4.1 Cumulative incidence of cause-specific deaths ................................................. 138 
5.4.2 Mortality risk ..................................................................................................... 146 
5.5 Discussion .............................................................................................................. 152 
5.6 References .............................................................................................................. 156 
Chapter 6: Cardiovascular and other competing causes of death among cancer 
patients, 2006-2015: An Australian population-based study ........................................... 159 
6.1 Abstract .................................................................................................................. 159 
6.2 Introduction ............................................................................................................ 161 
6.3 Methods.................................................................................................................. 162 
6.3.1 Study population ................................................................................................ 162 
6.3.2 Ascertainment of cause of death ........................................................................ 162 
6.3.3 Statistical analysis .............................................................................................. 163 
6.3.3.1 Internal comparison within the cohort ...................................................... 163 
6.3.3.2 Comparison with the general population .................................................. 164 
6.4 Results .................................................................................................................... 164 
6.4.1 Cumulative incidence of cause-specific deaths ................................................. 168 
6.4.2 SMRs and AERs for non-cancer events............................................................. 174 
6.5 Discussion .............................................................................................................. 180 
Table of Contents 
XXVIII 
6.6 References .............................................................................................................. 187 
Chapter 7: Discussion...................................................................................................... 190 
7.1 Background ............................................................................................................ 190 
7.2 Summary of findings.............................................................................................. 191 
7.3 Implications of Research........................................................................................ 192 
7.4 Limitations in current studies................................................................................. 194 
7.5 Future directions .................................................................................................... 195 
7.6 Conclusion ............................................................................................................. 197 
7.7 References .............................................................................................................. 198 
Chapter 1: Introduction  
29 
Chapter 1: Introduction 
This chapter aims to provide an overall background to the studies presented in this thesis. The 
introduction starts with the rationale for studying multiple primary cancers and the definition 
of multiple primary cancers. A particular emphasis will be placed on the factors associated 
with temporal change in the risk of developing multiple primary cancers. Mortality from 
multiple primary cancers and non-cancer events among adult-onset cancer patients in the 
presence of competing risks will be introduced.  
1.1 The rationale for studying multiple primary cancers 
1.1.1 Increased cancer incidence 
The number of new cancer cases has continued to increase worldwide 1. In Australia, the 
age–standardised incidence rates (ASR) (standardised to the Australian 2001 population) for 
all cancer types (excluding non-melanoma skin cancers) increased from 472 per 100,000 for 
males and 328 per 100,000 for females in 1982 to 562 per 100,000 for males and 416 per 
100,000 for females in 2013 2.  Cancer incidence in Tasmania (an island state of Australia) 
has a similar pattern to the national statistics. The ASR (standardised to the Australian 2001 
population) for all cancer types (excluding non-melanoma skin cancers) increased from 425 
per 100,000 for males and 316 per 100,000 for females in 1982 to 556 per 100,000 for males 
and 456 per 100,000 for females in 2013 (Figure 1.1) 3. The cancer types that contributed 
most to the increase in cancer incidence in Tasmania during the 31-year period were prostate 
cancer and malignant melanoma for males and malignant melanoma, breast cancer and lung 
cancer for females 3. The aging population, advances in diagnostic techniques and sensitive 
screening contributed to this growing number of new cancer diagnoses 2, 4.  
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Figure 1.1 Trends in age standardised incidence and mortality of all cancers (excluding 
non-melanoma skin cancers) in Tasmania (1980-2013) (Source: Reproduced from 
Cancer in Tasmania: Incidence and Mortality 2013. Tasmanian Cancer Registry, 2015) 
3
1.1.2 Improved cancer survivorship 
The past 30 years have seen gradual improvements in the prognosis of individuals with 
various malignant cancers in most developed countries 5-7. In Australia, the 5-year relative 
survival for all cancers combined (excluding non-melanoma skin cancers) rose from 48% in 
1984-1988 to 68% in 2009-2013 7. Relative survival is a standard approach for estimating 
population-based cancer survival which compares the survival probability for a given amount 
of time after cancer diagnosis with that expected in the general population of the same age 
and sex and at the same time 2, 7. In Tasmania, the 5-year relative survival for all cancers 
combined (excluding non-melanoma skin cancers) increased from 42% in 1984-1988 to 64% 
in 2004-2008 (Figure 1.2) 8. These improvements can be attributed to advances in early 
diagnosis, developments in treatment techniques and regimens, optimised supportive care and 
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the introduction of sensitive screening for specific cancer types in Australia since the 1990s 
and potential overdiagnosis of cancer 2, 7, 9.  
Figure 1.2 Trends in relative survival by periods of diagnosis for all cancers (excluding 
non-melanoma skin cancers) in Tasmania (1984-2008) (Source: Reproduced from 
Cancer survival and prevalence in Tasmania 1978-2008. Tasmanian Cancer Registry, 
2012) 8 
 
Increased cancer incidence and improved cancer survival have made cancer the leading cause 
of disease burden in Australia since 2003 10. In 2012, nearly one million Australians, were 
living with a history of cancer since 1982 2, 4.3% of all Australians in 2012.  People with a 
history of cancer are growing older as they survive longer,  and represent a large population 
potentially susceptible to the development of second or subsequent (i.e. multiple) primary 
cancers 11-14.  
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1.2 Definition of multiple primary cancers (MPCs) 
1.2.1 History  
In 1889, Billroth reported a patient who developed a primary gastric carcinoma after the 
removal of a spinocellular epithelioma of the right ear 15. This is the first clear report of a 
case of MPC. This report validated that a patient could develop two independent cancers 
almost at the same time 16. The criteria applied in the definition of MPCs were not established 
until 1932 when Warren and Gates were able to review 1,259 MPC cases from the world’s 
literature 17. MPCs were defined by the following criteria: (1) each tumour must present a 
definite picture of malignancy; (2) each tumour must be distinct; (3) the probability that one 
lesion is metastatic from the other must be excluded 16.  
1.2.2 Current coding rules for MPCs 
The Surveillance, Epidemiology, and End Results (SEER) Program first published MPC rules 
in 1975 and revised the rules in 2007 18, 19. SEER coding rules were applied in the United 
States and the majority of Canadian provinces. To make consistent comparisons across 
various countries and registries, the World Health Organization’s International Agency for 
Research on Cancer (IARC) and the International Association of Cancer Registries (IACR) 
developed International Rules for Multiple Primary Cancers (International Classification of 
Diseases for Oncology, Third Edition) in 2004 20. IARC coding rules for MPCs were applied 
in most parts of the world including Australia, and have been used in this thesis. According to 
IARC rules, two or more primary cancers occurring in an individual that originate in a 
primary site or tissue and that are neither an extension, nor a recurrence, nor metastasis were 
classified as MPCs.  IARC rules state that a person can have only one cancer per organ or 
pair of organs or tissue except when multiple cancers within an organ have different 
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morphology. In general, IACR rules are more restricted than SEER rules in allowing the 
registration of MPCs, particularly for cancers that occur in paired organs, at the same 
anatomic site and with the same histologic type. Overall, IACR rules result in fewer MPCs 
being registered than SEER rules 21.  
1.3 Factors associated with trends in the development of MPCs 
The research community has made great efforts in elucidating factors associated with the 
development of MPCs (Figure 1.3). In summary, first and subsequent primary cancers may 
share the same genetic susceptibility, environmental exposure or lifestyle factors 12.  
Increased medical surveillance such as increased screening programs and the use of medical 
imaging technologies after the diagnosis of a first cancer may increase the possibility of 
detecting new primary cancers among cancer survivors. Treatment for the first cancer could 
also induce treatment-related MPCs as has been found for radiotherapy, chemotherapy and/or 
hormonal therapy 22-24. 
 
Figure 1.3 Factors associated with ascertainment of multiple primary cancers 
 
For most MPC patients, it is likely that a combination of several risk factors result in the 
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there is an interaction with another factor (e.g. a gene – environment interaction) may 
temporal trends in the development of MPCs arise 12, 22-23. Therefore, factors associated with 
trends in the development of MPCs are described by changes in medical investigations, 
treatment regimens for cancer and lifestyle, environmental factors in the next section. 
1.3.1 Medical investigations 
1.3.1.1 Medical imaging 
The use of medical imaging procedures has increased dramatically worldwide since the 1980s 
25. In the United States, the number of radiologic and nuclear medicine procedures has 
increased about 10-fold and 2.5-fold respectively from 1980 to 2006 25, 26. In Australia, the 
outlays for diagnostic imaging provided by the government rose from $255 million in 
1984/85 to $2,150 million in 2009/10 (Figure 1.4) 27. Diagnostic radiology contributed most 
to the cost of diagnostic imaging services in recent years. Cancer survivors usually receive 
more frequent radiologic imaging than the general population due to post-treatment 
surveillance 28-30. More frequent radiologic imaging tests is also associated with a higher 
probability of incidental findings. A systematic review of 44 articles published until 
December 2007 identified a mean frequency of 31.1% incidental findings from computed 
tomography (CT) scans 31. Cancers ascertained from incidental findings are sometimes 
referred to as ‘incidentalomas’ and may be of minor clinical significance 32. Therefore, cancer 
survivors may have a higher chance of being detected with a new cancer than the general 
population due to more frequent medical imaging 33.  
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Figure 1.4 Annual Medicare (Australia’s publicly funded universal health care system) 
outlays on diagnostic imaging in Australia ($ millions) (Source: Reproduced from 
Review of Funding for Diagnostic Imaging Services: Final Report. Medical Benefits 
Reviews Task Group, Diagnostic Imaging Review Team, Department of Health and 
Ageing, Australia 2011) 26 
 
 
The growing application of radiologic imaging such as CT scanning could also be a source of 
increased radiation exposure to cancer survivors. The association between ionizing radiation 
exposure and cancer risk was well documented in studies of cancer incidence among 
Japanese atomic bomb survivors 34, 35. Since the introduction of CT scanning in the 1970s, the 
application of medical imaging procedures has become the largest man-made source of 
ionizing radiation 26, 36. Evidence from epidemiological studies has linked the risk of cancer 
with common diagnostic imaging procedures such as CT examinations 37-43. This evidence 
includes two large retrospective studies which quantified “lifetime attributable risk” (LAR) 
subsequent to cardiac CT scanning. The LAR is defined as additional cancer risk above and 
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years to 1 in 270 for women at age 40 years, and 1 in 600 for men at age 40 years to 1 in 
3261 for men at age 80 years 38, 41. In addition, a large cohort study of over 31,000 patients 
who underwent 190,712 CT scans over 22 years found that the increased cumulative CT 
radiation exposure due to recurrent CT scans increased baseline cancer risk 44. As cancer 
survivors usually undergo frequent CT imaging during follow-up, their risk of developing 
MPCs may also increase as a consequence 45.  
1.3.1.2 Cancer screening   
Cancer screening programs were established in most developed countries around the 1990s, 
although non-programmatic screening would have been available earlier. In the United 
States, the application of cancer screening for cervical cancer, breast cancer, colorectal cancer 
and prostate cancer has increased since 1987 46, 47. In the European Union, screening practice 
for cancer varied across countries and the starting time ranged from the 1970s for Finland to 
the 2000s, with most commencing in the 1980s  48, 49. In Australia, national cancer screening 
programs for breast and cervical cancer were implemented in 1991 and bowel cancer 
screening started in 2006 2. Non-programmatic screening for prostate cancer through prostate 
specific antigen (PSA) testing began to be subsidised by Medicare (Australia’s publicly 
funded universal health care system) in 1989. This was associated with a sharp increase of 
prostate cancer incidence in the early 1990s (Figure 1.5), with an overall 144% increase in 
prostate cancer incidence between 1982 to 2009 50 .  
A meta-analysis of 20 studies published until 2010 found that cancer survivors undertook 
27% more frequent cancer screening tests  for breast, cervical, colorectal and prostate cancers 
than individuals without cancer 51. Therefore, the chance of detecting MPCs may be higher 
since the 1990s, the screening era, than previously. 
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Figure 1.5 Prostate cancer incidence among males in Australia 1982-2009 (ASR was 
standardised to the Australian 2001 population) (Source: Reproduced from Prostate 
cancer in Australia. Australian Institute of Health and Welfare 2013) 52 
 
1.3.1.3 Overdiagnosis in cancer 
Increased medical investigation contributes to the increased ascertainment of new primary 
cancers and cancer survivors generally experience more radiologic imaging and/or screening 
procedures than the general population 28-30, 51. However, despite benefits from early 
detection of cancer, increased application of imaging techniques or screening for specific 
cancer types presents potential adverse effects through the detection of more ‘indolent 
cancers’. ‘Indolent cancers’ are cancers that achieve the pathological criteria for cancer but 
do not cause symptoms or death. Diagnosis of these cancers is considered as overdiagnosis 32.  
Welch and Black described four types of cancer progression as illustrated in Figure 1.6 32. 
The arrows labelled ‘Fast’ and ‘Slow’ represent fast-growing and slow-growing cancers. 
Cancers of these two types will cause symptoms or death before the person dies of other 
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causes. The arrows labelled ‘Very Slow’ and ‘Non-progressive’ represent cancers that grow 
very slowly or never progress during the person’s lifetime respectively. These cancers will 
not cause symptoms or death before the patient dies of other causes. Overdiagnosis usually 
occurs through the detection of ‘Very slow’ and ‘Non-progressive’ cancer types.  
Figure 1.6 Four types of cancer progression (Source: Reproduced from Overdiagnosis 
in cancer. Journal of the National Cancer Institute 2010) 32 
  
Screening for breast cancer and increased use of PSA testing appears to identify cancer types 
that were potentially overdiagnosed in Australia, as well as in other developed countries 50, 52-
55. Screening for lung cancer may also follow this pattern 56, 57. A recent meta-analysis 
combining 20 studies observed 27% more frequent screening practices among cancer 
survivors than in the general population 51. In addition, a Korean study of 512 cancer 
survivors  found that these cancer survivors proactively pursued screening for potential MPCs 
if their first cancers were screen-detected 58. As a result, overdiagnosis may more likely occur 
in cancer survivors than the general population. 
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1.3.2 Cancer treatment 
Innovation in the development of therapeutic drugs for cancer and progress in combined 
cancer therapy regimens have successfully prolonged the survival time after first cancer 
diagnosis 59-61. However, the potential risk of developing treatment-related MPCs has raised 
concerns in relation to the use of aggressive treatment regimens 24. Numerous studies have 
illustrated and quantified the risk of treatment-related cancers following radiotherapy or 
chemotherapy 62-68.  
The awareness of the risk of MPCs following radiotherapy came from the association 
between ionizing radiation and cancer risks 69, 70. Different organs have different 
susceptibility to radiation. Solid cancers that are easily induced by radiotherapy include 
second cancers of lung cancer, female breast cancer, head and neck cancer and male 
oesophageal cancers 64, 71-73. Haematological malignancies such as acute myeloid leukaemia 
(AML) could also be triggered by radiotherapy for cancer 66, 68, 74. 
For radiotherapy-related MPCs, two meta-analyses reported a 22% higher risk of MPCs 
following radiotherapy for breast cancer and 67%-79% higher risk of MPCs following 
radiotherapy for prostate cancer 75, 76. A large cohort study of 647,672 cancer patients 
collected from the United States cancer registries reported that the relative risks for 
radiotherapy-related MPCs ranged from 1.08 (95%CI 0.79-1.46) following first cancer of the 
eye and orbit to 1.43 (95%CI 1.13-1.84) following testicular cancer 63.  
Innovations in radiotherapy techniques have changed clinical practice and advanced imaging 
helps to target tumour issues more accurately 77, 78. However, some modern techniques such 
as intensity-modulated radiation therapy may enhance the risk of radiation-induced second 
cancers and the risks vary with technique used 78-82.  It is worthy of note that although the risk 
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of MPCs increases after radiotherapy for cancer, the proportion of second cancers that could 
be attributable to radiotherapy in adults appears to be relatively small 63. The large United 
States cohort study of 647,672 cancer patients estimated that for all MPCs developed in 
patients with radiotherapy, only 8% of them could be considered as radiotherapy-related 63. 
Some chemotherapy drugs such as alkylating agents could induce chemotherapy-related 
AML 23, 67, 83. As chemotherapy regimens evolved during the past decades, the risk of MPCs 
that could be attributable to chemotherapy may have changed over time. Evidence from a 
large-scale cohort study of 426,068 patients who initially received chemotherapy showed 
various trends in the risk of chemotherapy-related AML over time, and the trends were 
generally consistent with changes in treatment regimens for different cancer types 62. It is also 
noted that the occurrence of chemotherapy-related MPCs is rare and data from this study 
reported only 801 chemotherapy-related AML cases among 426,068 patients (less than 
0.2%).  
1.3.3 Lifestyle or environmental factors 
First and subsequent primary cancers may share the same environmental or lifestyle factors. 
The association between the development of MPCs and smoking or alcohol intake have been 
well documented 84-91. The prevalence of smoking in Australian adults has continued to 
decrease from 1980 to 2013 92. Alcohol consumption in the general Australian population has 
presented a decreasing trend since 1991 also 93. Changing trends in cigarette smoking and 
alcohol intake may result in corresponding changes in the risk of smoking-related MPCs and 
alcohol-related MPCs over time 89, 90, 94.  
A shift in the pattern of oncogenic environmental factors may also contribute to temporal 
changes in the risk of developing MPCs. For example, the aetiology of head and neck cancer 
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has altered from being primarily smoking and alcohol-associated to primarily Human 
Papillomavirus (HPV)-associated in the United States and in European countries during the 
past two decades 95-97. Temporal trends in the risk of developing smoking and alcohol-related 
MPCs and HPV-related MPCs may be impacted as a result 94, 98. 
As the factors associated with MPC development have changed over time, whether the risk of 
MPCs has also changed as a consequence remains unknown. A systematic review of temporal 
trends in the risk of developing MPCs worldwide will be presented in Chapter 3. Temporal 
trends in the risk of second primary cancers among Tasmanian cancer patients during 1980-
2013 will be described in Chapter 4. 
1.4 Mortality from MPCs and the presence of competing risks 
For patients with MPCs, the occurrence of MPCs will compete with their first cancer and 
potential non-cancer events (e.g. cardiovascular events) as the primary cause of death. 
Traditional methods such as Kaplan-Meier (KM) survival analysis and Cox regression 
models consider the time from the diagnosis of first cancer to the primary outcome of 
interest. These methods have been appropriately applied in estimating overall survival and 
all-cause mortality for patients with MPCs 99-103. However, they usually overestimate the 
mortality risk due to a specific cause (e.g. death due to a MPC) because they fail to account 
for the presence of competing risks 104-110. Competing risk settings are present when the 
occurrence of an event (e.g. death due to a cardiovascular event) precludes the occurrence of 
the primary outcome (death due to MPC) 106. For KM analyses, when a specific cause of 
death is the primary outcome of interest, patients who died of other causes were considered as 
‘censored’ events. The KM method assumes that ‘censored’ patients have the same prognosis 
as patients who are still alive at the end of the study. Obviously, this assumption is not valid 
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because patients who died of other causes have a probability of zero to reach the primary 
outcome of interest. In competing risk settings, patients who experience a competing event 
(e.g. die of a cardiovascular event) are not censored and will not reach the primary outcome 
of interest anymore. Competing risk approach estimates “real world” probabilities of cause-
specific deaths. A more detailed illustration of the difference between KM settings and 
competing risk settings will be described in Chapter 2. 
Despite these benefits, competing risk analyses have not been frequently used by researchers. 
This may be due to limitations of the major statistical software, in that they may require 
several days to run the competing risk models  in Stata for a large cohort study 111. In 2016, 
Circulation and Journal of the National Cancer Institute published statistical tutorials to 
introduce competing risk models for survival analyses 106, 112. The competing risk models run 
more efficiently using the R package ‘cmprsk’ released in February 2015 113. A recent study 
has applied competing risk analysis to estimate cause-specific mortality among individuals 
with diabetes 114. However, studies of MPC mortality among cancer patients in the presence 
of competing risks are limited. The first population-based study describing temporal trends in 
MPC mortality since 1980 among adult-onset cancer patients considering the presence of 
competing risks will be presented in Chapter 5 of the thesis.      
1.5 Non-cancer events as a competing cause of death 
An important competing cause of death among cancer patients is death from a non-cancer 
event. Some cancer treatments may increase the chance of developing treatment-related non-
cancer events such as radiation-associated or chemotherapy-related cardiovascular events 115, 
116. Cancer survivors may also experience multiple chronic diseases with aging and longer 
survival. Evidence from Sweden and the United States has shown that, over time, patients 
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with prostate cancer have become less likely to die from their primary cancer and more likely 
to die from non-cancer events (e.g. death due to cardiovascular events) 117. This study 
analysed cause of death among 210,112 men diagnosed with prostate cancer registered in the 
national Swedish Cancer Registry during 1961-2008 and 490,341 men diagnosed with 
prostate cancer registered in the United States registries during 1973-2008. Increased 
mortality due to non-cancer events has also been found for advanced cancer types other than 
prostate cancer. For example, non-cancer events were the leading cause of competing 
mortality among Korean patients with advanced head and neck cancer treated at one tertiary 
referral hospital between 2001-2010 118. Of the non-cancer events, increased risk of 
cardiovascular death among cancer patients has led to growing concern in the clinical and 
research communities 119-121. In part this is due to some life-threatening cardiovascular events 
being induced by cancer treatment such as chest radiation or conventional chemotherapeutic 
drugs (e.g. cytotoxic agents and anthracyclines) 122, 123. Cancer diagnosis and treatment may 
also aggravate underlying cardiovascular disease among cancer patients 124. In this era of 
personalized cancer therapy, better understanding of how non-cancer events, especially how 
cardiovascular events contribute to death among cancer patients is important to the 
stratification of individualized treatments. 
1.6 Summary 
The use of medical imaging and cancer screening tests has increased worldwide during recent 
decades. Cancer patients tend to receive more frequent investigations than the general 
population due to follow-up care after primary diagnosis. Treatment protocols and therapeutic 
agents for cancer have evolved and some environmental and lifestyle factors associated with 
cancer development have changed over the past decades. The risk of MPCs may have 
changed over time due to these changing factors. Therefore, a systematic review was 
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undertaken to determine if there has been a temporal change in the risk of developing MPCs 
worldwide. Based on findings from the systematic review, we used original data from the 
Tasmanian Cancer Registry (TCR), a population-based registry covering the entire state of 
Tasmania, Australia, to explore temporal trends in the risk of second primary cancers among 
Tasmanian cancer patients during 1980-2013.  
The aging population, successful treatment of first cancers and advanced imaging increase 
the chance of detecting MPCs. The numbers of patients with MPCs may increase 
consequently. Cancer patients may also experience devastating non-cancer events related to 
their cancer treatment (e.g. chemotherapy–related cardiac dysfunction) or as a result of a 
deterioration of pre-existing non-cancer disease. The occurrence of MPCs and non-cancer 
events compete with the first cancer as the cause of death among cancer patients. Traditional 
studies frequently used Kaplan-Meier analysis and Cox regression models for cause-specific 
mortality analysis which failed to consider the presence of competing risks. We performed 
competing risk analysis to assess the competing mortality from MPCs and non-cancer events 
among Tasmanian cancer patients. The detailed research aims are outlined below. 
1.7 Research aims 
1. To conduct a systematic review of the scientific literature to determine whether the 
risk of MPCs has increased over recent decades (Chapter 3).   
2. To investigate trends in the risk of second primary cancer among adult cancer 
survivors in Tasmania during 1980-2013 (Chapter 4). 
3. To assess subsequent primary cancer mortality among Tasmanian adult-onset cancer 
patients in competing risk models and to investigate their patterns since 1980 (Chapter 
5). 
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4. To assess the risk of non-cancer deaths among Tasmanian cancer patients in 
competing risk models during 2006-2015 (Chapter 6). 
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Chapter 2: Methods  
Except for the systematic review presented in Chapter 3, Chapters 4, 5 and 6 conducted 
analyses using data from the Tasmanian Cancer Registry (TCR). This Methods chapter 
provides an overview of the data handling, collection and coding practices used by the TCR 
and linked cause of death information held in the Cause of Death Unit Record File (COD-
URF). Descriptions of statistical analyses performed for each study are presented in the 
corresponding chapters. This section presents additional details relevant to the statistical 
analyses.  
2.1 Data sources 
2.1.1 Tasmanian Cancer Registry (TCR) 
The TCR was established in 1977 as a population-based registry covering all of Tasmania, an 
island state of Australia. The TCR is responsible for collecting and collating all malignant 
neoplasms in Tasmanian residents, reporting accurate cancer incidence and mortality 
statistics to the State Government and for reporting cancer incidence and mortality trends. 
The TCR also contributes data to the Australian Cancer Database (ACD) on an annual basis 
in support of national cancer reporting. The ACD is managed by the Australian Institute of 
Health and Welfare. Cancer was declared a notifiable disease in Tasmania in December 1992, 
and has had a legislative basis since this time. TCR records are not considered to be complete 
for the years 1977-1979 during the establishment of the Registry, therefore these years were 
excluded from analyses in this thesis. Cancer incidence remained stable after cancer was 
declared a notifiable disease suggesting there was already high ascertainment prior to 1992. 
All pathology laboratories in Tasmania, both public and private, provide the TCR with copies 
of histopathological and cytology reports of cancer and cell marker reports in electronic form 
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on no less than a weekly basis. Private and public hospitals in Tasmania provide the TCR 
with International Classification of Diseases, Version 10 (ICD-10) coded episodes in 
electronic form for inpatients treated for cancer on either a monthly or an annual basis. Paper-
based reports are received where there is no capacity to obtain electronic notifications of 
cancer, and are typically received from interstate hospitals, other Australian cancer registries 
and pathology laboratories on an ad-hoc basis. (See figure below). 
TCR Secure Server






Births, Deaths & 
Marriages





Non-melanoma Skin Cancers (NMSCs) are non-reportable by law in Tasmania, but are 
received electronically by the TCR on a regular basis. They are not routinely registered due to 
funding limitations and are excluded in the data reported within this thesis. The topography 
(primary site) and morphology of cancer cases were coded by TCR clinical coders according 
to International Classification of Disease for Oncology, Third Edition (ICD-O3). 
Ascertainment of MPCs followed the International Rules for Multiple Primary Cancers (ICD-
O Third Edition) proposed by the International Association of Cancer Registries (IACR) and 
the International Agency for Research on Cancer (IARC). 
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All deaths in Tasmania, for which a coronial inquiry is not required, must be certified as to 
cause and date of death by a registered medical practitioner with the certificate in turn 
registered by the Registry of Births, Deaths and Marriages (RBDM). Details of all registered 
deaths in Tasmania are forwarded to the Australian Bureau of Statistics (ABS) by the RBDM 
Tasmania, who in turn check and code each death according to ICD-10. The TCR similarly 
receives registrations of all deaths in the population from the RBDM monthly in electronic 
format and code cancer related deaths in ICD-O3 using the TCR cause of death coding 
guidelines. Each death recorded in the TCR dataset included up to five causes of death, up to 
eight antecedent causes of death and up to two other significant conditions noted at time of 
death. Deaths coded to ICD-O3 are subsequently converted to ICD-10; causes of deaths that 
were considered not related to cancer were coded using a uniform code of ‘9999’.  
2.1.2 Cause of Death Unit Record File (COD-URF) 
The Cause of Death Unit Record File (COD-URF) is a dataset covering all deaths and the 
causes of deaths registered in Australia since 2006. It is managed by the Australian 
Coordinating Registry (ACR), who receive this data from the ABS. Under a contractual 
agreement, the ACR provides the COD-URF to the Tasmanian Data Linkage Unit. TCR 
records of deceased individuals with a first cancer registered during 2006-2013, and followed 
up to December 2015, were linked by the TDLU with the nationally coded COD-URF for 
Tasmania. Through the process of data linkage with the nationally coded COD-URF, we are 
able to gain a better understanding of competing mortality from specific non-cancer events 
among cancer patients. Where variations were identified in the TCR coded cause of death, 
and that recorded in the COD-URF, individual medical records were accessed to obtain 
further information to more accurately identify if death was cancer related. 
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2.2 MPC incidence risk 
2.2.1 Person-years at risk (PYR) 
We used a standard person-years approach to conduct the analysis 1, 2. Person-years at risk 
(PYR) started 2 months after a first cancer diagnosis and ended at the date of the second 
cancer diagnosis, the date of death, or the end of follow-up, whichever came first. Most 
cancer registries use a 2-month rule to define the development of a MPC because for MPCs 
occurring within 2 months, it is difficult to determine which one was the first cancer. Below 
is an example of the calculation of PYR in our study cohort (Figure 2.1).  
Figure 2.1: Example illustrating the calculation of person-years at risk (PYR) 
 
 
The first patient had a first cancer diagnosis in late 2008 and PYR started at the beginning of 
2009 (2 months after a first cancer diagnosis). The first patient was still alive at the end of 
2013. The PYR for the first patient is 5 years. The PYR for the second patient started at the 
beginning of 2009 and the patient died in the middle of 2013 and had PYR for 4.5 years. The 
PYR for the third patient started in the middle of 2009 and the patient developed a second 
primary cancer in the middle of 2011. The PYR for the third patient is 2.0 years. Similar 
calculations were applied for the fourth and fifth patients. Therefore, we had the PYR for 
P Y R  f o r  c o h o r t  p a t i e n t s  i n  e a c h  c a l e n d a r  y e a r 
PY
R for each patient 
Chapter 2: Methods 
59 
each patient at each row. If we look at the column, the PYR could also be accumulated within 
1-year calendar period strata. Then we could sum the PYR within specific sex, 5-year age 
group and 1-year calendar period strata. 
2.2.2 Outcome measures 
2.2.2.1 Standardised incidence ratio (SIR) 
The standardised incidence ratio (SIR) is a relative measure and was calculated as the ratio of 
observed to expected numbers of MPCs 2-4. The estimation of expected numbers of MPCs 
assume that patients with a first cancer experienced the same cancer rates as the general 
population. The expected number was then calculated using the accumulated person-years 
within specific sex, 5-year age group and 1-year calendar period strata, multiplied by the 
corresponding cancer incidence rates in the general population. The SIR is more informative 
than the crude incidence of MPC because it takes into account the natural increase of cancer 
risk with age and variation of the background cancer incidence in each year 5. In comparison, 
crude incidence of MPCs simply reflects the number of MPC cases occurring in the study 
cohort during a year. Poisson regression models were used to derive 95% confidence 
intervals (95% CIs) for SIRs, assuming that the observed number followed a Poisson 
distribution. The outcome measure used for the model was the observed number of MPCs 
and offset/exposure variable was the expected number of MPCs. Tests for linear trends in 
SIRs were performed by entering calendar periods of first cancer diagnosis as a consecutive 
non-negative integer variable in relevant Poisson regression models. Evidence for a linear 
trend was assessed by comparing the likelihood function of the model including the variable 
for calendar periods of first cancer diagnosis with the likelihood function of the model 
without that variable. 
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2.2.2.2 Absolute excess risk (AER) 
The absolute excess risk (AER) is an absolute measure. We subtracted the expected number 
of MPCs from the observed number of MPCs; the difference was then divided by 10,000 
person-years. The AER is often interpreted as the absolute number of excess second cancers 
per 10,000 PYR among cancer survivors. Generally, the AER is more informative for public 
health purposes because it measures the absolute impact of the MPC burden among cancer 
patients. High SIRs may occasionally produce low AERs when the cancer incidence in the 
general population is low. For example, when the baseline leukaemia incidence in the general 
adulthood population is low, the AER for treatment-related leukaemia among adult cancer 
patients may have a low value. However, the relevant SIR value may be high because of the 
small value of the denominator (the expected number of treatment-related leukaemia using 
leukaemia incidence in the general adulthood population is low). In contrast, when the 
relevant cancer incidence in the general population is high, a slight increase in SIRs may 
produce a great increase in the AERs. 
2.3 MPC mortality risk 
2.3.1 Competing risk analysis 
We applied competing risk models as an alternative to Kaplan-Meier methods to assess the 
competing mortality from subsequent primary cancers and non-cancer events among cancer 
patients. Here is a simple example to illustrate the overestimation of cause-specific mortality 
using the Kaplan-Meier method and the more accurate estimation using competing risk 
analysis 6. Three patients were diagnosed with lung cancer at the same time. The first patient 
died one month after lung cancer diagnosis and the cause of death was heart failure. The 
second patient died two months after lung cancer diagnosis because of the progression of the 
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lung cancer. The third was still alive at the end of follow-up. The primary outcome of interest 
is the death due to lung cancer. In Kaplan-Meier (KM) estimates, the patient who died of 
heart failure is censored in the risk setting (the denominator) at one month. Therefore, the 
chance of death due to lung cancer at the third month is 1/2 in this group of three patients. In 
a competing risk (CR) setting, the patient who died of heart failure is still kept in the risk set 
(the denominator), but the chance of reaching the endpoint of interest (death due to lung 
cancer) is zero. As a result, the chance of death due to lung cancer at the third month is 1/3.  
 
2.3.2 Outcome measures 
As an absolute measure, the cumulative incidence function (CIF) was used to estimate the 
cumulative incidence of cause-specific deaths in the presence of competing risks 6, 7. For a 
relative measure, the subdistribution hazard ratios (SHRs) of cause-specific deaths were 
calculated in competing risk models 8. We also derived hazard ratios from Cox regression 
models and made comparisons with the SHRs to illustrate the difference in results in the 
presence of competing risks. Detailed descriptions of the analyses are presented in Chapter 5. 
2.4 Non-cancer mortality among cancer patients 
We conducted competing risk analysis to assess the cumulative incidence of non-cancer 
deaths among cancer patients. Standardised mortality ratios (SMRs) and absolute excess risks 
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(AERs) for non-cancer deaths were used to compare mortality due to non-cancer events 
among cancer patients with that expected in the general population. The rationale and 
calculation of SMRs were similar to that for SIRs.  
2.5 Statistical analysis 
Detailed descriptions of all statistical analyses performed are presented in the relevant 
chapters. Statistical analyses presented in Chapter 4 were performed using Stata software 
(StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP). 
Statistical analyses presented in Chapter 5 were performed in R version 3.3.2 (R Project for 
Statistical Computing, http://www.r-project.org) using the ‘cmprsk’ 9 and ‘survival’ 10 
packages. Statistical analyses presented in Chapter 6 were performed in R version 3.4.2 (R 
Project for Statistical Computing, http://www.r-project.org) using the ‘cmprsk’ 9 and 
‘survival’ 10 packages, and Stata software (StataCorp. 2017. Stata Statistical Software: 
Release 15. College Station, TX: StataCorp LLC). A two-sided P value less than 0.05 was 
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Chapter 3: Temporal trends in the risk of developing 
multiple primary cancers: A systematic review 
3.1 Abstract 
Background: Cancer survivors are at risk of developing second and subsequent primary 
cancers, referred to as multiple primary cancers (MPCs). It is not clear whether the risk of 
MPCs has increased over recent decades, but increasing use of radiological imaging and 
potentially harmful effects of certain cancer treatments raise this possibility. A systematic 
review was undertaken to assess whether there has been a temporal change in the risk of 
developing MPCs. 
Methods: A systematic search to identify population-based studies of MPCs was performed 
in Medline/PubMed and Embase databases from inception to August 2016. Included studies 
were those reporting risk of MPCs for all sites combined following a first cancer at any site 
or a specific site, using standard incidence ratios (SIRs) or equivalent, and with analysis 
stratified by calendar years.  
Results: We identified 28 articles eligible for inclusion, comprising 26 population-based 
studies and two monographs. MPC incidence was reported in nearly 6.5 million cancer 
survivors. For all first cancer sites combined, a higher rate of MPCs was reported in more 
recent than earlier calendar periods in four of the six relevant studies. The SIRs ranged from 
1.14 for a first cancer diagnosis in the early 1980s to 1.21-1.46 in the late 1990s in the USA 
and Australia. Two studies from Italy and France showed no significant difference in SIRs 
across time periods 1978-2010 and 1989-2004. The remaining 22 studies reported various 
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temporal trends in the risk of developing MPCs after a first cancer at a specific site, but most 
showed little change. 
Conclusion: Overall, the risk of developing MPCs appears to have increased since the 1980s 
when considering studies of all primary cancer sites combined from the USA and Australia 
but not from Europe. With the introduction of more routine nuclear medical imaging over the 
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3.2 Introduction  
Survival for most cancers has increased steadily over the last three decades, mainly due to 
increased detection of early-stage cancers and advances in cancer treatment 1, 2. This has been 
a global phenomenon and has led to a growing number of cancer survivors worldwide 3, 4. 
Increasing attention has been given to the long-term outcomes of cancer survivors including 
the risk of developing new primary cancers 5, 6. In a seminal report from the USA, up to 10% 
of cancer survivors were diagnosed with a second or higher-order primary cancers during a 
27-year period 1973 to 2000 7. A higher rate of new cancers was observed among cancer 
survivors with a first cancer diagnosed in more recent (between 1995 and 2000) than in 
earlier time periods (1973-79). 
Two or more primary cancers occurring in the same individual that are neither extensions, 
recurrences nor metastases of each other are defined as Multiple Primary Cancers (MPCs) 8. 
Factors associated with any change in the risk of developing MPCs might include increased 
use of diagnostic imaging and adverse cancer treatment effects. The past 30 years has seen a 
large increase in the use of diagnostic imaging, particularly radiologic medicine examinations 
such as diagnostic X-rays and computed tomography (CT) scanning 9-11. Medical radiation 
exposure to the USA population has increased approximately 600% since the 1980s 12. In 
addition, cancer survivors tend to receive more frequent radiologic imaging than the general 
population due to follow-up care after primary treatment 13-15. The rising use of various 
imaging modalities might be expected, therefore, to increase the possibility of incidental 
findings of new cancers during a routine follow-up examination and/or may increase the 
future risk of cancer due to the radiation exposure 16. 
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Some MPCs may also be treatment-related 17, 18. Patients treated with radiotherapy and some 
specific chemotherapeutics can experience a number of significant late effects. One of the 
most serious potential long-term side effects is the development of MPCs 19-21. The risk of 
developing MPCs is increased among survivors treated with radiotherapy, alkylating agents, 
anthracyclines and epipodophyllotoxins 3, 21-23. A mutation in a susceptibility gene may also 
promote two or more cancers in an individual 22, 24, 25. However, genetic risk factors for MPCs 
would not be expected to change over recent decades, unless they interact with other risk 
factors that demonstrate temporal trends. 
In order to better understand temporal trends in the risk of developing MPCs, we performed a 
systematic review of the scientific literature to determine whether the risk of MPCs has 
increased over recent decades. 
3.3 Methods  
3.3.1 Scope of the review  
We conducted a systematic literature search to identify studies describing adult cancer 
survivors with the diagnosis of MPCs. The review was focused on the following question: 
has there been an increase in the risk of developing MPCs over time? 
3.3.2 Search strategy and selection criteria 
We used two approaches to conduct the systematic search in two phases (Table 3.1). The 
original review was conducted in PubMed and Embase databases for eligible articles 
published prior to 1st March 2015. The update was conducted to August 2016. The MeSH 
terms related to “multiple primary cancers” and “second cancers” and related subcategories 
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were used in separate searches: Neoplasms/ Multiple Primary, Neoplasms/ Second Primary 
and epidemiology/ prevention and control. A number of key words (“multiple primary 
cancer* or malignanc* or tumo*”, “population-based” and “time period* or interval* or 
calendar years”) were also used and combined in different databases.  
Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) statement 26, 27, eligibility criteria for included studies were as follows: (i) Type of 
studies: published population-based studies and reports published in English; (ii) Types of 
patients: adult cancer survivors (≥19 years) who were diagnosed with a first primary cancer 
(index cancer); (iii) Types of outcomes measures: adult cancer survivors (≥19 years) who 
developed a second or higher-order primary cancer (all sites combined). Studies of cancer 
survivors who developed MPCs at a specific site and studies based on autopsy cases were 
excluded because we were interested in the overall MPC risk among adult cancer survivors. 
Studies of MPCs in patients undergoing specific therapies or by treatment periods were also 
excluded given we were interested in all factors that affected the trends in MPC risk rather 
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Table 3.1: Search strategy for Medline and Embase (1 March 2015)  
Approach 1 
Search strategy using MeSH terms in Medline 
No. Search  
1 "Neoplasms, Multiple Primary/epidemiology"[Mesh] OR "Neoplasms, Multiple 
Primary/prevention and control"[Mesh] OR "Neoplasms, Second 
Primary/epidemiology"[Mesh] OR "Neoplasms, Second Primary/prevention and 
control"[Mesh] AND "Time Factors"[Mesh] 
 N = 657 
2 Limits: adults 
 N = 498 
  
Search strategy using keywords in Medline 
1 multiple primary cancer*[Title/Abstract] 
 N = 576 
2 multiple primary malignanc*[Title/Abstract] 
 N = 208 
3 multiple primary tumo*[Title/Abstract] 
 N = 386 
4 multiple primary carcinoma*[Title/Abstract] 
 N = 130 
5 second cancer*[Title/Abstract] 
 N = 1,272 
6 second malignanc*[Title/Abstract] 
 N = 1,622 
7 second tumo*[Title/Abstract] 
 N = 951 
8 second carcinoma*[Title/Abstract] 
 N = 82 
9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8  
 N = 4,801 
10 time[Title/Abstract] OR period*[Title/Abstract] OR interval*[Title/Abstract] OR calendar 
year*[Title/Abstract] 
 N = 3,401,312 
11 population[Title/Abstract] 
 N = 936,431 
12 risk[Title/Abstract] 
 N = 1,328,908 
13 #9 AND #10 AND #11 AND #12 
 N = 302 
17 Limits: adult: 19+ years 
 N = 236 
  
Search strategy using keywords in Embase 
1 Multiple AND primary AND (‘cancer’/exp OR cancer) OR multiple AND primary AND 
malignanc* OR multiple AND primary AND tumo* OR multiple AND primary AND 
carcinoma* OR second AND (‘cancer’/exp OR cancer) OR second AND malignanc* OR 
second AND tumo* OR second carcinoma*  
 N = 236,978 
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2 Time AND period* OR time AND interval* OR calendar AND year* 
 N = 691,550 
2 #1 AND #2 AND population AND risk AND [embase]/lim 
 N = 457 
Approach 2 
Search strategy using MeSH terms in Medline 
No. Search  
1 "Neoplasms, Multiple Primary"[Mesh] OR "Neoplasms, Multiple Primary"[Mesh] OR 
"Neoplasms, Second Primary"[Mesh] OR "Neoplasms, Second Primary"[Mesh] AND 
"Risk Assessment"[Mesh] 
 N = 613 
2 Limits: adults 
 N = 455 
  
Search strategy using keywords in Medline 
1 multiple primary cancer*[Title/Abstract] 
2 multiple primary malignanc*[Title/Abstract] 
3 multiple primary tumo*[Title/Abstract] 
4 multiple primary carcinoma*[Title/Abstract] 
5 multiple cancer*[Title/Abstract] 
6 multiple malignanc*[Title/Abstract] 
7 multiple tumo*[Title/Abstract] 
8 multiple carcinoma*[Title/Abstract] 
9 second primary cancer*[Title/Abstract] 
10 second primary malignanc*[Title/Abstract] 
11 second primary tumo*[Title/Abstract] 
12 second primary carcinoma*[Title/Abstract] 
13 second primary cancer*[Title/Abstract] 
14 second primary malignanc*[Title/Abstract] 
15 second primary tumo*[Title/Abstract] 
16 second primary carcinoma*[Title/Abstract] 
17 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR 
#13 OR #14 OR #15 OR #16 
 N = 12,841 
18 time OR period* OR year* 
 N = 5,764,460 
19 population-based[Title/Abstract] 
20 risk[Title/Abstract] 
21 #17 AND #18 AND #19 AND #20 
 N = 232 
17 Limits: adult: 19+ years 
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3.3.3 Data extraction and analysis 
Titles and abstracts of identified articles were assessed against the inclusion criteria by one 
author (YY). The full text of potentially relevant studies and the reference lists of included 
studies were read to identify further original articles. Two authors (YY and AV) developed 
an extraction sheet to record first author’s name, publication year, source of data, the number 
of Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) criteria 
met, site of first primary cancer, study period and follow-up, study size, study population 
(definition and inclusion criteria), definition of MPCs, calendar year of first cancer diagnosis, 
and the standardised incidence ratios (SIRs) or relative risks (RRs) and 95% confidence 
intervals (95% CIs) for MPCs by time periods. Typically, SIRs were derived from the 
observed number of MPCs divided by the expected number (O/E), with the expected number 
calculated from age-, sex- and calendar year- specific incidence rates in the general 
population 7, 28. Alternatively, RRs were calculated as the risk of MPCs occurring in one time 
period compared with a reference period 29. 
The STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) 
criteria were used to assess the strengths, weaknesses, and generalizability of included studies 
30. The STROBE statement was developed to help readers when critically appraising 
published articles. Two authors (YY and AV) used a modified checklist of items for cohort 
studies to assess the number of criteria met in each study. We evaluated the coding rules of 
MPCs (i.e. Surveillance, Epidemiology, and End Results (SEER) 31 or International 
Association of Cancer Registries (IACR) and the International Agency for Research on 
Cancer (IARC) (IARC/IACR) 8 coding rules for MPCs) applied in each study as the 
diagnostic criteria in the STROBE checklist.  




3.4.1 Literature search 
The defined search criteria identified 1,832 relevant articles and four were added through 
manual review of references. Of the 225 articles assessed as eligible for full-text review, 23 
articles met the inclusion criteria and were included in the narrative synthesis. After 
combining five eligible articles in the updated search, 28 studies were included in the final 
analysis comprising 26 population-based studies and two monographs (Figure 3.1).  
3.4.2 Study characteristics 
All 28 included studies were population-based, published between 1987 and 2015, presenting 
data from Europe, North America, Australia and Japan (Table 3.2). 26 were peer-reviewed 
publications, reporting on more than 2.8 million survivors of adult cancer over the period of 
1943 to 2012 32-57, with 178,091 MPCs identified. Four of them reported the risk of 
developing MPCs following first cancer with all sites combined 46, 47, 49, 53. Others focused on 
the risk of MPCs following first cancer at a specific site. The remaining were two 
monographs from the USA and Italy. One was a SEER monograph that used data from nine 
cancer registries in the USA, reported on more than 2 million cancer survivors during the 
follow-up period from 1973 to 2000, and a total of 185,407 MPCs were observed 7. The other 
was a monograph of the Italian Association of Cancer Registries (AIRTUM), using data from 
38 general and five specialised cancer registries in Italy, that reported on more than 1.6 
million cancer survivors during the period of 1976-2010 with 85,399 MPCs identified 58.  
The coding rules to define MPCs varied across studies. Seven studies and the SEER 
monograph used incidence and follow-up data from SEER program registries, and employed 
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SEER coding rules 7, 40-45, 54. Eight studies and the Italian monograph used coding rules 
proposed by the IARC/IACR 38, 39, 46, 48, 49, 51, 53, 57, 58. While it may be difficult to directly 
compare risk estimates derived using different coding rules, comparisons of temporal trends 
will be valid if the rules used to define MPCs are consistent over time within a single study 
population 59. 
3.4.3 Study quality 
The number of STROBE criteria met in all population-based studies ranged from 18 to 28 of 
30 items in total, with 21 studies meeting at least 25 criteria. Included studies had various 
objectives, data sources, study sizes and STROBE criteria met, but they all reported the risk 
of MPCs over different time periods.  
3.4.4 Risk of MPCs following first primary cancer with all sites combined 
Six studies reported temporal trends in MPC risk among survivors of adult cancer with all 
first cancer sites combined. Four of them observed an increasing trend in MPC risk from 
earlier to more recent periods. The SEER monograph reported a 14% higher risk of 
developing MPCs than would be expected in the general SEER population during the 25 
years of follow-up, with a total of 185,407 observed MPCs compared with 162,602 expected 
(SIR, 1.14; 95% CI, 1.14 to 1.15). There was an increasing trend of SIRs rising from 1.12 
with periods of first cancer diagnosis during 1973-79 to 1.21 during 1995-2000 7. Three large 
population-based studies from Australia, Finland and Japan (Australia and Japan including 
more than 200,000 cancer survivors, Finland including 470,000 cancer survivors) also 
showed an increase in the risk of developing MPCs across the whole study period when all 
first cancer sites are combined. In Australia, the SIRs grew from 1.14 with periods of first 
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diagnosis in 1982-1986 to 1.46 in 1997-2001 47. In Finland, the SIRs increased from 4.96 in 
the 1950s to 7.64 in the 1980s 53. In Japan, the relative risk increased from 1.00 in 1966-1971 
(reference) to 2.89 in 1984-1986 46. However, two studies from Italy and France showed no 
significant difference in SIRs across different time periods. The Italian monograph reported 
SIRs of 1.10 in 1978-1987, 1.08 in 1988-1997 and 1.10 in 1998-2010, with a 10% higher risk 
of developing MPCs than expected across the entire study period 1976-2010 (SIR, 1.10; 
95%CI, 1.09 to 1.10) 58. The French study was a large population-based study using data 
from 10 French population-based cancer registries, with a first cancer diagnosis between 
1989 and 2004 49.  
3.4.5 Risk of MPCs following first primary cancers at specific sites 
The risk of MPCs following first cancers at specific sites did not differ significantly across 
calendar periods of first cancer diagnosis in 14 studies 34, 36, 37, 39-42, 44, 45, 48, 50-52, 56. Six studies 
reported an increasing temporal trend in MPC risk 33, 35, 43, 54, 55, 57, whilst two studies reported 
a decreasing trend in MPC risk after breast cancer during the study period 1943- 2000 32, 38. 
There were a total of three studies on breast cancer as the first cancer. 
3.4.5.1 MPCs following leukaemia, lymphoma and myeloma 
Eight studies assessed the risk of MPCs following first cancers of the hematopoietic and 
lymphoid system 33, 35-37, 41, 44, 52, 55. The risk of MPCs did not reveal any particular trends with 
respect to variations in SIRs over time in either of two major leukaemia (chronic myeloid 
leukaemia, chronic lymphocytic leukaemia) 36, 37 or the uncommon hairy cell leukaemia 41, 52. 
These studies compared the risk of MPCs before and after a time point around 1990 when 
novel therapeutics such as interferon, fludarabine and other nucleoside analogues were 
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introduced. Three studies with first cancers of Hodgkin or non-Hodgkin lymphoma reported 
an increasing trend in the risk of MPCs over time 33, 35, 55. The risk of MPCs increased from 
1.2 in the 1960s to 1.6 in the 1970s among 3,139 cases of Hodgkin’s disease 33. For MPCs 
following non-Hodgkin lymphoma (NHL), the risk was higher in the time interval of 2000-
2006 (RR=1.00, reference) than in 1980-1984 (RR=0.65; 95%CI: 0.59-0.72) in more than 
60,000 registered cases from three Nordic countries 35. A similar pattern was also confirmed 
in France. The risk of MPCs was 1.37 (95%CI: 1.08-1.74) times higher for NHL diagnoses in 
2000-2004 than in the 1989-1994 reference category 55. For MPCs following multiple 
myeloma, there was no significant change in the risk before and after 2000. However, the 
overall risk of MPCs was also not significant (SIR=0.98; 95% CI: 0.94–1.02) 44. 
3.4.5.2 MPCs following breast and ovarian cancer 
No statistically significant change or decreasing trends in MPCs risk was observed in three 
breast cancer studies, two from multicentre studies and one from a single cancer registry 32, 38, 
39. One large multicentre study used data on 525,527 breast cancer survivors from 13 
population-based cancer registries from Europe, Australia, Canada and Singapore covering 
the study period 1943-2000. The risk of MPCs decreased from 1.32 (95%CI 1.30-1.35) 
before 1975 to 1.18 (95%CI 1.14-1.22) after 1991 38. Another multicentre study 
encompassing four Scandinavian cancer registries reported data on more than 300,000 one-
year survivors of breast cancer during a similar period, 1943-2002. The risk of MPCs was 
lower after 1980 than before (SIR = 1.09 and 1.19, respectively). However, second 
haematological cancers were excluded from the analysis 32. No significant change in trend 
was observed in a study from a single cancer registry in Spain during the period of 1985-2007 
(SIR 1.37, 95%CI 1.16-1.58 in 1985-1995 and SIR 1.41, 95%CI 1.18-1.64 in 1996-2007) 39. 
The risk of MPCs following ovarian cancer increased from 1.1 in 1961-69 to 1.2 in 1970-80 
Chapter 3: Temporal trends in the risk of developing multiple primary cancers: A systematic 
review 
76 
(no 95%CI provided), using data from a single cancer registry in the UK. However, the 
observed numbers were mostly too small to obtain reliable estimates 33. 
3.4.5.3 MPCs following thyroid cancer 
In the USA, the risk of MPCs was higher in patients diagnosed with a first thyroid cancer 
during 2004-2008 (SIR 1.45, 95%CI 1.28-1.62) than in 1973-1983 (SIR 1.02, 95%CI 0.97-
1.07) 43. In Korea, however, the risk only reached statistical significance for a first thyroid 
cancer diagnosis between 2003 and 2007 (SIR 1.09, 95%CI 1.03-1.15), with smaller 
increases in other periods (SIR= 0.92 in 1993-1997, 1.05 in 1998-2002 and 1.06 in 2008-
2010).  
3.4.5.4 MPCs following prostate cancer  
Interestingly, the risk of MPCs following a first prostate cancer was significantly lower than 
expected in two relevant studies from the USA and Korea 34, 56. The value of SIRs was 
consistently 0.7 from 1974 to 1994 using data from SEER (USA) cancer registries 34 and 
ranged from 0.6 to 0.7 during 1993-2011 using data from a nationwide hospital-based cancer 
registry in Korea 56. 
3.4.5.5 MPCs following first cancers at other sites 
From the early 1970s to the mid-2000s, the temporal trends in the risk of MPCs did not 
change significantly with a first cancer diagnosis of malignant meningioma, oesophageal 
cancer and ocular melanoma 40, 45, 48, but varied for first cancer at head and neck 51. The risk 
of MPCs following testicular cancer remained consistent and lower than expected from 1961 
to 1980. Although the SIRs for first cancer of Merkel Cell carcinoma increased from 1.09 
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(95%CI 0.83-1.70) in 1986-1994 to 1.37 (95%CI 1.05-1.76) in 1995-2002, the increase was 
not statistically significant 42. For MPCs following colorectal cancer and bladder cancer, both 
risks increased with the year of first cancer diagnosis. The SIRs increased significantly from 
1.53 (95%CI 1.37-1.71) in 1989-1992 to 2.02 (95%CI 1.79-2.27) in 2001-2004 for first 
bladder cancer 57. For first cancer at colon and rectum, the SIRs were higher in 2002-2012 
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Records identified through 
database searching (n = 1832) 
Additional records identified 
through manual review (n = 4) 
Records screened after duplicates removed (n = 1567) 
Records excluded by title and abstract (n = 1342) 
Case reports: 57 
Irrelevant: 532 (No data on MPC or MPC after 
non-neoplastic disease) 
Non-English language: 74 
MPC clinicopathologic or genetic features: 51 
MPC definition: 4 
MPC after carcinoid primary cancer: 4 
MPC in specific area or population: 9 
MPC in childhood cancer survivors: 95 
MPC surveillance and prevalence: 19 
MPC survival and treatment: 78 
Narrative reviews: 17 
Second cancer at a specific site: 272 
MPC after specific treatment: 130 
Full-text articles assessed for eligibility (n = 225) 
Full-text articles excluded (n = 202) 
MPC analysis based on autopsy: 3 
Not SIR or equivalent reported: 53 
SIR or equivalent reported, not by calendar years: 
135 
SIR by treatment subgroups or age subgroups, not 
by the whole population: 6 
Treatment-related MPC: 5 
Studies included in qualitative synthesis (n = 23) 
Studies included in final qualitative synthesis (n = 28) 
Eligible articles in updated search (n = 5) 
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Curtis RE  
et al (2006) 
SEER, 
U.S.  
27/30 Any site 1973-2000 More than 2 
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185,407 The study population 
includes nearly 2 
million cancer 
patients reported to 
the 9 SEER registries 
from 1973 to 2000, 
with follow-up for 
subsequent cancer 
occurrence extending 
up to 27 years. 
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data from the 
AIRTUM Database 
(at December 2012) 
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presenting with a first 
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204,962 23,580 All patients diagnosed 
with a first primary 
invasive cancer 
between 1982 and 
2001 who survived 
for a minimum of 2 
months, restricting to 
15 years or older at 
the time of first 
diagnosis. 
MPC coding rules: 
Included 
histologically similar 
cases of cancer at the 





within 2 months of the 















22/30 Any site 1953-1991 470,000 19,800 All 470,000 patients 
registered in Finland 
from 1953 to 1991 
with malignant 
neoplasms [primary 






carcinomas of the 
skin, carcinoma in 
situ of the uterine 
cervix, and papilloma 
of the urinary organs. 





















4,436 All reported cases 
aged 0-79 who were 
initially diagnosed 
with a first primary 
cancer (invasive 
cancer and benign 
intracranial tumour) 















leukaemia, lymphoma and myeloma 
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All adult cases of 
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code 205.1, age at 
diagnosis ≥ 18 years) 
arising between 
January 1, 1970, and 
December 31, 1995. 



















MPC coding rules: 
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cancers diagnosed less 















3104 358 All hairy cell 
leukaemia patients 
who survived for at 
least 2 months after 
diagnosis. 










Federico M et al 
(2002) 
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22/30 Hairy cell 
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recorded in the Italian 
Registry of HCL 
between January 1981 
and December 1996. 
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All patients registered 
with Hodgkin's 
disease in the South 
Thames Cancer 
Registry during the 
period 1961-80. 
Excluded patients if 
they had had another 
tumour registered 
either before or at the 
same time as the 
index tumour, or if 
their index tumour 
had been registered at 
death (no follow-up) 
or at age 85 years or 
more. 
Second cancer defined 
as the site and the 
histology are distinct 
from the first. Second 
cancers at the same 
site as the first or at a 
different site but with 
the same histology as 
the first will be 
registered only if the 
hospital record or 
pathology report 
explicitly states that it 
is a new primary, 
distinct from the 
previous cancer. 
Excluded second 
tumours occurring at 
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7,546 580 NHL patients was 
extracted from the K2 
France cohort, which 
includes cancer cases 
diagnosed between 
1989 and 2004 






cancer (<61 days of 
follow-up) were 
excluded. 
MPC coding rules: A 
Second Primry Cancer 
was defined as the 
first subsequent 
primary cancer 
occurring at least two 
months (≥61 days) 
after the first 
















1973-2008 36,491 2021 All cases were 
identified by site code 
ICD-0-3: C9732 and 
C9734. 
Excluded cases whose 
reporting sources 
were coded as autopsy 
or death-certificate-
only (n=775), cases 
where MM was not 
the first primary 
(n=3545) and cases 
with second cancer 
diagnosed within the 
first 2 months of MM 
diagnosis (n=365) 
MPC coding rules: 
SEER 
All second cancers 
except cancers within 
the first two months 
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26/30 Breast cancer 1943-2000 525,527 31,399 All women with a 
first primary breast 
cancer (ICD-9 5 174) 
except patients for 
whom the first 
primary cancer 
diagnosis and death 
were recorded at the 
same time or who had 
2 first primary cancers 
recorded 
simultaneously (same 
dates of diagnosis). 
MPC coding rules: 
IARC/IACR 
Second cancers except 
contralateral breast 
cancer, brain and 

























27/30 Breast cancer 1943-2002 376,825 23,158 All women diagnosed 
with a first primary 
cancer of the breast 
between January 1, 
1943 and December 
31, 2002 who 
survived at least 1 
year. 
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All patients registered 
with cancer of the 
ovary in the South 
Thames Cancer 
Registry during the 
period 1961-80. 
Excluded patients if 
they had had another 
tumour registered 
either before or at the 
same time as the 
index tumour, or if 
their index tumour 
had been registered at 
death (no follow-up) 
or at age 85 years or 
more. 
Second cancer defined 
as the site and the 
histology are distinct 
from the first. Second 
cancers at the same 
site as the first or at a 
different site but with 
the same histology as 
the first will be 
registered only if the 
hospital record or 
pathology report 
explicitly states that it 
is a new primary, 
distinct from the 
previous cancer. 
Excluded second 
tumours occurring at 


















25/30 Thyroid cancer 1993-2010 178,844 2,895 Records code C73.9 




developed a second 
malignancy within the 
first 2 months of 
follow-up (n=628) 
were excluded. 
















24/30 Thyroid cancer 1973-2008 52,103 4457 All cases were 
identified by site code 
ICD-0-3: C739, 
reported to a SEER 9 
database 
between 1973-2008 
MPC coding rules: 
SEER  
All second cancers 
except cancers within 
the first two months 
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22/30 Prostate cancer 1993-2011 55,378 2,578 Patients diagnosed 
with a first prostate 
cancer between 1993 
and 2011. Excluded 
patients who 
presented with a SPC 
within two months of 




cancer after the 
diagnosis of another 
primary cancer, and 
patients for whom 
only death certificate 
information was 
available. 
















1974-1994 4,503 380 Cases of first 
diagnosed prostate 
carcinoma registered 
between 1974 and 
1994 with histologic 
confirmation available 
for 89.7%. 









Other sites (malignant meningioma, head and neck, oesophageal, ocular melanoma, merkel cell, colorectal cancer, bladder, testis) 







1973-2007 1,603 56 All patients in the 
SEER database with 
the diagnosis of 
malignant 
meningioma were 
identified via SEER 
program 6.6.2 (1973–
2007). 
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28/30 Head and neck 
squamous cell 
carcinomas 
1975-2006 7,329 1,326 All patients were 
followed-up for 10 
years or until 
December 31, 2006. 
HNSCC included here 
were squamous cell 
carcinomas (ICD-O-3 
histology codes 8070–
8076, 8078) localized 
at the oral cavity, 
oropharynx, 
hypopharynx and 
larynx (ICD-O-3 site 
codes C01–C06, C09–
C10, C12–C13, C32). 























1973-2007 24,557 985 All oesophageal 
cancer patients who 
survived for at least 2 
months after 
diagnosis. 
MPC coding rules: 
SEER 




















1943-2000 10,396 1,029 All cases of ocular 
melanoma without 
stratifying by subsite. 















26/30 Merkel cell 
carcinoma 
1986-2002 1,306 122 All patients with a 
first primary 
cutaneous MCC in 1 
of 11 population-
based cancer 
registries of SEER 
program (1986-2002). 
MPC coding rules: 
SEER 
Subsequent primary 
cancers were invasive 
primary neoplasms 
that developed at least 
1 month after a 
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1992-2012 240,584 27,731 Invasive CRC patients 
who were diagnosed 
at the age of more 
than 20 years. 
Excluded patients: 1) 
diagnosed with 
unknown age, 2) 
reported only on 
death or autopsy 
certificate only, 3) 
being stage of in situ. 
SPMs diagnosed 
during six months 
period after the 
primary diagnosis 
were also excluded. 
























28/30 Bladder cancer 1989-2004 
Followed up 
to 2007 
10,047 1,291 All patients with a 
first bladder cancer 
(BCa) diagnosed 
between 1989 and 
2004 and followed up 
to 31 December 2007. 
Excluded patients 
with a known history 
of previous cancer 
before BCa diagnosis 
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27 All patients registered 
with cancer of the 
testis in the South 
Thames Cancer 
Registry during the 
period 1961-80. 
Excluded patients if 
they had had another 
tumour registered 
either before or at the 
same time as the 
index tumour, or if 
their index tumour 
had been registered at 
death (no follow-up) 
or at age 85 years or 
more. 
Second cancer defined 
as the site and the 
histology are distinct 
from the first. Second 
cancers at the same 
site as the first or at a 
different site but with 
the same histology as 
the first will be 
registered only if the 
hospital record or 
pathology report 
explicitly states that it 
is a new primary, 
distinct from the 
previous cancer. 
Excluded second 
tumours occurring at 








STROBE= STrengthening the Reporting of OBservational studies in Epidemiology. MPCs=Multiple Primary Cancers. N=number of patients. SEER=Surveillance, Epidemiology, and End Results. 
IARC/IACR= International Association of Cancer Registries (IACR)/the International Agency for Research on Cancer (IARC). CI=confidence interval. ICD=International Classification of Diseases. 











To our knowledge, this is the first systematic review focusing on the temporal trends in the 
risk of MPCs. There was an increasing time trend in the risk of developing MPCs in the USA 
and Australia when all first cancer sites were combined. Risk increased from 1.12-1.14 
following a first cancer diagnosis in the early 1980s, to 1.21-1.46 in the late 1990s. In 
European countries, the risk remained similar during 1978-2010 for Italian cancer survivors 
and showed no significant change between 1989 and 2004 for French cancer survivors. Three 
potential explanations are postulated for the increasing trends in the USA and Australia: 1) 
increased detection of MPCs, both intended and incidental; 2) increased radiation exposure 
and 3) changed cancer treatments. The trends in the risk of developing MPCs varied by site 
of first cancer from 1943 to 2012, but mostly there was little change.  
3.5.1 Increased detection 
Increasing risk of MPCs might be a result of increased detection arising from the introduction 
of cancer screening programs for the early detection of cancers in the community; and 
incidental findings arising from the increased use of sensitive imaging tests in the routine 
clinical follow-up of cancer survivors. Early detection and incidental findings are not 
necessarily of benefit, as they can lead to “overdiagnosis”. Overdiagnosis is the detection of a 
“cancer” that would not cause symptoms or death in a patient’s lifetime 60. 
Higher MPCs risk was observed in studies from the USA and Australia in the late 1990s 7, 47. 
These findings coincide with the introduction of national cancer screening programs for 
cervical cancer and breast cancer in Australia in the early 1990s 61. In the USA, the use of 
cancer screening for cervical cancer, breast cancer, colorectal cancer and prostate cancer has 
Chapter 3: Temporal trends in the risk of developing multiple primary cancers: A systematic 
review 
91 
increased since 1987, particularly for breast cancer 62-64. As well as providing benefits, 
screening has led to the overdiagnosis of non-progressive or low progressing cancers 65-68. 
Cancer survivors are considered at increased risk for future cancers, and screening has been 
specifically recommended for survivors of some cancer types 69. A meta-analysis of 20 
studies demonstrated that cancer survivors tended to receive more frequent screening for new 
primary cancers, especially for breast, cervical, colorectal and prostate cancer than non-
cancer controls 70. This may thus differentially lead to increased detection among cancer 
survivors compared with the general population. 
Another activity leading to a higher rate of MPCs may be the increased use and 
improvements in diagnostic imaging in recent time periods. The use of diagnostic imaging, 
especially computed tomography (CT) scans, has increased dramatically worldwide since 
1980, particularly in the USA, Australia and Japan 9, 11, 71. Cancer survivors routinely undergo 
CT scanning and other imaging procedures during follow-up, the detection of a new primary 
cancer, therefore, becomes more likely than in the general population with no prior cancer 
diagnosis 72. Some of these incidental findings might be clinically unimportant, leading to 
overdiagnosis 10, 60, 73. 
3.5.2 Increased radiation exposure during the follow-up after a first cancer diagnosis 
Radiation exposure due to monitoring may of itself lead to harmful effects 74. This possibility 
is consistent with our finding that the highest risk of MPCs, from the late 1990s, has occurred 
since radiation exposure has increased enormously 9. Since the 1980s, the average annual per-
capita effective dose from medical radiological procedures doubled worldwide 9, 11. In the 
USA, the average annual per capita dose for medical procedures increased almost six-fold 
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from 0.5mSv in 1980 to 3.0mSv in 2006 9, with X-rays and CT scan the two most common 
imaging procedures leading to radiation exposure 11. 
The lifetime risk of cancer attributable to diagnostic X-rays is estimated to vary between 
0.6% and 1.8% across 15 countries, including the USA and Australia, between 1991 and 
1996 75. In Japan, the attributable risk has been estimated at 3.2%, but the Japanese results are 
confounded by the impact of background radiation following the atomic bombings in World 
War II 75.  
CT scanning has been widely used since the 1990s and delivers a much higher radiation dose 
than diagnostic X-rays 76. In Australia, the cancer risk in children and adolescents who 
underwent CT scanning between 1985-2005 was found to be 24% higher than in their peers 
who did not undergo CT scanning 16. The impact on lifetime risk could not be ascertained 
given that cancer excess was still occurring at the end of the study. Increased risk of cancer 
due to CT scanning is not, however, limited to children. Adults are also at increased risk of 
cancer from the radiation exposure 77. Imaging-based evaluation, especially CT scans, is the 
preferred modality to assess response to treatment, and for routine surveillance of most 
cancer survivors 78. Therefore, increased risk of MPCs could be partly attributable to 
cumulative radiation exposure due to recurrent CT scans 79. 
3.5.3 Changed cancer treatments 
Studies of MPCs consequent to a primary cancer at a specific site can help us understand the 
impact of treatment changes on trends of MPC risk. No statistically significant change in risk 
of MPC was observed in most specific site studies, including after the 1990s when many 
newer (and improved) treatments or management strategies were introduced 34, 36, 37, 39-42, 44, 45, 
52, 56. A decrease in risk was observed in two of three breast cancer studies, which may reflect 
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the improvement in radiation techniques 32, 38. On the other hand, an increase in MPC risk 
was observed for a first non-Hodgkin lymphoma diagnosis in the mid-2000s than in the early 
1990s, which may suggest an adverse treatment effect with increased use of nucleoside 
analogues (e.g. Fludarabine) at the end of the 1990s 35, 55. The increase in the risk of MPCs 
following thyroid cancer might occur as a consequence of aggressive radiation treatment 43. 
This is particularly concerning in regard to the more recent increased detection and treatment 
of microcarcinoma 80, largely considered to encompass overdiagnosis and overtreatment 73.  
Together these findings suggest that most treatments have not impacted the baseline risk of 
MPCs in persons recently diagnosed with a primary cancer (post-1990), with the exceptions 
of breast cancer (reduction), non-Hodgkin lymphoma and thyroid cancer (increase).  
3.5.4 Other factors to be considered 
Changing patterns in lifestyle or environmental risk factors may also affect the value of SIRs 
over time. Temporal trends in population exposure to carcinogenic factors such as alcohol 
and tobacco consumption, differed across countries 49. Any differences over time in exposure 
in the reference population compared with the population of cancer survivors could 
contribute to changing SIRs. 
3.5.5 Limitations  
Several factors limit the interpretation of our findings. First, studies of all first cancer sites 
combined from the USA and Australia did not cover the last 15 years. This period is of 
particular relevance given the introduction of nuclear medicine imaging, for example, 
PET/CT scanning. Second, cancer survivor profile (age at first cancer diagnosis, site of first 
cancer) may have varied according to year of first cancer diagnosis and these factors may 
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contribute to changing SIRs 49. For example, cancer survivor profiles have changed with the 
implementation of cancer screening programs. Third, variation in screening guidelines, 
follow-up care, management and treatment for cancer across countries potentially affect the 
generalizability of the results. Fourth, some included studies did not clearly specify the 
coding rules or definition of MPCs, which may result in misclassification and less reliable 
estimation of the observed number of MPCs. Fifth, different timeframes of the study cohorts 
may limit the ability to evaluate long-term effects of changing patterns in medical 
surveillance and treatment of the primary cancer. Some studies published before 2000 lack 
sufficient data to compare SIRs pre-1990s and post-1990s when treatment improved 33, 34, 46, 
53. Sixth, articles in languages other than English were excluded, which could lead to 
language bias. Last, although we defined the age of the study population as adults, some 
studies, mostly those using SEER cancer registries, reported across all ages 7, 33, 35, 37, 40-46, 48, 
50, 53, 55, 58. However, childhood cancer survivors accounted for a limited proportion of all 
cancer survivors (no more than 2% in SEER cancer registries), and the types of cancer 
developed in children were limited 7, which should minimise any impact on the overall 
results.  
3.5.6 Conclusion 
The overall risk of developing MPCs appears to have increased in the USA and Australia 
from the 1980s to 2000 when all first cancer sites are combined. Increased detection due to 
the more frequent use of diagnostic imaging and increased medical radiation exposure may 
be potential explanations. Studies from Italy and France, however, showed no significant 
change in MPC risk in patients diagnosed with a first cancer after 2000. Given the 
implementation of new cancer screening programs and the growth of nuclear medical 
imaging (e.g. PET/CT scanning) since 2000, continued long-term surveillance is needed from 
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non-European as well as European countries. Future studies are needed to assess the extent of 
overdiagnosis and overtreatment among cancer survivors relative to the general population, 
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Chapter 4: Temporal trends in the risk of second primary 
cancers among survivors of adult-onset cancers, 1980-2013: An 
Australian population-based study 
4.1 Abstract 
Background: Our systematic review indicated an increasing trend in the risk of second 
primary cancers (SPCs) from the 1980s to 2000 when considering studies from the USA and 
Australia. It is uncertain whether this trend has continued to increase since 2000. 
Methods: Population-based study of 51,802 individuals with adult-onset cancers identified in 
the Tasmanian Cancer Registry. Patients with a first cancer diagnosis between 1980-2009 
were followed up to December 2013. SPC risks were quantified using standardized incidence 
ratios (SIRs) and absolute excess risks (AERs). Trends in SPC risk were assessed in 
multivariable Poisson models.   
Results: With a median follow-up of 4.8 years (mean=6.9 years), 5,339 SPCs were observed. 
The SIRs for any SPC increased from 0.98 (95%CI, 0.90-1.07) after a first cancer diagnosis 
in 1980-1984 to 1.12 (95%CI, 1.05-1.20) in 2005-2009. In multivariable Poisson models 
accounting for patient sex, age at first cancer diagnosis, follow-up intervals and first cancer 
types, the trend in SIRs increased significantly from 1980-2009 for all SPCs (Ptrend < 0.001) 
and for specific SPCs of head and neck, lung, digestive tract and prostate (all Ptrend < 0.05). 
From 2000 onwards, the AER for specific SPCs after specific first cancers was highest for 
prostate cancer after first cancers of the urinary tract (AER, 54.3/10,000 person-years). 
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Conclusion: In Tasmania, the risk of SPCs among survivors of adult-onset cancers has 
increased with periods of first cancer diagnosis from 1980-2009. Increased cancer screening 
and improved medical imaging may have contributed to the greater risk in recent years.   
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4.2 Introduction  
Survivors of adult-onset cancer are at risk of developing second primary cancers (SPCs) 1, 2 
and have been reported to have a 7%-36% higher cancer risk than expected in the general 
population 3-7. Our recent systematic review of temporal change in subsequent cancer risk 
indicated an increasing trend in the risk among adult cancer survivors from the 1980s to 2000 
when considering studies from the USA and Australia but not from elsewhere 8. However, 
few studies have more than 20 years’ surveillance to assess time patterns on overall SPC risks 
into the most recent era 5. 
Factors associated with changing trends in SPC risk might include increased detection of 
SPCs and changing patterns of cancer treatment or other shared carcinogenic factors (e.g. 
tobacco and/or alcohol consumption). Both radiotherapy and chemotherapy can induce 
treatment-related cancers but evidence suggests this explains a relatively small proportion of 
SPCs in adults 9, 10. 
Cancer survivors tend to undergo repeated medical imaging for treatment response evaluation 
and post-treatment surveillance. In addition, they may receive more frequent screening for 
new cancers than people without a history of cancer 11. While patients are expected to benefit 
from follow-up care, they may also be more likely to have indolent cancers or 
“incidentalomas” detected leading to cancer overdiagnosis 12. The use of diagnostic imaging 
and cancer screening tests has increased sharply in Australia and other developed countries 
(e.g. the USA) since the 1980s 13-15. Studies from Australia and the USA have observed a 
gradual increase in SPC risk over the period 1982-2001 and 1973-2000 as a potential 
consequence 3, 4. It is unclear if the risk of SPCs has continued to increase since then.  
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To better understand trends in SPC risk, this study aimed to (i) investigate changes in SPC 
risk over time in survivors of adult-onset cancer in Tasmania, an island state of Australia with 
limited out-migration 16; and (ii) assess any changes in SPC burden in survivors of specific 
types of first cancer during the recent three decades.   
4.3 Methods   
4.3.1 Study population 
This study included 51,802 cancer patients identified in the Tasmanian Cancer Registry 
(TCR). They were diagnosed with a first cancer at age 15 years or older from 1980 to 2009, 
and survived at least two months. Follow-up of the cohort ended on December 31, 2013. The 
TCR is a population-based registry covering the entire state. Most registered cases include 
data from both pathology laboratories and hospital services (inpatient or radiation oncology 
clinic) 17. Access to de-identified records was approved by Tasmanian Health and Medical 
Human Research Ethics Committee. 
4.3.2 Ascertainment of SPCs 
Ascertainment of SPCs followed the International Rules for Multiple Primary Cancers (ICD-
O Third Edition) proposed by the International Association of Cancer Registries (IACR) and 
the International Agency for Research on Cancer (IARC) 18. SPCs occurring within 2 months 
of the date of first cancer diagnosis were excluded to reduce detection bias. Site and 
morphology for first primary cancers and SPCs were coded using the International 
Classification of Disease for Oncology, Third Edition (ICD-O3). Cancers of different sites 
were grouped as shown in Table 4.1. We only included cases of invasive cancer; cases of 
Chapter 4: Temporal trends in the risk of second primary cancers among survivors of adult-
onset cancers, 1980-2013: An Australian population-based study 
106 
benign tumours, cancers in situ or of uncertain behaviour were all excluded. Non-melanoma 
skin cancers (NMSC) were also excluded as they are not routinely registered in the TCR. 
4.3.3 Statistical analysis 
Using a standard person-years approach 19, 20. person-years at risk (PYR) was assessed from 2 
months after the first cancer diagnosis to the date of second cancer diagnosis, the date of 
death, or the end of follow-up (31 December 2013), whichever came first. PYR for each 
patient in the study cohort were accumulated within specific sex, 5-year age group and 1-year 
calendar period strata. The expected number of SPCs (E) was calculated using PYR within 
strata multipled by corresponding site-specific cancer incidence rates in the Tasmanian 
population.  
4.3.3.1 Comparisons with the general population 
Standardized incidence ratios (SIR) were calculated as the ratios of observed to expected 
numbers of SPCs (O/E). Poisson regression models were used to derive 95% confidence 
intervals (95%CIs) of SIRs, assuming that the observed number followed a Poisson 
distribution 3, 19, 20. It has been suggested that including SPCs occurring in the same site as the 
first cancer leads to underestimation of SIRs for all sites of SPC combined 21. For example, 
SPCs of the same anatomical site as a first cancer are very rare in prostate cancer patients, 
leading to a lower number of observed SPCs (the SIR numerator). To maintain consistency 
with IARC coding rules that neoplasms diagnosed simultaneously in the same site of 
different morphology should be regarded as multiple cancers, here we aimed to describe the 
risk of all SPCs rather than second discordant primary cancers. SIRs were stratified by first 
cancer types, second cancer types and calendar year of first cancer diagnosis on 5-year 
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intervals (1980-1984, 1985-1989, 1990-1994, 1995-1999, 2000-2004, 2005-2009). Absolute 
excess risks (AER) were calculated by subtracting the expected number of second cancers 
from the observed number, then dividing by 10,000 person years ([O− E]/[PYR × 10,000]) 3, 
22. The AER is interpreted as the absolute measure of SPC burden in a specific population of 
cancer survivors 3, 23. For survivors of specific first cancer types, we computed the SIRs and 
AERs by three calendar periods of first cancer diagnosis (1980-1989, 1990-1999 and 2000-
2009) to identify the types of SPC that contributed changes in SPC burden during the recent 
three decades.  
4.3.3.2 Internal comparisons within the study cohort 
We used multivariable Poisson regression models to estimate trends and heterogeneity in 
SIRs within the study cohort by categories of sex, age at first cancer diagnosis (15-49, 50-64, 
65-84, 85+ years), period of first diagnosis (1980-1984, 1985-1989, 1990-1994, 1995-1999, 
2000-2004 and 2005-2009), follow-up intervals (<1 year, 1-4 years, 5-9 years, 10+ years) and 
first cancer sites 10, 22. The P-value for trend was estimated using the likelihood ratio test. We 
also analysed the data using negative binomial regression to test the robustness of the Poisson 
regression model. The results were almost identical so we only present results derived from 
the Poisson regression model. A two-sided P value less than 0.05 was considered as 
statistically significant. All analyses were performed using Stata software (version 12; 
StataCorp LLC, College Station, Texas).  
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4.4 Results 
4.4.1 Characteristics of the study population 
A total of 5,339 SPCs were identified among the 51,803 eligible cancer patients who 
accumulated 347,830 person-years at risk during 1980-2013 (Table 4.1). The mean age of 
patients at the first cancer diagnosis was 64.3 years (median 66.2 years). The occurrence of 
SPCs was most common among those diagnosed with their first cancer between the ages of 
65-84 years. The mean follow-up was 6.9 years (median 4.8 years; 25th-75th percentiles, 1.2-
10.2 years). In terms of absolute numbers, SPCs occurred most frequently in patients with a 
first diagnosis of prostate cancer (n=986), colorectal cancer (n=827), skin cancer (excluding 
NMSC) (n=658) and breast cancer (n=635). The most commonly observed SPCs were 
colorectal cancer (n=848), lung cancer (n=761), prostate cancer (n=694) and cancers of 
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Table 4.1: Characteristics of the study population 
* Malignancies in haematological systems means all malignancies in the hematopoietic and reticuloendothelial systems 
using the “C42” ICD-O-3 code. § The reported data includes melanoma of the skin and the invasive non-melanoma skin 
cancers such as Merkel Cell Carcinomas. The more common non-melanoma skin cancers, Basal Cell Carcinomas and 
Squamous Cell Carcinomas (SCCs) are not registered by the Tasmanian Cancer Registry, and therefore not included in these 
analyses.  
Characteristics Patients Person-years at risk 
Second Primary Cancers 
(all sites combined) 
 No. %  No. % 
Total  51,802 100.0 347,830 5,339 100.0 
Sex       
    Male 28,242 54.5 166,051 3,334 62.4 
    Female  23,560 45.5 181,779 2,005 37.6 
Age at first cancer diagnosis, years      
    15-49 8,508 16.4 99,178 577 10.8 
    50-64 15,687 30.3 117,907 1,760 33.0 
    65-84 24,916 48.1 124,345 2,866 53.7 
    85+ 2,691 5.2 6,400 136 2.5 
Period of first cancer diagnosis      
    1980-1984 5,252 10.1 41,245 513 9.6 
    1985-1989 6,241 12.1 50,517 707 13.2 
    1990-1994 8,370 16.2 67,350 1,009 18.9 
    1995-1999 9,429 18.2 71,361 1,119 21.0 
    2000-2004 10,176 19.6 63,504 1,078 20.2 
    2005-2009 12,334 23.8 53,853 913 17.1 
Maximum follow-up      
    2 months – less than 1 year 11,270 21.7 37,701 584 11.0 
    1 – 4 years 15,263 29.5 127,597 1,901 35.6 
    5 – 9 years 11,954 23.1 92,894 1,427 26.7 
    ≥10 years 13,315 25.7 89,638 1,427 26.7 
Type of first cancer (ICD-O codes)      
    Head and neck (C00 - C14, C30-C32) 2,525 4.9 19,366 473 8.9 
Digestive organs, except colorectal  
(C15-C17, C22-C26) 3,460 6.7 7,366 141 2.6 
    Colorectal (C18-C21) 7,567 14.6 47,229 827 15.5 
    Lung and Thymus (C33-C34, C37-C38) 5,010 9.7 9,075 151 2.8 
    Haematological systems* (C42) 2,165 4.2 10,930 282 5.3 
    Skin§ (C44) 5,046 9.7 53,929 658 12.3 
    Breast (C50) 6,833 13.2 65,749 635 11.9 
    Female organs (C51-C58) 2,590 5.0 23,593 252 4.7 
    Prostate (C61) 7,924 15.3 52,384 986 18.5 
    Urinary tract (C64-C68) 3,077 5.9 21,063 465 8.7 
    All lymphoma(C77) 1,913 3.7 14,343 229 4.3 
    Others  3,692 7.1 22,803 240 4.5 
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Table 4.2: Number of second primary cancers, by type of first and second cancer 
 Second primary cancer type 



















 Head and neck  473 62 50 46 116 32 27 15 1 76 25 23 
Digestive, except colorectal  141 5 24 14 21 6 12 7 4 28 16 4 
Colorectal  827 28 90 73 121 57 80 66 21 182 68 41 
Lung and Thymus 151 17 27 20 8 16 8 6 3 28 10 8 
Haematological systems  282 10 23 28 35 48 42 12 4 46 12 22 
Skin   658 34 57 105 57 60 23 74 24 141 32 51 
Breast  635 20 66 137 75 57 74 10 101 3 41 51 
Female organs  252 6 18 59 37 21 10 52 7 0 21 21 
Prostate  986 45 128 242 158 123 108 2 0 2 116 62 
Urinary tract  465 17 41 54 81 39 27 19 9 131 25 22 
All lymphoma 229 8 13 36 24 38 26 22 5 26 11 20 
Others 240 9 26 34 28 21 25 25 7 31 17 17 
All sites 5339 261 563 848 761 518 462 310 186 694 394 342 
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4.4.2 SPCs at any site 
For the whole study period, the SIR of any SPC was 1.06 (95%CI 1.03-1.09) and AER was 
8.7/10,000 person-years. The SIRs increased from 0.98 (95%CI, 0.90-1.07) with a first 
cancer diagnosis in 1980-1984 to 1.12 (95%CI, 1.05-1.20) in 2005-2009 (Table 4.3).  
We did a sensitivity analysis to examine the effect of including SPCs occurring within two 
months of a first cancer diagnosis and of excluding SPCs within four months of a first cancer 
diagnosis on SIRs by 5-year calendar periods. Both the overall SIRs and the time patterns 
were similar to the main results when SPCs in the first 2 months were excluded. The overall 
SIR was 1.08 (95%CI 1.05-1.10) for all SPCs and 1.05 (95%CI 1.02-1.08) when we excluded 
SPCs occurring within 4 months. The SIRs increased from 0.98 (95%CI 0.90-1.07) in 1980-
1984 to 1.20 (95%CI 1.13-1.28) in 2005-2009 with all SPCs included. The SIRs increased 
from 0.98 (95%CI 0.90-1.07) in 1980-1984 to 1.11 (95%CI 1.04-1.19) in 2005-2009 when 
excluding SPCs within 4 months.  
There was a significantly increasing temporal trend in the SIRs for any SPC, with 
adjustments for patient sex, age at first diagnosis, follow-up interval and first cancer type 
(adjusted Ptrend < 0.001) (Figure 4.1). We checked the trends across single calendar years and 
found a significant increasing trend in SPC risk in the multivariable Poisson model (Ptrend < 
0.001). We also assessed potential non-linear associations in the model. The goodness of fit 
did not significantly improve after adding a quadratic term for single-year to the model 
(likelihood-ratio test, P = 0.6826), therefore suggesting a linear trend across single-year 
periods. The multivariable Poisson models revealed that age at first cancer diagnosis, period 
of first diagnosis, and first cancer type were independently associated with the risk of any 
SPC (all P values < 0.05) (Table 4.4). To reduce the risk of residual confounding due to 
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different follow-up intervals, we assessed the pattern of risk over time after restricting the 
follow up interval for all cases to a maximum of 9 years. The same patterns were apparent for 
SIRs by period of first cancer diagnosis and in the multivariable Poisson model adjusting for 
sex, age at first cancer diagnosis and first cancer types. 
Analysis by specific first cancer types revealed various changes in SPC risk over time (Table 
4.5). The SIRs for all SPCs were highest for individuals with a first cancer diagnosis of head 
and neck cancer in 2005-2009 and the trend in SIRs increased over time (Ptrend = 0.040). The 
trends in SIRs for any SPC also increased over time for individuals with a first diagnosis of 
skin cancer, prostate cancer and cancers of the urinary tract (all Ptrend < 0.05).  
4.4.3 SPCs at specific sites 
For individuals with a first diagnosis of any cancer type, the SIRs for a second cancer of the 
digestive tract including colorectal cancer, were significantly elevated in more recent periods 
compared to earlier periods (all Ptrend < 0.05) (Table 4.6). The SIRs for prostate cancer after 
any first cancer tended to decline over time. However, after adjustment for age at first 
diagnosis, follow-up interval and first cancer type, the risk of prostate cancer as a SPC 
increased significantly over time (adjusted Ptrend = 0.013) (Figure 4.1). Individuals with any 
first cancer diagnosis in recent periods were also more likely to have a SPC diagnosis of head 
and neck cancer, digestive cancer (including colorectal cancer) and lung cancer compared to 
earlier periods after adjusting for sex, age at first diagnosis, follow-up interval and first 
cancer type (all adjusted Ptrend < 0.05) (Figure 4.1). 
Table 4.7 shows SIR and AER estimates for SPCs following a first cancer diagnosis in 1980-
1989, 1990-1999 and 2000-2009 for specific first cancer and SPC types where the observed 
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number of relevant SPCs was at least 50 and AER value for at least one of the three periods 
was more than 5 cases per 10,000 PYR. For individuals with a first diagnosis of head and 
neck cancer, lung cancer accounted for the largest AER in both the earlier and more recent 
periods but AERs for prostate cancer showed the greatest increase in AERs from 1980-1989 
to 2000-2009 (AERs increased from -7.1/10,000 PYR to 15.0/10,000 PYR). Both the SIRs 
and AERs for SPCs of the head and neck continued to increase from 1980 to 2009 among 
survivors of first head and neck cancer. For survivors of first cancers of the urinary tract, 
prostate cancer contributed most to SPC burden in 2000-2009 with a striking increase in 
relevant AERs (from 0.5/10,000 PYR in 1980-1989 to 54.8/10,000 PYR in 2000-2009). 
Prostate cancer was also responsible for the greatest SPC burden among survivors of skin 
cancer in 2000-2009 (AER, 15.0/10,000 PYR). Colorectal cancer contributed most to the 
SPC burden in 2000-2009 among survivors of first cancers of female reproductive organs. 
However, there was a decrease in the relevant AERs from 1980-1989 (8.5/10,000 PYR) to 
1990-1999 (3.8/10,000 PYR) before an increase to 2000-2009 (AER, 18.3/10,000 PYR). For 
colorectal cancer survivors, the SPC that demonstrated the greatest increase in AERs was 
skin cancer, the AERs increased from 1.2/10,000 PYR in 1980-1989 to 12.5/10,000 PYR in 
2000-2009.
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Table 4.3: Temporal trends of standardized incidence ratios (SIRs) for all second primary cancers in Tasmania, 1980-2009. 
Calendar periods of 
first cancer diagnosis 




Observed  Second 
Primary Cancers 




1980-2009 51,802 347,830 5,339 5,036 1.06 (1.03 to 1.09) 
1980-1984 5,252 41,245 513 521 0.98 (0.90 to 1.07) 
1985-1989 6,241 50,517 707 677 1.04 (0.97 to 1.12) 
1990-1994 8,370 67,350 1,009 1025 0.98 (0.93 to 1.05) 
1995-1999 9,429 71,361 1,119 1057 1.06 (1.00 to 1.12) 
2000-2004 10,176 63,504 1,078 941 1.15 (1.08 to 1.22) 
2005-2009 12,334 53,853 913 815 1.12 (1.05 to 1.20) 
*P trend     <0.001 
*P-value was derived from multivariable Poisson regression models with adjustment for sex (not for female organs and prostate), age at first cancer diagnosis, follow-up 
intervals and first cancer types. Bold numbers indicated statistically significance.
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Figure 4.1: Ratio of SIRs for all SPCs and specific SPC types after any first cancer by 
calendar periods of first cancer diagnosis. 
P-values were derived from multivariable Poisson regression models with adjustment on sex (not for female 
organs and prostate), age at first cancer diagnosis, follow-up intervals and first cancer types. *For digestive 
cancers, colorectal cancers were excluded.
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Table 4.4: Multivariable Poisson regression for Ratio of SIRs for all SPCs and specific SPC types 
 All Head and neck Digestive, except colorectal Colorectal Lung 
Haematological and 
lymphoma 
 Adjusted SIRs (95%CI) Adjusted SIRs (95%CI) Adjusted SIRs (95%CI) Adjusted SIRs (95%CI) Adjusted SIRs (95%CI) Adjusted SIRs (95%CI) 
Sex        
Male  1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
Female  0.99 (0.92-1.06) 1.24 (0.87-1.76) 1.06 (0.85-1.33) 1.06 (0.87-1.29) 1.14 (0.93-1.39) 1.11 (0.81-1.34) 
P heterogeneity 0.762 0.245 0.590 0.576 0.224 0.362 
Age at first cancer diagnosis, y      
15-49 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
50-64 0.96 (0.87-1.05) 0.95 (0.63-1.41) 0.70 (0.50-0.98) 0.75 (0.58-0.96) 0.79 (0.60-1.05) 1.00 (0.72-1.40) 
65-84 0.93 (0.84-1.02) 0.89 (0.59-1.35) 0.59 (0.42-0.83) 0.73 (0.57-0.95) 0.67 (0.50-0.90) 0.96 (0.69-1.34) 
85+ 0.71 (0.58-0.86) 1.00 (0.43-2.33) 0.51 (0.30-0.88) 0.78 (0.51-1.22) 0.31 (0.15-0.64) 0.86 (0.48-1.54) 
P trend 0.012 0.633 0.002 0.054 <0.001 0.649 
Period of first cancer diagnosis      
1980-1984 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
1985-1989 1.08 (0.97-1.21) 1.24 (0.73-2.14) 1.32 (0.92-1.89) 1.11 (0.83-1.49) 1.00 (0.75-1.33) 1.14 (0.80-1.63) 
1990-1994 1.09 (0.98-1.21) 1.52 (0.92-2.51) 1.42 (1.01-1.99) 1.06 (0.80-1.40) 1.01 (0.77-1.33) 0.91 (0.65-1.29) 
1995-1999 1.20 (1.08-1.34) 1.63 (0.99-2.69) 1.37 (0.97-1.93) 1.30 (1.00-1.71) 1.36 (1.04-1.77) 0.91 (0.64-1.28) 
2000-2004 1.32 (1.19-1.48) 1.58 (0.93-2.67) 1.80 (1.28-2.54) 1.33 (1.00-1.76) 1.16 (0.87-1.55) 1.10 (0.78-1.57) 
2005-2009 1.34 (1.20-1.51) 2.28 (1.34-3.88) 1.38 (0.95-1.99) 1.38 (1.03-1.85) 1.56 (1.17-2.09) 1.42 (0.99-2.03) 
P trend <0.001 0.002 0.022 0.006 <0.001 0.085 
Maximum follow-up      
2 – 11 months 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
1 – 4 y 0.97 (0.88-1.06) 1.59 (0.98-2.59) 1.05 (0.79-1.39) 1.01 (0.79-1.29) 1.04 (0.80-1.34) 1.17 (0.85-1.61) 
5 – 9 y 0.99 (0.89-1.09) 1.98 (1.19-3.27) 1.03 (0.76-1.39) 1.01 (0.78-1.31) 1.16 (0.89-1.51) 1.24 (0.89-1.74) 
≥10 y 1.05 (0.94-1.16) 1.90 (1.10-3.26) 0.82 (0.59-1.14) 1.10 (0.84-1.44) 1.04 (0.78-1.39) 1.28 (0.89-1.83) 








Type of first cancer       
Head and neck  1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
Digestive, except 
colorectal 0.74 (0.61-0.89) 0.23 (0.09-0.58) 1.15 (0.71-1.89) 0.72 (0.39-1.31) 0.47 (0.29-0.75) 0.46 (0.19-1.10) 
Colorectal  0.65 (0.58-0.73) 0.20 (0.12-0.31) 0.64 (0.45-0.91) 0.54 (0.37-0.78) 0.40 (0.31-0.52) 0.62 (0.40-0.96) 
Lung and Thymus  0.63 (0.53-0.76) 0.64 (0.37-1.10) 1.09 (0.68-1.74) 0.86 (0.51-1.47) 0.13 (0.07-0.28) 1.04 (0.57-1.90) 
Haematological systems  1.02 (0.88-1.19) 0.31 (0.16-0.61) 0.76 (0.46-1.25) 0.99 (0.62-1.59) 0.55 (0.38-0.81) 2.48 (1.58-3.90) 
Skin   0.69 (0.61-0.78) 0.29 (0.19-0.44) 0.58 (0.40-0.86) 1.08 (0.76-1.54) 0.27 (0.19-0.37) 0.91 (0.59-1.40) 
Breast  0.58 (0.51-0.66) 0.20 (0.11-0.36) 0.58 (0.38-0.86) 1.05 (0.73-1.52) 0.31 (0.22-0.43) 0.68 (0.43-1.09) 
Female organs  0.72 (0.61-0.85) 0.19 (0.08-0.47) 0.50 (0.29-0.89) 1.41 (0.93-2.13) 0.48 (0.32-0.72) 0.75 (0.42-1.34) 
Prostate  0.47 (0.42-0.53) 0.18 (0.12-0.27) 0.60 (0.43-0.84) 1.28 (0.93-1.77) 0.31 (0.24-0.40) 0.95 (0.64-1.41) 
Urinary tract  0.79 (0.69-0.90) 0.24 (0.14-0.41) 0.65 (0.43-0.99) 0.93 (0.63-1.38) 0.57 (0.43-0.75) 0.97 (0.61-1.55) 
All lymphoma 0.89 (0.76-1.05) 0.25 (0.12-0.52) 0.48 (0.26-0.89) 1.37 (0.89-2.13) 0.40 (0.26-0.62) 2.11 (1.32-3.39) 
Others  0.76 (0.65-0.89) 0.21 (0.10-0.43) 0.82 (0.51-1.32) 1.09 (0.70-1.71) 0.40 (0.26-0.61) 0.97 (0.56-1.69) 
P heterogeneity <0.001 <0.001 0.006 <0.001 <0.001 <0.001 
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Table 4.5: Standardized incidence ratios (SIRs) for specific first cancer types by calendar year of first cancer diagnosis, 1980-2013 
 
P values for trends in SIRs were derived from univariable Poisson regression models. Bold numbers indicated statistically significance. 
 
 
  Calendar year of first cancer diagnosis, y 


























(95% CI) AER 
 P-trend 
in SIR 
Head and neck  68 1.46 74.2  77 1.50 77.6  85 1.40 66.3  94 1.59 89.3  90 1.83 122.1  59 1.91 124.9  0.040 




 14 1.18 26.3  13 0.79 -33.0  25 1.05 8.7  33 1.53 88.4  32 1.39 62.7  24 1.04 7.3  0.443 
  (0.70 to 1.99)    (0.46 to 1.35)    (0.71 to 1.55)    (1.09 to 2.16)    (0.98 to 1.96)    (0.70 to 1.56)    
Colorectal  86 0.84 -25.9  127 1.02 3.9  154 0.96 -6.9  181 1.13 23.5  155 1.12 21.1  124 1.04 7.2  0.057 
   (0.68 to 1.04)    (0.86 to 1.22)    (0.82 to 1.13)    (0.98 to 1.31)    (0.96 to 1.31)    (0.88 to 1.24)    
Lung  13 0.87 -18.5  20 0.88 -18.4  34 1.01 2.4  26 0.99 -1.4  28 0.98 -3.6  30 1.27 45.8  0.219 
   (0.50 to 1.49)    (0.57 to 1.36)    (0.72 to 1.42)    (0.68 to 1.46)    (0.68 to 1.42)    (0.89 to 1.82)    
Haematological  19 1.43 57.9  45 1.81 128.2  48 1.50 87.8  45 1.62 93.1  53 1.34 55.2  72 2.08 166.2  0.383 
   (0.91 to 2.25)    (1.35 to 2.42)    (1.13 to 1.99)    (1.21 to 2.17)    (1.02 to 1.75)    (1.65 to 2.62)    
Lymphoma  29 1.46 45.0  43 1.73 74.5  38 1.23 25.0  48 1.51 9.1  44 1.54 10.1  27 1.19 23.9  0.465 
   (1.01 to 2.09)    (1.28 to 2.33)    (0.89 to 1.69)    (1.14 to 2.01)    (1.14 to 2.06)    (0.81 to 1.73)    
skin  49 0.90 -9.5  82 0.95 -5.1  114 0.96 -4.0  139 1.11 12.4  156 1.37 42.8  118 1.37 44.8  <0.001 
   (0.68 to 1.19)    (0.76 to 1.18)    (0.80 to 1.16)    (0.94 to 1.31)    (1.17 to 1.61)    (1.15 to 1.64)    
Breast  62 0.85 -15.3  91 0.88 -13.0  136 0.97 -3.5  136 0.96 -3.8  131 0.97 -3.4  79 0.95 -5.3  0.393 
   (0.66 to 1.09)    (0.72 to 1.08)    (0.82 to 1.14)    (0.81 to 1.14)    (0.82 to 1.15)    (0.76 to 1.18)    
Female organs  54 1.09 8.5  46 1.04 3.8  56 1.31 30.2  33 0.87 -12.1  33 1.18 17.8  30 1.48 47.6  0.390 
   (0.83 to 1.42)    (0.78 to 1.39)    (1.01 to 1.71)    (0.61 to 1.22)    (0.84 to 1.67)    (1.03 to 2.11)    
Prostate  36 0.69 -75.7  54 0.64 -103.2  181 0.70 -84.7  252 0.80 -49.5  220 0.80 -48.0  243 0.81 -38.8  0.039 
   (0.50 to 0.96)    (0.49 to 0.83)    (0.60 to 0.80)    (0.71 to 0.91)    (0.70 to 0.92)    (0.72 to 0.92)    
Urinary tract  46 0.89 -18.1  73 1.14 25.3  96 1.13 24.7  15 1.30 52.7  78 1.54 88.8  79 1.56 94.2  <0.001 
   (0.67 to 1.19)    (0.91 to 1.43)    (0.92 to 1.38)    (1.06 to 1.59)    (1.23 to 1.92)    (1.25 to 1.95)    
Other  37 1.19 15.9  36 1.22 19.7  42 1.15 12.2  39 0.93 -6.2  58 1.81 68.4  28 1.24 20.8  0.276 
   (0.86 to 1.64)    (0.88 to 1.70)    (0.85 to 1.55)    (0.68 to 1.27)    (1.40 to 2.34)    (0.85 to 1.79)    
Total  513 0.98 -2.0  707     1.04 6.0  1009 0.98 -2.3  1119 1.06 8.7  1078 1.15 21.6  27 1.12 18.2  0.001 
   (0.90 to 1.07)    (0.97 to 1.12)    (0.93 to 1.05)    (1.00 to 1.12)    (1.08 to 1.22)    (1.05 to 1.20)    
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Table 4.6: Standardized incidence ratios (SIRs) for specific second cancer types by calendar year of first cancer diagnosis, 1980-2013. 
P values for trends in SIRs were derived from univariable Poisson regression models. Bold numbers indicated statistically significance. 
 
  Calendar year of first cancer diagnosis, y   


























(95% CI) AER  
P-trend 
in SIR 
Head and neck  22 1.05 0.2  33 1.27 1.4  54 1.37 2.2  56 1.42 2.3  45 1.35 1.8  51 1.63 3.7  0.104 




 48 0.96 -0.5  75 1.24 2.9  112 1.29 3.8  109 1.24 2.9  130 1.70 8.4  89 1.30 3.8  0.016 
  (0.72 to 1.27)    (0.99 to 1.56)    (1.07 to 1.55)    (1.03 to 1.49)    (1.43 to 2.02)    (1.05 to 1.59)    
Colorectal  79 0.94 -1.3  107 1.02 0.4  148 0.97 -0.7  191 1.19 4.3  168 1.19 4.2  155 1.22 5.2  0.008 
   (0.75 to 1.17)    (0.84 to 1.23)    (0.83 to 1.14)    (1.03 to 1.37)    (1.02 to 1.38)    (1.04 to 1.43)    
Lung  86 1.28 4.5  99 1.20 3.3  135 1.10 1.9  181 1.43 7.6  127 1.19 3.2  133 1.50 8.2  0.138 
   (1.03 to 1.58)    (0.99 to 1.47)    (0.93 to 1.30)    (1.23 to 1.65)    (1.00 to 1.42)    (1.26 to 1.77)    
Haematological 
and lymphoma 
 52 1.27 2.7  78 1.47 5.0  89 1.15 1.8  93 1.13 1.5  101 1.39 4.4  105 1.74 8.3  0.090 
  (0.97 to 1.67)    (1.18 to 1.84)    (0.94 to 1.42)    (0.93 to 1.39)    (1.14 to 1.68)    (1.44 to 2.11)    
skin  30 0.97 -0.2  53 1.17 1.5  88 1.19 2.1  89 1.04 0.5  109 1.36 4.5  93 1.30 3.9  0.121 
   (0.68 to 1.39)    (0.89 to 1.53)    (0.97 to 1.47)    (0.84 to 1.28)    (1.13 to 1.64)    (1.06 to 1.59)    
Breast  36 0.65 -4.8  45 0.63 -5.2  61 0.67 -4.4  70 0.75 -3.3  58 0.69 -4.1  40 0.67 -3.7  0.648 
   (0.47 to 0.90)    (0.47 to 0.84)    (0.52 to 0.87)    (0.59 to 0.95)    (0.53 to 0.89)    (0.49 to 0.91)    
Female organs  29 1.23 1.3  29 1.03 0.2  37 1.16 0.8  38 1.23 1.0  38 1.37 1.6  15 0.75 -0.9  0.671 
   (0.85 to 1.77)    (0.72 to 1.49)    (0.84 to 1.60)    (0.90 to 1.70)    (1.00 to 1.89)    (0.45 to 1.24)    
Prostate  60 0.82 -3.3  89 0.80 -4.4  138 0.64 -11.6  124 0.57 -13.1  161 0.78 -7.1  122 0.63 -13.2  0.256 
   (0.63 to 1.05)    (0.65 to 0.98)    (0.54 to 0.75)    (0.48 to 0.68)    (0.67 to 0.91)    (0.53 to 0.75)    
Urinary tract  39 1.19 1.5  47 1.10 0.9  78 1.23 2.2  90 1.40 3.6  80 1.41 3.6  60 1.23 2.1  0.341 
   (0.87 to 1.63)    (0.83 to 1.47)    (0.98 to 1.53)    (1.14 to 1.72)    (1.13 to 1.75)    (0.96 to 1.59)    
Other  32 0.78 -2.2  52 1.02 0.2  69 0.97 -0.3  78 1.14 1.3  61 1.10 0.9  50 1.10 0.9  0.106 
   (0.55 to 1.10)    (0.77 to 1.33)    (0.77 to 1.23)    (0.91 to 1.42)    (0.86 to 1.41)    (0.84 to 1.45)    
Total  513 0.98 -2.0  707     1.04 6.0  1009 0.98 -2.3  1119 1.06 8.7  1078 1.15 21.6  27 1.12 18.2  0.001 
   (0.90 to 1.07)    (0.97 to 1.12)    (0.93 to 1.05)    (1.00 to 1.12)    (1.08 to 1.22)    (1.05 to 1.20)    
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Table 4.7: Standardized incidence ratios (SIRs) and absolute excess risks (AERs) for selected second cancer types, by first cancer types 
and periods of first cancer diagnosis, 1980-1989, 1990-1999 and 2000-2009. 
Bold numbers indicated statistically significance. 
   Calendar periods of first cancer diagnosis 
   1980-1989  1990-1999  2000-2009 
First cancer sites Second cancer sites  No. Obs 
Person-








Years SIR (95%CI) AER 
Head and neck  Head and neck  16 6174 3.31 (2.03 to 5.40) 18.1  25 7612 4.70 (3.17 to 6.95) 25.9  21 5,581 6.12 (3.99 to 9.39) 31.5 
 Digestive, except colorectal  19  2.11 (1.35 to 3.31) 16.2  14  1.40 (0.83 to 2.36) 5.2  17  2.53 (1.57 to 4.07) 18.4 
 Lung   38  2.67 (1.95 to 3.68) 38.5  45  3.04 (2.27 to 4.07) 39.7  33  3.81 (2.71 to 5.36) 43.6 
 Prostate  19  0.81 (0.52 to 1.27) -7.1  27  0.88 (0.60 to 1.28) -4.8  30  1.39 (0.97 to 1.98) 15.0 
Colorectal Digestive, except colorectal  22 13733 0.99 (0.65 to 1.50) -0.2  40 18214 1.40 (1.03 to 1.91) 6.2  28 15,282 1.25 (0.86 to 1.81) 3.6 
 Lung   34  1.16 (0.83 to 1.63) 3.5  54  1.40 (1.07 to 1.82) 8.4  33  1.13 (0.80 to 1.58) 2.4 
 skin   15  1.12 (0.68 to 1.86) 1.2  24  1.02 (0.68 to 1.52) 0.2  41  1.88 (1.38 to 2.55) 12.5 
 Prostate   39  1.02 (0.75 to 1.40) 0.5  81  1.26 (1.01 to 1.56) 9.1  62  1.15 (0.90 to 1.48) 5.4 
Skin   Digestive, except colorectal  8 14673 0.68 (0.34 to 1.36) -2.5  22 22208 1.13 (0.74 to 1.71) 1.1  27 17,048 1.66 (1.14 to 2.43) 6.3 
 Colorectal   25  1.16 (0.78 to 1.72) 2.3  40  1.12 (0.82 to 1.53) 2.0  40  1.34 (0.98 to 1.82) 5.9 
 Haematological  15  1.37 (0.83 to 2.27) 2.8  17  0.92 (0.57 to 1.48) -0.7  28  1.83 (1.27 to 2.65) 7.5 
 Breast   16  0.81 (0.50 to 1.32) -2.5  27  1.02 (0.70 to 1.49) 0.3  31  1.60 (1.12 to 2.27) 6.8 
 Prostate   24  1.28 (0.86 to 1.91) 3.6  50  1.09 (0.83 to 1.44) 1.9  67  1.62 (1.27 to 2.05) 15.0 
Breast Colorectal  35 16937 1.09 (0.78 to 1.51) 1.7  63 27020 1.31 (1.03 to 1.68) 5.6  39 21,792 1.08 (0.79 to 1.48) 1.4 
 Female organs  30  1.81 (1.26 to 2.58) 7.9  44  1.82 (1.35 to 2.44) 7.3  27  1.43 (0.98 to 2.08) 3.7 
Female organ Colorectal   25 10025 1.52 (1.03 to 2.25) 8.5  17 8661 1.24 (0.77 to 2.00) 3.8  17 4,906 2.12 (1.32 to 3.41) 18.3 
 Breast  13  0.58 (0.33 to 0.99) -9.5  26  1.26 (0.86 to 1.85) 6.2  13  1.02 (0.59 to 1.75) 0.5 
Prostate  Digestive, except colorectal   9 5108 0.69 (0.36 to 1.33) -7.9  56 21701 1.15 (0.89 to 1.50) 3.4  63 25,574 1.30 (1.01 to 1.66) 5.7 
 Colorectal   24  1.34 (0.90 to 1.99) 11.8  98  1.25 (1.02 to 1.52) 8.9  120  1.43 (1.19 to 1.71) 14.1 
 Haematological  15  1.51 (0.91 to 2.51) 10.0  46  1.09 (0.82 to 1.46) 1.8  62  1.49 (1.16 to 1.91) 7.9 
 Urinary   11  0.97 (0.54 to 1.75) -0.7  60  1.44 (1.12 to 1.86) 8.5  45  1.15 (0.86 to 1.54) 2.2 
Urinary tract Colorectal   10 6562 0.57 (0.31 to 1.06) -11.4  23 8400 1.00 (0.66 to 1.50) 0.0  17 6,102 1.35 (0.88 to 2.07) 8.9 
 Lung   26  1.62 (1.10 to 2.38) 15.2  38  1.92 (1.40 to 2.64) 21.7  17  1.49 (0.93 to 2.40) 9.2 
 Prostate   26  1.01 (0.69 to 1.49) 0.5  46  1.13 (0.84 to 1.51) 6.2  59  2.31 (1.79 to 2.98) 54.8 
All sites combined All sites combined  1,220 91,761 1.02 (0.96 to 1.08) 2.4  2,128 138,711 1.02 (0.98 to 1.07) 3.3  1,991 117,358 1.13 (1.09 to 1.18) 20.0 
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4.5 Discussion 
In this population-based study with more than 30 years surveillance, the risk of SPC 
continued to increase beyond 2000 among adult-onset cancer survivors after accounting for 
background cancer occurrence in the general population and patient characteristics (sex, age 
at first cancer diagnosis, follow-up intervals and first cancer types) within the study cohort. In 
particular, the SPC burden due to prostate cancer increased greatly in male survivors of head 
and neck cancer, skin cancer and cancers of the urinary tract. Site-specific time trends in SPC 
risk may reveal changing patterns of medical surveillance after a first cancer diagnosis. 
Several factors need to be considered in interpreting the results. First, some SPCs may be 
misclassified as metastases and vice versa. This issue is inevitable in clinical practice and 
may be more intractable when new cancers arise at the same site and with the same 
morphology as the first cancer. Applying IARC rules helps to partially avoid this issue as 
SPCs that originate in the same site and with the same morphology as the first were excluded. 
As such, using IARC rules resulted in coding fewer SPCs compared to using other coding 
rules (e.g. Surveillance, Epidemiology, and End Results (SEER) rules) for paired organs (e.g. 
breast cancer) and therefore, produced lower SIR values 24. Second, the first cancers 
diagnosed in 1980-1984 might be second or higher-order cancer in a few cases. The TCR was 
established in 1978 but records were not as complete in the first two years. Third, the TCR 
did not record cancer risk factors, treatment data and follow-up procedures making it difficult 
to investigate the factors that might have contributed to the increase in SPC risk over time. 
Fourth, the exclusion of SPCs occurring within two months of a first cancer diagnosis may 
have introduced error but our sensitivity analysis including all SPCs, and excluding SPCs 
occurring within four months, showed similar results. Additionally, there is the possibility 
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that multiple testing of stratified data may increase the likelihood of significant differences by 
chance alone. 
Previous studies have reported substantially elevated risk of SPCs among head and neck 
cancer survivors, with head and neck cancer and lung cancer accounting for the largest SPC 
burden 23, 25. We confirmed these findings in the current study and reported novel findings of 
increasing temporal trends in the risk of head and neck cancer and lung cancer among all 
cancer survivors during 1980-2009. This finding coincided with the gradual increase of head 
and neck and chest CT scanning in Tasmania since 1994, and thus may reflect improving 
detection of SPCs at these sites. In addition, improvement in imaging techniques may have 
allowed better identification of SPCs that were previously thought to be metastases. It is 
important to note that in the current study risks of smoking-related SPCs continued to 
increase and remain high in individuals with a smoking-related first primary cancer. Elevated 
SPC risks in these survivors might be explained by increased smoking prevalence among 
these survivors 26. The decreasing trends of tobacco-related cancer incidence in the general 
Australian population since the 1980s may also contribute to the increase in SIRs. The 
decline in expected tobacco-related cancers (the SIR denominator) would lead to a 
consequent slight increase in relevant SIRs over time 13.  
An important finding was the large increase in AERs for prostate cancer among survivors of 
specific cancer types from 2000 onwards. A recent meta-analysis combining 20 studies 
reported more frequent screening for breast, cervical, colorectal and prostate cancers among 
cancer survivors than non-cancer controls. However, all the evidence came from North 
America and the United Kingdom 11. In Tasmania, Medicare (Australia’s publicly funded 
universal health care system) records showed a dramatic increase in prostate specific antigen 
(PSA) tests between 1994 and 2013, from 3,647/100,000 men to 16,572/100,000 respectively 
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27. Thus our findings of increases in AER for prostate cancer among male survivors of head 
and neck cancer, skin cancer and cancers of the urinary tract may indicate increased 
screening for prostate cancer among these cancer survivors. The benefits of PSA testing 
remain controversial given the potential for overdiagnosis of prostate cancer 28. 
For all cancer survivors, the risk of a SPC of the prostate was lower than expected in the 
general population, probably due to the low risk of a second prostate cancer following radical 
treatment of a first prostate cancer. Prostate cancer survivors accounted for the largest 
proportion of all cancer survivors in our study but we only observed two second prostate 
cancer cases among them. In comparison, there were 419.9 cases expected assuming general 
population incidence rates. After excluding males with a first prostate cancer, the SIR for 
prostate cancer among all cancer survivors was significantly higher (SIR, 1.16; 95%CI, 1.08-
1.25). This finding could also explain the reversal of trend in SIRs for prostate cancer 
following any first cancer in the multivariable regression model. The SIR values were 
decreasing over time, whereas the trend in SIRs was increasing over time after adjusting for 
first cancer types and other patient characteristics including age at first cancer diagnosis and 
follow-up intervals. We performed additional analyses excluding SPCs occurring in the same 
site as the first cancer. The SIRs increased from 1.13 (95%CI, 1.03-1.23) with a first cancer 
diagnosis in 1980-1984 to 1.35 (95%CI, 1.26-1.44) in 2005-2009 (Table 4.8). Although the 
SIR values increased in each period, the time pattern of SIR values and ratio of SIRs in 
multivariable Poisson model were almost identical to our main results. 
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Table 4.8: Temporal trends of standardized incidence ratios (SIRs) for second 
discordant primary cancers (excluding SPCs occurring in the same site as a first cancer) 
in Tasmania, 1980-2009. 
Calendar periods of first 
cancer diagnosis Observed SPCs Expected SPCs 
SIR 
(95%CI) 
1980-1984 512 454 1.13 (1.03 to 1.23) 
1985-1989 695 582 1.19 (1.11 to 1.29) 
1990-1994 997 847 1.18 (1.11 to 1.25) 
1995-1999 1,105 868 1.27 (1.20 to 1.35) 
2000-2004 1,053 766 1.38 (1.29 to 1.46) 
2005-2009 880 653 1.35 (1.26 to 1.44) 
*P trend   <0.001 
*P-value was derived from multivariable Poisson regression models with adjustment for sex (not for female 
organs and prostate), age at first cancer diagnosis, follow-up intervals and first cancer types. Bold numbers 
indicated statistically significance. 
 
The increasing temporal trend in the risk of colorectal SPCs may reflect increased screening 
for colorectal cancer among cancer survivors. There was some evidence that cancer survivors 
were more likely to receive SPC screening if their first cancer was screen-detected 29. The 
PSA-testing, national cervical and bowel cancer screening programs were implemented in 
Australia in 1987, 1991 and 2006 respectively 13. In the current study, colorectal cancer 
accounted for the largest AER of SPC among survivors of first cancers of the female organs 
and prostate during 2000-2009. Intensive screening for colorectal cancer among these cancer 
survivors may be a possible explanation, especially if their first cancers (cervical cancer or 
prostate cancer) were screen-detected. Another possible cause is the increased use of 
abdomen/pelvic CT scan as one of the follow-up procedures for survivors of cancers of the 
female organs. Alternatively, patients may more actively pursue screening given known 
benefits. Additional studies are needed to investigate if variations in the mode of second 
cancer ascertainment explain temporal trends in diagnosis.  
Findings from SEER data and Australian data previously observed increasing trends in the 
overall SPC risks from 1970s and 1980s to 2000 3, 4. A recent study of SEER data reported 
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SPC risk from 1992-2008 but did not assess time patterns and did report SIRs to allow 
comparisons with previous findings 30. One Italian study reported nearly constant SIR values 
in Italy from 1978 to 2010 5. However, they did not report change in SIRs with adjustment 
for patient characteristics (sex, age at first cancer diagnosis, follow-up interval and first 
cancer type). The association between these patient characteristics and the risk of SPCs has 
been identified in recent studies 6, 22. Our study observed an increasing trend in SPC risks 
from 1980-2000 which was consistent with previous findings in the USA and Australia and 
reported novel findings of a continued increasing trend in SPC risks from 2000 onwards in 
multivariable models. The TCR data also has its own advantage due to the relative stable 
population (less out-migration), therefore less underascertainment of SPCs 16. However, there 
were likely to be some SPCs missing from our analysis as a result of migration out of 
Tasmania to other parts of Australia or beyond. An investigation of data held in the 
Australian Cancer Database determined that in our study period the proportion of all 
Tasmanian cancer cases with a subsequent primary cancer registered in another Australian 
state or territory was very small (0.34%, personal communication). 
In summary, the trend in the risk of SPCs among adult-onset cancer survivors has continued 
to increase over the last three decades. While the patterns of increasing risk were generally 
consistent with developments in medical imaging and screening programs for some cancer 
types, the degree to which this explains the increase in SPC risk remains uncertain. The 
increase in prostate SPC burden among survivors of specific cancer types may reflect active 
PSA-testing. Patient anxiety, overestimation of the benefits and underestimation of the 
potential harms of prostate cancer screening could lead to overdiagnosis 12, 28. Further studies 
are needed to quantify potential overdiagnosis of SPC among cancer survivors, and thus to 
assess whether there is potential for optimizing follow-up strategies. 
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Chapter 5: Temporal trends in competing mortality from 
second and subsequent primary cancers, 1980-2014: An 
Australian population-based study 
5.1 Abstract 
Background: Subsequent primary cancers (SPCs) compete with first cancers and non-cancer 
events as the primary cause of death among cancer patients. We aimed to assess temporal 
trends in SPC mortality since 1980 among adult-onset cancer patients in competing risk 
models. 
Methods: Patients registered with a first cancer in the population-based Tasmanian Cancer 
Registry, Australia, between 1980-2009 were followed up to December 2014. Cumulative 
incidence function (CIF) was used to estimate the cumulative incidence of cause-specific 
deaths in the presence of competing risks. The hazard ratios of SPC-specific deaths were 
assessed in two regression models: subdistribution hazard ratios from competing risk models 
(SHRs) and hazard ratios from Cox models (CHRs).    
Results: Overall, 5,339 (9.3%) of 57,288 patients developed SPCs and 2,494 died from SPCs 
during the follow-up. While the cumulative incidence of first cancer deaths at 5, 10, 15 and 
20-years gradually decreased over periods of first cancer diagnosis, the cumulative incidence 
of SPC deaths did not. The SHRs for SPC-specific deaths increased from the reference period 
1980-1984 to a peak for first cancers diagnosed in 1995-1999 (SHR=1.18, 95%CI 1.03-1.35), 
before a decrease in 2005-2009 (SHR=0.82, 95%CI 0.70-0.95) in competing risk models. 
However, this pattern was not consistent in CHRs. For individuals with specific first cancers, 
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those with a first prostate cancer in 1995-1999 had the greatest SPC mortality risk 
(SHR=2.08, 95%CI 1.29-3.36). 
Conclusion: Competing risk models, but not Cox models, demonstrated temporal increases 
in SPC-specific mortality. Greater detection of non-fatal first prostate cancers appears to have 












Chapter 5: Temporal trends in competing mortality from second and subsequent primary 
cancers, 1980-2014: An Australian population-based study 
131 
5.2 Introduction  
Survival for most cancers increased steadily on a global scale from 1995 to 2009 1. In 
Australia, the 5-year relative survival for all cancers increased from 47% in 1982-1987 to 
66% in 2006-2010 2. For some patients, improved survival after a first cancer diagnosis is 
offset by risk of death from competing events (i.e. competing mortality) 3. Events that 
contribute to competing mortality among cancer patients include those relating to 
cardiovascular or respiratory complications of cancer treatment, as well as unrelated diseases 
4. Cancer patients are also at risk of competing mortality from subsequent primary cancers 
(SPCs) 4, 5.  
Previous studies have reported risks of SPCs in cancer patients that are greater than expected 
in the general population 6, as well as a rising incidence of SPCs since 1980 7-9. SPCs 
compete with first cancers and non-cancer events as the cause of death in cancer patients. 
Although SPCs now occur more frequently, studies of first cancer and SPC-specific mortality 
in the presence of competing risks are limited in Australia as well as in other parts of the 
world 10, 11. 
Traditional approaches have mostly used the Kaplan-Meier method and Cox proportional 
hazards models to take into account the time elapsed from onset of first cancer to cause-
specific death. However, their consideration of deaths from causes other than the primary 
interest as ‘independent censoring’ is biased: a cancer patient who dies from another cause 
cannot reach the endpoint of interest 3, 12. The presence of competing events precludes the 
observation of the endpoint of interest and alters the hazard of its occurrence 13.  
 
Chapter 5: Temporal trends in competing mortality from second and subsequent primary 
cancers, 1980-2014: An Australian population-based study 
132 
Recent studies have emphasised the importance of using competing risk models to estimate 
cause-specific mortality in studies of cancer, cardiovascular disease and diabetes 3, 11, 13-15. 
However, for cancer studies, the focus has generally been on mortality following cancers of 
specific types and with less than 15 years’ surveillance limiting the ability to assess time 
patterns for competing mortality from SPCs. While our recent study observed an increasing 
trend in the risk of developing SPCs from 1980-2009, the potential competing mortality from 
these SPCs was unknown 9. In the current study, we aimed to assess temporal trends in SPC 
mortality since 1980 among all adult-onset cancer patients, and patients with specific cancer 
types, in competing risk models.   
5.3 Methods   
5.3.1 Study population 
We extracted individual data from the population-based Tasmanian Cancer Registry (TCR) in 
Australia. Individuals registered with a first cancer diagnosis at age 15 years or older between 
1980 and 2009 were followed up to December 2014. The study was approved by the 
Tasmanian Health and Medical Human Research Ethics Committee. 
5.3.2 Ascertainment of SPC and deaths 
The TCR collected information on new cancer cases and deaths from multiple sources 
including pathology laboratories, public and private hospitals, radiotherapy centres, and the 
state’s Registrar of Births, Deaths and Marriages. Other state and territory cancer registries 
routinely notified the TCR of cancer-related deaths occurring outside Tasmania. The TCR 
coders reviewed death registrations of Tasmanian residents and for causes of death related to 
a notifiable cancer, coded them using the International Classification of Disease for 
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Oncology, Third Edition (ICD-O3) for site and morphology. Deaths from other causes were 
recorded and defined as non-cancer causes. Ascertainment of SPCs followed the International 
Rules for Multiple Primary Cancers (ICD-O Third Edition). Individuals with a first diagnosis 
of synchronous primary cancer (cancers diagnosed within 2 months of the first index cancer) 
were excluded because SPCs in this time frame are more likely to be ascertained as a result of 
detection bias. Cause-specific deaths were then allocated to three categories: 
• Death caused by the first cancer (progression, recurrence or metastasis); 
• Death caused by a SPC; 
• Non-cancer death.  
Cancer cases registered solely on the basis of death certificate notification (diagnosis of 
cancer at date of death or autopsy) were excluded from the analysis. 
5.3.3 Measures of Outcomes 
The absolute measure was the cumulative incidence of cause-specific deaths. The relative 
measure was the hazard ratio of cause-specific deaths. 
5.3.4 Statistical analysis 
5.3.4.1 Cumulative incidence of cause-specific deaths 
Cumulative incidence function (CIF) was used as an alternative to Kaplan-Meier estimates 
for the cumulative incidence of cause-specific deaths in the presence of competing risks. 
Kaplan-Meier analysis tends to overestimate cause-specific mortality in cohorts with high 
competing risks 3. To illustrate this effect we calculated both Kaplan-Meier estimates and CIF 
for cumulative incidence of cause-specific deaths (Table 5.3).  
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5.3.4.2 Mortality risk 
The hazard ratios of cause-specific deaths were assessed in two regression models: 
subdistribution hazard ratios from competing risk models (SHRs) and hazard ratios from Cox 
models (CHRs). The SHRs evaluate the effect of patient characteristics on cause-specific 
deaths in the presence of competing risks. When one cause of death is the primary endpoint 
of interest, patients who die from other causes are still maintained in the risk set. For CHRs 
of cause-specific deaths, patients who died from causes other than the primary interest are 
treated as censored events. It is important to note that CHRs describe the effect of covariates 
on the rate at which events occur in subjects who are currently event-free and SHRs describe 
the effect of covariates on the rate at which events occur in subjects who are currently event-
free or have experienced a competing event 16. Multivariable models were fitted for the SHRs 
and CHRs by periods of first cancer diagnosis, adjusting for potential confounders: sex (not 
for prostate cancer and female breast cancer) and age at first cancer diagnosis. Model 
diagnostics of plots of Schoenfeld residuals support the assumption of proportional hazard 
subdistribution in competing risk models and proportional hazards in Cox regression models 
17, 18. Compared to the CHR it is possible that the SHR will be disproportionally affected by 
the length of follow-up (since subjects do not leave the risk set upon experiencing a 
competing event), so additional analyses are provided to assess the patterns over decades with 
follow up time restricted to 5 years. 
Subgroup analyses in the cumulative incidence and hazard ratios of cause-specific deaths 
were conducted for the four most common specific first cancers, and for the first cancer with 
the highest proportion of SPCs. We also conducted a sensitivity analysis of the trends for all 
cancers combined after excluding specific cancer patients who presented the highest SPC 
mortality risk. R project for statistical computing (version 3.3.2, package ‘cmprsk’ and 
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‘survival’) were used. A two-sided P value less than 0.05 was considered as denoting 
statistical significance. 
5.4 Results 
57,288 individuals were registered with a first primary cancer between January 1980 and 
December 2009, generating 392,688 person-years at risk at the end of follow-up (December 
2014). Median follow-up of the entire cohort was 4.8 years (IQR 0.8-10.5). 5,339 individuals 
(9.3% of the total sample) developed SPCs. 39,976 (69.8%) individuals died during the 
follow-up, including 27,140 who died from their first cancer, 2,494 from SPCs and 10,164 
from non-cancer causes. The proportion of first cancer deaths gradually decreased with a 
steady increase in the proportion of SPC deaths and non-cancer deaths from 1980 to 2009 
(Figure 5.1). The median age at first cancer diagnosis was 67.0 years (IQR 56.5-75.7). The 
four most common first cancers in our cohort were colorectal cancer, prostate cancer, female 
breast cancer and lung cancer. Individuals with a first diagnosis of head and neck cancer had 
the highest proportion of SPCs (18.3% affected). Therefore, subgroup analyses in the 
cumulative incidence and hazard ratios of cause-specific deaths were conducted for 
individuals with a first diagnosis of head and neck cancer, lung cancer, colorectal cancer, 
female breast cancer and prostate cancer. Table 5.1 shows patient characteristics for those 
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 All causes  First primary  SPC  Non-cancer  unknown 
 No. (%)  No. (%)  No. (%)  No. (%)  No. (%) 
All types 57,288 5,339 67.0 (56.5-75.7) 4.8 (0.8-10.5)  39,976 (100)  27,140 (67.9)  2,494 (6.2)  10,164 (25.4)  178 (0.5) 
Head and neck 2,588 473 63.2 (53.7-72.1) 6.7 (2.0-13.1)  1,752 (100)  802 (45.8)  258 (14.7)  684 (39.0)  8 (0.5) 
Lung 6,439 151 68.7 (60.9-75.7) 0.5 (0.2-1.4)  6,257 (100)  5,647 (90.2)  54 (0.9)  552 (8.8)  4 (0.1) 
Colorectal 8,246 827 69.1 (60.4-77.4) 3.9 (1.0-9.7)  6,167 (100)  4,093 (66.3)  368 (6.0)  1,682 (27.3)  24 (0.4) 
Female breast 6,876 625 59.7 (49.3-70.5) 9.2 (5.2-14.9)  3,461 (100)  1,979 (57.2)  289 (8.3)  1,166 (33.7)  27 (0.8) 
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5.4.1 Cumulative incidence of cause-specific deaths 
Overall, the 5-year cumulative incidences of first cancer deaths, SPC deaths and non-cancer 
deaths were 41.2% (95%CI 40.8-41.6), 1.4% (95%CI 1.3-1.5) and 8.2% (95%CI 7.9-8.4), 
respectively for individuals with any first cancer diagnosis from 1980-2009 (Figure 5.2). 
With longer follow-up, the cumulative incidence of first cancer deaths began to plateau while 
the cumulative incidence of non-cancer and SPC deaths tended to rise steadily (almost 
linearly). Non-cancer deaths became the leading cause of death at 25 years since first head 
and neck cancer diagnosis, or at 10 years since first prostate cancer diagnosis.  
For individuals with any first cancer type, there was a gradual decrease in the cumulative 
incidence of first cancer deaths over periods of first cancer diagnoses (Table 5.2). The 5-year 
cumulative incidence of first cancer deaths decreased from 57.2% (95%CI 55.9-58.4) for 
cancers diagnosed in 1980-1984 to 30.3% (95%CI 29.6-31.1) in 2005-2009. In contrast, the 
5-year cumulative incidence of SPC deaths increased from 1.0% (95%CI 0.8-1.3) for 
individuals with a first cancer diagnosis in 1980-1984 to a peak of 1.7% (95%CI 1.4-1.9) in 
1995-1999, before decreasing to 1.5% (95%CI 1.3-1.7) in 2005-2009. For non-cancer causes, 
the 5-year cumulative mortality increased from 7.5% (95%CI 6.8-8.1) in 1980-1984 to 9.3% 
(95%CI 8.7-9.9) in 1990-1994, and then decreased to 7.1%CI (95%CI 6.7-7.6) in 2005-2009. 
The Kaplan-Meier method overestimated the cumulative incidence of cause-specific deaths at 
each time interval since first cancer diagnosis (Table 5.3). 
For individuals with specific first cancer types, the 5-year cumulative incidence of first 
cancer deaths steadily decreased from 1980-1984 to 2005-2009 if the first cancer was head 
and neck, colorectal, female breast or prostate cancer. The cumulative incidence of first 
cancer deaths remained high across all periods for lung cancer patients. The cumulative 
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incidence of SPC deaths increased from 1980-1984 to 1995-1999 but fell afterwards for 
individuals with a first colorectal or prostate cancer. Trends in cumulative incidence of SPC 
deaths fluctuated over time after a first cancer of the head and neck or female breast. For non-
cancer causes, decreasing trends in cumulative mortality were observed only in prostate 
cancer patients and only for 5 years and 10 years after first diagnosis.
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Table 5.2: Cumulative incidence of cause-specific deaths (%) at 5-, 10-, 15- and 20-years after first cancer diagnosis, by periods of first 
cancer diagnosis, with follow-up to December 2014 
 
 All causes  First primary cancer  Subsequent primary cancer  Non-cancer causes 
 Years after first diagnosis  Years after first diagnosis  Years after first diagnosis  Years after first diagnosis 
 5 10 15 20  5 10 15 20  5 10 15 20  5 10 15 20 
All cancer patients                
All periods 50.7 62.4 70.5 76.8  41.1 45.9 48.1 49.3  1.4 3.0 4.4 5.5  8.2 13.3 17.6 21.6 
1980-1984 65.6 75.4 81.3 85.2  57.2 61.8 63.8 64.5  1.0 2.1 2.9 3.6  7.5 11.5 14.7 17.1 
1985-1989 60.8 70.9 77.4 82.5  51.4 56.3 58.4 59.4  1.1 2.3 3.3 4.2  8.2 12.3 15.7 19.0 
1990-1994 54.9 66.0 73.7 79.6  44.3 49.0 51.0 52.0  1.3 2.7 4.1 5.1  9.3 14.4 18.7 22.2 
1995-1999 49.9 61.7 69.6   39.9 44.6 46.5   1.7 3.3 4.9   8.4 13.7 17.9  
2000-2004 46.9 58.7    36.5 41.0    1.6 3.3    8.6 14.0   
2005-2009 39.2     30.3     1.5     7.1    
Head and neck cancer patients                 
All periods 39.3 54.2 65.9 75.3  25.7 29.2 30.5 32.2  3.4 6.6 9.7 11.9  10.2 18.3 25.4 30.7 
1980-1984 45.7 60.6 72.9 81.7  33.4 36.6 38.5 39.4  3.2 6.6 8.5 11.4  9.1 17.4 25.9 30.9 
1985-1989 48.1 61.7 69.8 78.3  32.3 36.7 37.8 39.1  3.8 7.1 9.2 10.9  12.0 17.9 22.8 28.3 
1990-1994 42.1 57.0 67.8 77.5  26.2 29.6 30.7 32.9  3.3 6.4 8.7 11.1  12.5 21.0 28.4 33.1 
1995-1999 37.1 51.2 62.6   22.0 25.3 25.9   3.7 6.7 11.0   11.4 19.2 25.5  
2000-2004 34.6 50.2    20.5 24.0    3.9 6.3    10.2 19.3   
2005-2009 33.1     23.8     2.5     6.7    
Lung cancer patients                  
All periods 91.4 95.3 97.3 98.3  84.9 87.1 87.8 88.1  0.3 0.6 0.9 1.0  6.2 7.6 8.5 9.1 
1980-1984 93.9 96.4 98.4 98.9  88.2 90.0 90.8 90.9  0.3 0.6 0.7 0.7  5.3 5.8 6.9 7.3 
1985-1989 92.0 95.3 97.4 98.4  86.1 88.2 89.1 89.4  0.2 0.2 0.6 0.9  5.6 6.9 7.7 8.1 
1990-1994 90.5 94.8 97.0 98.2  83.6 85.8 86.4 86.6  0.5 1.0 1.4 1.4  6.4 8.0 9.2 10.0 
1995-1999 92.1 96.0 97.2   86.8 88.7 89.0   0.2 0.5 0.6   5.1 6.9 7.6  
2000-2004 90.4 94.9    81.8 84.1    0.2 0.6    8.4 10.2   
2005-2009 90.3     84.0     0.2     5.8    





Continued All causes  First primary cancer  Subsequent primary cancer  Non-cancer causes 
 Years after first diagnosis  Years after first diagnosis  Years after first diagnosis  Years after first diagnosis 
 5 10 15 20  5 10 15 20  5 10 15 20  5 10 15 20 
Colorectal cancer patients                
All periods 54.3 66.4 74.2 81.0  44.1 49.0 50.2 50.8  1.4 3.0 4.4 5.5  8.7 14.3 19.4 24.2 
1980-1984 65.0 75.9 82.3 86.3  57.2 61.8 63.0 63.2  1.0 2.1 3.1 3.8  6.8 12.0 16.1 19.4 
1985-1989 62.6 73.8 79.0 85.5  52.6 57.6 58.8 59.2  1.0 2.3 3.1 4.1  9.0 13.9 17.1 22.2 
1990-1994 57.3 67.7 75.2 81.1  48.9 52.6 53.5 54.3  1.1 2.8 4.5 5.7  7.2 12.4 17.1 21.0 
1995-1999 53.9 66.6 74.8   43.6 48.6 49.5   1.9 4.3 5.8   8.3 13.6 19.1  
2000-2004 52.1 63.3    40.2 44.7    1.7 3.0    10.2 15.4   
2005-2009 43.3     32.1     1.4     9.6    
Female breast cancer patients                 
All periods 23.8 39.0 50.2 59.8  16.9 25.2 29.4 32.6  1.1 2.6 4.1 5.6  5.7 10.9 16.4 21.2 
1980-1984 43.2 59.0 69.1 76.8  34.2 43.4 48.0 51.1  1.2 2.3 2.9 3.9  7.8 13.4 18.2 21.8 
1985-1989 32.8 49.9 61.8 69.0  25.4 35.4 38.7 41.1  0.8 1.9 3.0 4.0  6.6 12.6 20.2 23.9 
1990-1994 27.4 42.0 51.8 61.3  19.2 27.5 31.6 34.7  0.9 1.9 2.8 4.3  7.3 12.6 17.5 22.1 
1995-1999 21.5 37.5 47.5   14.6 23.7 27.9   1.1 2.5 4.5   5.7 11.2 15.0  
2000-2004 17.3 31.7    11.8 19.2    1.3 3.4    3.8 8.5   
2005-2009 16.4     10.4     1.0     4.8    
Prostate cancer patients                  
All periods 32.9 54.3 71.7 83.7  16.1 23.7 28.5 31.1  2.6 5.5 8.2 9.3  14.1 24.9 34.5 42.6 
1980-1984 60.4 84.3 93.5 96.3  34.0 45.1 50.0 50.5  1.9 3.5 3.9 4.4  24.5 35.6 39.6 41.4 
1985-1989 58.8 81.4 90.7 96.4  35.3 45.7 49.0 50.8  2.0 4.6 5.6 5.8  21.5 31.1 36.1 39.7 
1990-1994 46.7 67.3 81.8 89.5  23.6 31.9 36.1 37.6  2.5 4.7 7.0 7.7  20.6 30.6 38.6 43.8 
1995-1999 36.7 56.8 71.1   17.0 23.3 26.4   3.7 6.3 8.9   16.0 27.1 35.3  
2000-2004 30.6 49.5    14.1 19.8    2.6 5.2    13.8 24.1   
2005-2009 15.8     6.4     2.4     6.8    
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Table 5.3: Kaplan-Meier (KM) estimates and Cumulative Incidence Function (CIF) for cumulative incidence of cause-specific deaths by 
periods of first cancer diagnosis, with follow-up to December 2014 
  All causes  First primary  Subsequent primary  Non-cancer causes 
  Years after first diagnosis  Years after first diagnosis  Years after first diagnosis  Years after first diagnosis 
  5 10 15 20  5 10 15 20  5 10 15 20  5 10 15 20 
All cancer patients                   
All period KM 50.7 62.4 70.5 76.8  42.7 48.7 52.0 54.1  2.4 6.0 9.9 13.5  11.7 21.6 31.3 40.9 
 CIF      41.1 45.9 48.1 49.3  1.4 3.0 4.4 5.5  8.2 13.3 17.6 21.6 
1980-1984 KM 65.6 75.4 81.3 85.2  59.7 65.5 68.5 69.8  2.2 5.8 9.2 12.9  12.9 24.3 34.8 43.5 
 CIF      57.2 61.8 63.8 64.5  1.0 2.1 2.9 3.6  7.5 11.5 14.7 17.1 
1985-1989 KM 60.8 70.9 77.5 82.6  53.8 59.9 63.0 64.9  2.2 5.8 9.5 13.1  13.2 23.2 32.6 42.8 
 CIF      51.4 56.3 58.4 59.4  1.1 2.3 3.3 4.2  8.2 12.3 15.7 19.0 
1990-1994 KM 54.9 66.1 73.7 79.6  46.3 52.3 55.3 57.3  2.3 5.8 10.0 13.9  14.0 24.5 34.5 43.8 
 CIF      44.3 49.0 51.0 52.0  1.3 2.7 4.1 5.1  9.3 14.4 18.7 22.2 
1995-1999 KM 49.9 61.7 69.6   41.4 47.4 50.2   2.8 6.4 10.7   12.0 22.0 31.1  
 CIF      39.9 44.6 46.5   1.7 3.3 4.9   8.4 13.7 17.9  
2000-2004 KM 46.9 58.7    38.1 43.7    2.6 6.1    11.7 21.2   
 CIF      36.5 41.0    1.6 3.3    8.6 14.0   
2005-2009 KM 39.2     31.3     2.2     9.2    
 CIF      30.3     1.5     7.1    
Head and neck cancer patients                
All period KM 39.3 54.2 65.9 75.3  26.9 31.6 33.9 37.6  4.7 10.3 17.3 23.3  12.8 25.2 37.4 47.8 
 CIF      25.7 29.2 30.5 32.2  3.4 6.6 9.7 11.9  10.2 18.3 25.4 30.7 
1980-1984 KM 45.7 60.6 72.9 81.7  35.0 39.4 42.6 44.8  4.6 11.6 17.0 26.9  12.5 26.4 43.0 54.6 
 CIF      33.4 36.6 38.5 39.4  3.2 6.6 8.5 11.4  9.1 17.4 25.9 30.9 
1985-1989 KM 48.1 61.7 69.8 78.3  34.3 40.2 42.1 45.2  5.7 12.5 18.0 22.8  16.2 26.8 36.4 48.6 
 CIF      32.3 36.7 37.8 39.1  3.8 7.1 9.2 10.9  12.0 17.9 22.8 28.3 
1990-1994 KM 42.1 57.0 67.8 77.5  27.6 32.1 34.3 39.2  4.6 10.4 15.8 23.1  16.2 29.3 41.9 51.0 
 CIF      26.2 29.6 30.7 32.9  3.3 6.4 8.7 11.1  12.5 21.0 28.4 33.1 
1995-1999 KM 37.1 51.2 62.6   23.1 27.3 28.5   5.0 10.1 18.8   13.9 25.3 35.3  
 CIF      22.0 25.3 25.9   3.7 6.7 11.0   11.4 19.2 25.5  
2000-2004 KM 34.6 50.2    21.7 26.1    5.2 9.3    11.8 24.9   
 CIF      20.5 24.0    3.9 6.3    10.2 19.3   
2005-2009 KM 33.1     24.6     3.2     8.2    
 CIF      23.8     2.5     6.7    
 




Continued  All causes  First primary  Subsequent primary  Non-cancer causes 
  Years after first diagnosis  Years after first diagnosis  Years after first diagnosis  Years after first diagnosis 
  5 10 15 20  5 10 15 20  5 10 15 20  5 10 15 20 
Lung cancer patients                   
All period KM 91.4 95.3 97.3 98.3  89.1 92.1 93.4 94.4  1.6 6.1 14.6 19.0  19.3 35.8 51.1 62.3 
 CIF      84.9 87.1 87.8 88.1  0.3 0.6 0.9 1.0  6.2 7.6 8.5 9.1 
1980-1984 KM 93.9 96.4 98.4 98.9  92.6 94.9 96.1 96.5  2.5 7.3 11.1 11.1  15.1 23.0 54.0 63.9 
 CIF      88.2 90.0 90.8 90.9  0.3 0.6 0.7 0.7  5.3 5.8 6.9 7.3 
1985-1989 KM 92.0 95.3 97.4 98.4  90.0 92.8 94.3 95.1  1.4 1.4 13.9 26.9  18.2 34.8 47.7 56.1 
 CIF      86.1 88.2 89.1 89.4  0.2 0.2 0.6 0.9  5.6 6.9 7.7 8.1 
1990-1994 KM 90.5 94.8 97.0 98.2  87.6 90.7 92.1 92.9  3.5 9.7 18.5 18.5  19.9 37.5 53.4 68.0 
 CIF      83.6 85.8 86.4 86.6  0.5 1.0 1.4 1.4  6.4 8.0 9.2 10.0 
1995-1999 KM 92.1 96.0 97.2   90.2 92.8 93.3   0.4 5.9 11.3   19.5 41.5 52.9  
 CIF      86.8 88.7 89.0   0.2 0.5 0.6   5.1 6.9 7.6  
2000-2004 KM 90.4 94.9    87.5 90.8    1.0 6.5    22.3 40.3   
 CIF      81.8 84.1    0.2 0.6    8.4 10.2   
2005-2009 KM 90.3     87.9     1.4     18.1 87.9   
 CIF      84.0     0.2     5.8    
Colorectal cancer patients                
All period KM 54.3 66.4 74.2 81.0  46.2 52.4 54.3 55.5  2.5 6.6 10.9 15.2  12.6 24.4 36.3 48.8 
 CIF      44.1 49.0 50.2 50.8  1.4 3.0 4.4 5.5  8.7 14.3 19.4 24.2 
1980-1984 KM 65.0 75.9 82.3 86.3  59.4 65.1 67.1 67.5  2.3 5.8 10.5 13.8  11.8 26.6 39.8 51.2 
 CIF      57.2 61.8 63.0 63.2  1.0 2.1 3.1 3.8  6.8 12.0 16.1 19.4 
1985-1989 KM 62.6 73.8 79.0 85.5  55.6 62.1 63.9 64.8  2.1 6.1 9.4 14.2  13.9 26.2 35.7 51.8 
 CIF      52.6 57.6 58.8 59.2  1.0 2.3 3.1 4.1  9.0 13.9 17.1 22.2 
1990-1994 KM 57.3 67.7 75.2 81.1  51.1 55.5 57.0 58.5  2.0 6.3 12.0 16.4  10.8 22.6 34.5 45.2 
 CIF      48.9 52.6 53.5 54.3  1.1 2.8 5.7   7.2 12.4 17.1 21.0 
1995-1999 KM 53.9 66.6 74.8   45.5 51.9 53.3   3.3 9.1 13.7   12.6 23.6 36.8  
 CIF      43.6 48.6 49.5   1.9 4.3 5.8   8.3 13.6 19.1  
2000-2004 KM 52.1 63.3    42.4 48.2    3.1 5.9    14.2 24.3   
 CIF      40.2 44.7    1.7 3.0    10.2 15.4   
2005-2009 KM 43.3     33.7     2.1     12.3    
 CIF      32.1     1.4     9.6    
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Continued  All causes  First primary  Subsequent primary  Non-cancer causes 
  Years after first diagnosis  Years after first diagnosis  Years after first diagnosis  Years after first diagnosis 
  5 10 15 20  5 10 15 20  5 10 15 20  5 10 15 20 
Female breast cancer patients                  
All period KM 23.8 39.0 50.2 59.8  17.5 26.9 32.3 36.8  1.3 3.4 6.0 9.1  6.3 13.2 21.4 29.5 
 CIF      16.9 25.2 29.4 32.6  1.1 2.6 4.1 5.6  5.7 10.9 16.4 21.2 
1980-1984 KM 43.2 59.0 69.1 76.8  36.0 47.0 53.5 58.3  1.7 3.8 5.5 9.2  9.8 19.6 29.7 38.7 
 CIF      34.2 43.4 48.0 51.1  1.2 2.3 2.9 3.9  7.8 13.4 18.2 21.8 
1985-1989 KM 32.8 49.9 61.8 69.0  26.5 38.1 42.4 46.2  1.0 2.8 5.4 8.0  7.7 16.8 29.9 37.3 
 CIF      25.4 35.4 38.7 41.1  0.8 1.9 3.0 4.0  6.6 12.6 20.2 23.9 
1990-1994 KM 27.4 42.0 51.8 61.3  20.0 29.6 34.7 39.3  1.1 2.6 4.3 7.7  8.2 15.4 22.9 30.6 
 CIF      19.2 27.5 31.6 34.7  0.9 1.9 2.8 4.3  7.3 12.6 17.5 22.1 
1995-1999 KM 21.5 37.5 47.5   15.2 25.4 30.7   1.3 3.2 6.6   6.2 13.3 18.8  
 CIF      14.6 23.7 27.9   1.1 2.5 4.5   5.7 11.2 15.0  
2000-2004 KM 17.3 31.7    12.1 20.3    1.5 4.2    4.1 9.9   
 CIF      11.8 19.2    1.3 3.4    3.8 8.5   
2005-2009 KM 16.4     10.7     1.1     5.2    
 CIF      10.4     1.0     4.8    
Prostate cancer patients                
All period KM 32.9 54.3 71.7 83.7  17.6 27.9 36.9 43.8  3.3 8.1 14.8 18.9  15.7 30.8 46.8 63.4 
 CIF      16.1 23.7 28.5 31.1  2.6 5.5 8.2 9.3  14.1 24.9 34.5 42.6 
1980-1984 KM 60.4 84.3 93.5 96.3  42.0 61.7 75.3 77.3  2.8 8.5 14.0 22.5  29.8 55.0 69.4 79.0 
 CIF      34.0 45.1 50.0 50.5  1.9 3.5 3.9 4.4  24.5 35.6 39.6 41.4 
1985-1989 KM 58.8 81.4 90.7 96.4  40.8 59.2 68.5 77.0  3.4 11.2 18.4 20.0  28.0 48.6 63.9 80.2 
 CIF      35.3 45.7 49.0 50.8  2.0 4.6 5.6 5.8  21.5 31.1 36.1 39.7 
1990-1994 KM 46.7 67.3 81.8 89.5  26.8 39.8 48.9 54.1  3.6 8.5 17.1 20.5  24.6 40.6 57.0 70.5 
 CIF      23.6 31.9 36.1 37.6  2.5 4.7 7.0 7.7  20.6 30.6 38.6 43.8 
1995-1999 KM 36.7 56.8 71.1   18.9 27.9 33.9   4.7 9.4 15.8   18.1 33.8 47.3  
 CIF      17.0 23.3 26.4   3.7 6.3 8.9   16.0 27.1 35.3  
2000-2004 KM 30.6 49.5    15.3 23.0    3.2 7.3    15.2 28.8   
 CIF      14.1 19.8    2.6 5.2    13.8 24.1   
2005-2009 KM 15.8     6.7     2.6     7.1    
 CIF      6.4     2.4     6.8    
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5.4.2 Mortality risk 
The associations between patient characteristics (sex, age at first cancer diagnosis and period 
of first cancer diagnosis) and cause-specific deaths were estimated using multivariable 
competing risk models for SHRs and multivariable Cox regression models for CHRs. For all 
cancer patients, both SHRs and CHRs of first cancer and non-cancer deaths generally 
decreased over time, after adjusting for sex (not for female breast cancer and prostate cancer) 
and age at first cancer diagnosis (Table 5.4). However, the change was not monotonic for 
SPC deaths. In competing risk models, the risk of SPC deaths increased from 1980-1984 and 
reached a peak for individuals with a first cancer diagnosis in 1995-1999 (SHR = 1.18, 
95%CI 1.03-1.35), before decreasing to 0.82 (95%CI 0.70-0.95) in 2005-2009. However, 
there was no evidence for a similar pattern in the CHRs of SPC deaths. For the analysis with 
follow-up restricted to 5 years, the SHRs reflect the effect of periods of first diagnosis on 5-
year CIF after adjusting for sex and age at first cancer diagnosis (Table 5.5). 
For individuals with specific cancer types (head and neck, lung, colorectal, female breast and 
prostate), the risk of first cancer and non-cancer deaths generally decreased over time (Table 
5.4). The risk of SPC deaths generally decreased over time for head and neck cancer. 
However, the risk of SPC deaths increased from 1980-1984 (reference) to later periods for 
individuals with a first diagnosis of colorectal, female breast or prostate cancer in competing 
risk models. The increase was greatest for individuals with a first diagnosis of prostate cancer 
in 1995-1999 (SHR = 2.08, 95%CI 1.29-3.36). Individuals with a first colorectal or female 
breast cancer showed similar patterns of changes in SPC mortality risk but the peak was not 
statistically significantly greater than the reference period (SHR = 1.35, 95%CI 0.96-1.89 for 
colorectal and SHR = 1.22, 95%CI 0.81-1.84 for female breast). The peak was delayed to 
2000-2004 in female breast cancer. We also conducted a sensitivity analysis of the trends for 
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all cancers combined after excluding first prostate cancers. The sensitivity analysis showed a 
lower cumulative incidence of SPC deaths for individuals with a first cancer diagnosis in the 
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Table 5.4: The hazard ratios (HRs) of cause-specific deaths by periods of first cancer diagnosis, with adjustment on sex (not for female 
breast cancer and prostate cancer) and age at first cancer diagnosis 
Periods of first 
cancer 
diagnosis 
All causes  First primary cancer  Subsequent primary cancer  Non-cancer causes 
HR (95%CI) 
 SHR  CHR  SHR  CHR  SHR  CHR 
 HR (95%CI)  HR (95%CI)  HR (95%CI)  HR (95%CI)  HR (95%CI)  HR (95%CI) 
All cancer patients             
1980-1984 1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref) 
1985-1989 0.88 (0.85-0.91)  0.86 (0.82-0.89)  0.85 (0.82-0.89)  1.08 (0.92-1.25)  0.97 (0.83-1.14)  1.02 (0.95-1.10)  0.93 (0.86-1.00) 
1990-1994 0.72 (0.69-0.74)  0.67 (0.65-0.70)  0.66 (0.64-0.69)  1.13 (0.98-1.30)  0.90 (0.77-1.04)  1.06 (0.99-1.14)  0.82 (0.76-0.88) 
1995-1999 0.63 (0.61-0.65)  0.59 (0.56-0.61)  0.57 (0.55-0.60)  1.18 (1.03-1.35)  0.93 (0.80-1.08)  0.92 (0.86-0.98)  0.71 (0.66-0.77) 
2000-2004 0.57 (0.55-0.59)  0.52 (0.50-0.54)  0.51 (0.49-0.53)  0.97 (0.84-1.12)  0.87 (0.74-1.01)  0.80 (0.75-0.86)  0.68 (0.63-0.73) 
2005-2009 0.44 (0.43-0.46)  0.41 (0.39-0.43)  0.40 (0.38-0.42)  0.82 (0.70-0.95)  0.80 (0.67-0.94)  0.56 (0.52-0.61)  0.52 (0.48-0.56) 
Head and neck cancer patients             
1980-1984 1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref) 
1985-1989 0.93 (0.79-1.09)  0.95 (0.75-1.21)  0.98 (0.77-1.24)  0.92 (0.61-1.39)  0.89 (0.59-1.35)  0.91 (0.71-1.17)  0.85 (0.66-1.10) 
1990-1994 0.83 (0.71-0.97)  0.76 (0.60-0.97)  0.78 (0.61-0.98)  0.89 (0.60-1.32)  0.85 (0.57-1.29)  0.93 (0.74-1.18)  0.85 (0.67-1.09) 
1995-1999 0.71 (0.60-0.83)  0.60 (0.47-0.77)  0.62 (0.49-0.80)  0.94 (0.64-1.39)  0.90 (0.60-1.35)  0.75 (0.59-0.96)  0.72 (0.56-0.93) 
2000-2004 0.72 (0.61-0.85)  0.57 (0.45-0.73)  0.60 (0.47-0.77)  0.79 (0.52-1.19)  0.88 (0.57-1.37)  0.73 (0.57-0.94)  0.78 (0.60-1.02) 
2005-2009 0.66 (0.55-0.79)  0.65 (0.51-0.83)  0.67 (0.53-0.85)  0.55 (0.33-0.89)  0.78 (0.46-1.32)  0.40 (0.29-0.55)  0.52 (0.37-0.73) 
Lung cancer patients             
1980-1984 1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref) 
1985-1989 0.91 (0.83-1.00)  0.93 (0.84-1.02)  0.90 (0.82-0.99)  1.21 (0.46-3.15)  1.16 (0.42-3.19)  1.14 (0.83-1.57)  1.00 (0.73-1.38) 
1990-1994 0.78 (0.71-0.85)  0.80 (0.73-0.89)  0.76 (0.69-0.84)  1.75 (0.71-4.30)  1.12 (0.43-2.92)  1.33 (0.98-1.81)  0.91 (0.67-1.25) 
1995-1999 0.78 (0.71-0.85)  0.83 (0.76-0.91)  0.78 (0.71-0.85)  0.79 (0.28-2.24)  0.68 (0.23-2.05)  1.01 (0.73-1.39)  0.81 (0.58-1.12) 
2000-2004 0.76 (0.69-0.83)  0.74 (0.67-0.81)  0.72 (0.66-0.79)  1.00 (0.38-2.62)  1.02 (0.36-2.83)  1.37 (1.01-1.85)  1.14 (0.84-1.54) 
2005-2009 0.78 (0.71-0.85)  0.82 (0.74-0.90)  0.77 (0.70-0.85)  0.51 (0.16-1.57)  0.72 (0.21-2.48)  0.81 (0.58-1.12)  0.77 (0.55-1.08) 
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Continued All causes  First primary cancer  Subsequent primary cancer  Non-cancer causes 
HR (95%CI) 
 SHR  CHR  SHR  CHR  SHR  CHR 
 HR (95%CI)  HR (95%CI)  HR (95%CI)  HR (95%CI)  HR (95%CI)  HR (95%CI) 
Colorectal cancer patients             
1980-1984 1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref) 
1985-1989 0.92 (0.85-1.01)  0.87 (0.78-0.97)  0.90 (0.80-1.00)  0.97 (0.67-1.42)  0.92 (0.63-1.35)  1.02 (0.87-1.20)  1.00 (0.85-1.19) 
1990-1994 0.78 (0.72-0.86)  0.76 (0.68-0.85)  0.76 (0.68-0.84)  1.18 (0.83-1.67)  1.02 (0.71-1.46)  0.89 (0.76-1.05)  0.79 (0.67-0.94) 
1995-1999 0.72 (0.66-0.79)  0.66 (0.59-0.74)  0.66 (0.59-0.73)  1.35 (0.96-1.89)  1.19 (0.83-1.71)  0.82 (0.70-0.97)  0.78 (0.66-0.93) 
2000-2004 0.66 (0.60-0.72)  0.59 (0.53-0.66)  0.60 (0.54-0.67)  0.76 (0.52-1.12)  0.77 (0.51-1.17)  0.77 (0.65-0.91)  0.81 (0.67-0.96) 
2005-2009 0.53 (0.48-0.58)  0.45 (0.40-0.50)  0.45 (0.40-0.50)  0.64 (0.42-0.96)  0.75 (0.48-1.17)  0.68 (0.57-0.81)  0.78 (0.64-0.94) 
Female breast cancer patients             
1980-1984 1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref) 
1985-1989 0.83 (0.74-0.93)  0.75 (0.65-0.87)  0.74 (0.64-0.86)  0.95 (0.60-1.49)  0.89 (0.55-1.42)  1.07 (0.88-1.31)  0.95 (0.78-1.16) 
1990-1994 0.66 (0.59-0.74)  0.59 (0.51-0.68)  0.58 (0.50-0.67)  0.96 (0.63-1.47)  0.86 (0.54-1.36)  0.88 (0.73-1.07)  0.75 (0.61-0.91) 
1995-1999 0.56 (0.50-0.63)  0.48 (0.42-0.56)  0.47 (0.41-0.55)  1.16 (0.77-1.74)  1.09 (0.70-1.71)  0.71 (0.58-0.87)  0.61 (0.50-0.75) 
2000-2004 0.46 (0.40-0.51)  0.37 (0.32-0.43)  0.36 (0.31-0.42)  1.22 (0.81-1.84)  1.29 (0.81-2.04)  0.53 (0.43-0.66)  0.49 (0.39-0.61) 
2005-2009 0.40 (0.35-0.46)  0.29 (0.25-0.35)  0.30 (0.25-0.35)  0.94 (0.59-1.52)  1.16 (0.68-1.96)  0.45 (0.35-0.58)  0.53 (0.42-0.68) 
Prostate cancer patients             
1980-1984 1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref) 
1985-1989 0.87 (0.76-0.98)  1.01 (0.85-1.21)  0.92 (0.77-1.10)  1.32 (0.75-2.33)  1.13 (0.64-1.99)  0.84 (0.69-1.02)  0.78 (0.64-0.95) 
1990-1994 0.63 (0.56-0.71)  0.65 (0.56-0.77)  0.55 (0.47-0.65)  1.72 (1.05-2.81)  1.11 (0.68-1.82)  0.92 (0.77-1.08)  0.67 (0.57-0.79) 
1995-1999 0.47 (0.42-0.53)  0.45 (0.38-0.53)  0.36 (0.30-0.42)  2.08 (1.29-3.36)  1.16 (0.71-1.87)  0.79 (0.67-0.94)  0.52 (0.44-0.62) 
2000-2004 0.38 (0.34-0.43)  0.37 (0.31-0.43)  0.29 (0.24-0.34)  1.49 (0.91-2.44)  0.88 (0.54-1.45)  0.64 (0.53-0.76)  0.44 (0.37-0.52) 
2005-2009 0.23 (0.21-0.26)  0.19 (0.15-0.22)  0.15 (0.13-0.18)  1.57 (0.96-2.57)  0.92 (0.56-1.51)  0.35 (0.29-0.42)  0.25 (0.21-0.30) 
Note: Subdistribution hazard ratios (SHRs) were hazard ratios derived from competing risk models and CHRs were hazard ratios derived from Cox models. Both SHRs and CHRs for cause-
specific deaths by calendar periods of first cancer diagnosis (1980-1984, 1985-1989, 1990-1994, 1995-1999, 2000-2004 and 2005-2009) were assessed in multivariable competing risk models 
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Table 5.5: The hazard ratios (HRs) of cause-specific deaths by periods of first cancer diagnosis, with follow-up restricted to 5 years  
Periods of first 
cancer 
diagnosis 
All causes  First primary cancer  Subsequent primary cancer  Non-cancer causes 
HR (95%CI) 
 SHR  CHR  SHR  CHR  SHR  CHR 
 HR (95%CI)  HR (95%CI)  HR (95%CI)  HR (95%CI)  HR (95%CI)  HR (95%CI) 
All cancer patients             
1980-1984 1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref) 
1985-1989 0.87 (0.83-0.90)  0.85 (0.81-0.89)  0.87 (0.83-0.90)  1.10 (0.79-1.54)  0.98 (0.71-1.37)  1.11 (0.98-1.25)  1.03 (0.91-1.16) 
1990-1994 0.69 (0.66-0.72)  0.66 (0.63-0.69)  0.69 (0.66-0.72)  1.22 (0.90-1.66)  0.91 (0.67-1.23)  1.17 (1.04-1.31)  0.94 (0.84-1.06) 
1995-1999 0.60 (0.58-0.63)  0.58 (0.55-0.61)  0.60 (0.58-0.63)  1.61 (1.21-2.15)  1.10 (0.82-1.46)  1.05 (0.94-1.18)  0.80 (0.71-0.89) 
2000-2004 0.54 (0.52-0.56)  0.51 (0.49-0.54)  0.54 (0.52-0.56)  1.56 (1.17-2.08)  1.00 (0.75-1.33)  1.06 (0.95-1.19)  0.77 (0.69-0.86) 
2005-2009 0.42 (0.40-0.44)  0.41 (0.39-0.43)  0.42 (0.40-0.44)  1.42 (1.07-1.88)  0.79 (0.59-1.05)  0.86 (0.77-0.96)  0.57 (0.51-0.64) 
Head and neck cancer patients             
1980-1984 1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref) 
1985-1989 1.10 (0.88-1.37)  0.98 (0.75-1.27)  0.99 (0.76-1.29)  1.22 (0.54-2.75)  1.28 (0.57-2.88)  1.42 (0.89-2.28)  1.41 (0.88-2.25) 
1990-1994 0.86 (0.69-1.07)  0.75 (0.57-0.98)  0.75 (0.57-0.97)  1.02 (0.45-2.31)  0.96 (0.43-2.16)  1.35 (0.85-2.13)  1.22 (0.78-1.92) 
1995-1999 0.74 (0.59-0.93)  0.61 (0.47-0.81)  0.61 (0.47-0.81)  1.18 (0.54-2.58)  1.06 (0.48-2.31)  1.21 (0.77-1.90)  1.08 (0.69-1.70) 
2000-2004 0.68 (0.54-0.84)  0.56 (0.43-0.74)  0.56 (0.43-0.74)  1.29 (0.60-2.77)  1.13 (0.53-2.44)  1.08 (0.68-1.72)  0.95 (0.60-1.50) 
2005-2009 0.65 (0.52-0.81)  0.67 (0.52-0.87)  0.65 (0.50-0.85)  0.85 (0.37-1.94)  0.73 (0.32-1.66)  0.71 (0.44-1.17)  0.62 (0.38-1.02) 
Lung cancer patients             
1980-1984 1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref) 
1985-1989 0.91 (0.83-1.00)  0.93 (0.84-1.02)  0.91 (0.82-1.00)  0.58 (0.10-3.48)  0.52 (0.09-3.16)  1.07 (0.73-1.58)  1.00 (0.68-1.47) 
1990-1994 0.78 (0.71-0.85)  0.81 (0.73-0.89)  0.77 (0.70-0.84)  1.35 (0.31-5.85)  0.88 (0.21-3.71)  1.17 (0.80-1.71)  0.91 (0.62-1.32) 
1995-1999 0.77 (0.71-0.85)  0.83 (0.76-0.92)  0.78 (0.71-0.86)  0.53 (0.09-3.27)  0.33 (0.05-2.01)  0.93 (0.63-1.38)  0.73 (0.49-1.08) 
2000-2004 0.75 (0.68-0.82)  0.74 (0.67-0.82)  0.72 (0.66-0.79)  0.44 (0.07-2.90)  0.28 (0.05-1.71)  1.51 (1.06-2.15)  1.15 (0.81-1.63) 
2005-2009 0.77 (0.70-0.84)  0.82 (0.74-0.90)  0.77 (0.70-0.85)  0.66 (0.15-2.94)  0.38 (0.07-2.00)  1.03 (0.71-1.50)  0.79 (0.55-1.15) 
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Continued All causes  First primary cancer  Subsequent primary cancer  Non-cancer causes 
HR (95%CI) 
 SHR  CHR  SHR  CHR  SHR  CHR 
 HR (95%CI)  HR (95%CI)  HR (95%CI)  HR (95%CI)  HR (95%CI)  HR (95%CI) 
Colorectal cancer patients             
1980-1984 1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref) 
1985-1989 0.92 (0.83-1.03)  0.86 (0.77-0.97)  0.88 (0.79-0.99)  0.95 (0.41-2.24)  0.92 (0.39-2.16)  1.33 (0.98-1.82)  1.27 (0.93-1.73) 
1990-1994 0.79 (0.71-0.88)  0.77 (0.69-0.86)  0.77 (0.69-0.86)  1.10 (0.50-2.46)  0.95 (0.42-2.11)  1.06 (0.77-1.45)  0.94 (0.69-1.29) 
1995-1999 0.68 (0.62-0.76)  0.65 (0.58-0.73)  0.64 (0.57-0.72)  1.88 (0.92-3.87)  1.45 (0.70-2.98)  1.14 (0.84-1.53)  0.93 (0.69-1.26) 
2000-2004 0.65 (0.59-0.72)  0.58 (0.52-0.66)  0.59 (0.52-0.66)  1.66 (0.80-3.44)  1.25 (0.60-2.59)  1.37 (1.03-1.82)  1.10 (0.82-1.46) 
2005-2009 0.49 (0.45-0.55)  0.43 (0.39-0.49)  0.43 (0.38-0.48)  1.31 (0.63-2.72)  0.86 (0.41-1.80)  1.30 (0.98-1.72)  0.92 (0.69-1.22) 
Female breast cancer patients             
1980-1984 1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref) 
1985-1989 0.75 (0.63-0.88)  0.71 (0.59-0.86)  0.71 (0.59-0.86)  0.63 (0.22-1.83)  0.59 (0.20-1.70)  0.92 (0.62-1.37)  0.91 (0.62-1.33) 
1990-1994 0.61 (0.52-0.72)  0.53 (0.44-0.63)  0.53 (0.44-0.63)  0.76 (0.30-1.94)  0.69 (0.27-1.76)  1.01 (0.71-1.46)  0.98 (0.69-1.38) 
1995-1999 0.46 (0.39-0.54)  0.39 (0.32-0.48)  0.39 (0.32-0.47)  0.99 (0.41-2.39)  0.83 (0.35-1.99)  0.84 (0.58-1.22)  0.74 (0.52-1.06) 
2000-2004 0.36 (0.30-0.42)  0.31 (0.26-0.38)  0.30 (0.25-0.37)  1.15 (0.50-2.66)  0.93 (0.41-2.11)  0.56 (0.38-0.82)  0.48 (0.33-0.69) 
2005-2009 0.34 (0.29-0.40)  0.27 (0.22-0.33)  0.26 (0.22-0.32)  0.90 (0.38-2.15)  0.73 (0.31-1.71)  0.68 (0.47-0.98)  0.61 (0.43-0.87) 
Prostate cancer patients             
1980-1984 1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref)  1 (ref) 
1985-1989 0.92 (0.78-1.08)  0.99 (0.80-1.22)  0.92 (0.77-1.10)  1.05 (0.42-2.61)  1.00 (0.40-2.48)  0.81 (0.62-1.07)  0.82 (0.63-1.07) 
1990-1994 0.67 (0.58-0.77)  0.60 (0.49-0.73)  0.55 (0.47-0.65)  1.38 (0.64-2.99)  1.15 (0.53-2.48)  0.80 (0.63-1.02)  0.73 (0.58-0.91) 
1995-1999 0.49 (0.43-0.57)  0.41 (0.33-0.50)  0.36 (0.30-0.42)  2.07 (0.98-4.35)  1.54 (0.73-3.23)  0.64 (0.50-0.82)  0.53 (0.42-0.67) 
2000-2004 0.39 (0.34-0.45)  0.32 (0.26-0.39)  0.29 (0.24-0.34)  1.52 (0.71-3.23)  1.06 (0.50-2.27)  0.55 (0.43-0.69)  0.44 (0.35-0.55) 
2005-2009 0.21 (0.18-0.24)  0.15 (0.12-0.18)  0.15 (0.13-0.18)  1.47 (0.70-3.08)  0.93 (0.45-1.95)  0.30 (0.23-0.39)  0.23 (0.18-0.29) 
Note: Subdistribution hazard ratios (SHRs) were hazard ratios derived from competing risk models and CHRs were hazard ratios derived from Cox models. Both SHRs and CHRs for cause-
specific deaths by calendar periods of first cancer diagnosis (1980-1984, 1985-1989, 1990-1994, 1995-1999, 2000-2004 and 2005-2009) were assessed in multivariable competing risk models 
and multivariable Cox regression models respectively, with adjustment on sex (not for female organs and prostate) and age at first cancer diagnosis. 
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5.5 Discussion 
An aging population, greater uptake of cancer screening and the development of advanced 
imaging techniques has led to more frequent occurrence of SPCs among adult-onset cancer 
survivors and the possibility of competing mortality risk associated with them 9. In the 
current study, we found that the risk of first cancer deaths gradually decreased from 1980-
2009. In contrast, the risk of SPC deaths increased to a peak for individuals with a first cancer 
diagnosis in the late 1990s, then fell to a risk below that of the early 1980s in competing risk 
models. For individuals with specific cancers, the SPC mortality risk was greatest in 
individuals with a first diagnosis of prostate cancer in the late 1990s and the risk remained 
higher during 2000-2009 than in the early 1980s.  
A recent study reported the risk of cause-specific deaths in cancer patients using the 
proportion of deaths due to each cause 19. It concluded that there was a higher risk of non-
cancer death than cancer deaths in recent years. However, temporal trends in proportions of 
cause-specific deaths could be influenced by the follow-up time. Specifically, the longer the 
follow-up, the more likely deaths due to non-cancer causes will be observed. This is reflected 
in our study results with a steady increase in the proportion of non-cancer deaths from 1980 
to 2009 (Figure 5.1). However, in the competing risk models we showed that the risk of non-
cancer deaths was significantly lower for first cancers diagnosed in 2005-2009 than in the 
reference period 1980-1984. Thus, when accounting for follow-up time and the presence of 
competing causes of death, we no longer have evidence for an increase in the risk of non-
cancer deaths over time. 
The competing risk approach is a more advanced method for estimating a patient’s outcome 
beyond that achievable with traditional methods, especially for cancer patients who are at risk 
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of first cancer deaths as well as competing mortality from SPCs and non-cancer causes 11. 
Recent studies have reported competing mortality among individuals with specific cancers in 
one period (e.g. head and neck cancer, colorectal cancer, breast cancer and prostate cancer) 10, 
11, 20-22. The current study is novel in that it identified temporal trends in first cancer, SPC-
specific and non-cancer causes mortality among individuals with all cancer types from 1980-
2009. The gradual decrease in the risk of first cancer deaths could be due to early detection of 
first cancers through improved screening and diagnostic techniques, and advances in curative 
therapy 23. It could also be a result of increased detection of nonfatal first cancers which have 
low mortality rates 24.  
The most novel finding in our study is the increased cumulative mortality and mortality risk 
due to SPCs for patients with a first cancer diagnosis in the 1990s. The increase was largely 
influenced by first diagnoses of prostate cancer in the 1990s, confirmed through a sensitivity 
analysis of the trends for all cancers combined after excluding first prostate cancers. One 
possible explanation of this finding is increased detection of nonfatal first cancers of the 
prostate and subsequent registration of more lethal cancers as SPCs. The increase in diagnosis 
of prostate cancer coincides with the listing of prostate-specific antigen (PSA) testing on the 
Australian Medicare Benefits Schedule (a publicly funded universal health care system in 
Australia) in 1989 25. The incidence of prostate cancer in Australia maintained at around 82 
new cases per 100,000 males between 1982 to 1988, followed by a rapid increase to 184 per 
100,000 in 1994, a sharp decline to 130 per 100,000 in 1997, and then steady again until a 
gradual increase from 2002 to 2009 26. Prostate cancer incidence in Tasmania has the same 
pattern as the national statistics (data not shown). Individuals who had a prostate cancer 
diagnosis in the 1990s were more likely to die from their SPCs compared to any other periods 
during 1980-2009. This suggests that some prostate cancers identified in the peak PSA-
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testing era of the 1990s may have been of less clinical significance, and were potentially 
“overdiagnosed” 24, 27. The increase in SPC mortality risk may also be related to the decline in 
prostate cancer mortality. Improved treatment for prostate cancer has prolonged overall 
survival for prostate cancer patients 28, 29 providing the opportunity for SPCs to develop and 
cause death as a competing event. 
Although individuals with a first diagnosis of head and neck cancer had the highest 
proportion of SPCs, we did not observe an apparent trend in SPC mortality risk over periods 
of first cancer diagnosis. The most frequent SPC among head and neck cancer patients was 
lung cancer, which was likely to be smoking-related. Secondary prevention of cigarette 
smoking among these patients may help to reduce the development of smoking-related SPCs. 
Another possible contributor to the increased mortality risk due to SPCs could be the 
development of more lethal treatment-related SPCs as a result of aggressive treatment of first 
cancers 30. For individuals diagnosed with prostate cancer in 1995-1999, deaths due to 
colorectal cancer accounted for the second biggest proportion in SPC deaths. A recent meta-
analysis of 21 studies confirmed a higher risk of colorectal cancer following radiotherapy for 
prostate cancer 31. The role of radiotherapy or chemotherapy in the development of treatment-
related SPCs has also been identified with other first cancer sites 32-34. In our study, the risk of 
SPC deaths increased for females with breast cancer in 2000-2004 but the increase did not 
reach statistical significance. An increased number of deaths due to haematological 
malignancies may be related to breast cancer treatment 35. 
The greatest strength of our study was the application of the competing risk approach in a 
population-based sample to identify patterns of cause-specific mortality among patients with 
all cancer types and specific cancer types. The competing risk method calculated the “real” 
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probability of cause-specific deaths where individuals are at risk of death from more than one 
cause. Previous studies used standardized mortality ratios (SMRs) for cause-specific 
mortality among cancer patients 19, 36, 37. However, derivation of SMRs for first cancers 
deaths is inappropriate because expected mortality due to first cancer in the general 
population (unaffected by cancer) is zero and internal comparisons between first cancer 
mortality and other causes of mortality are not possible 36-38. Finally, the TCR data is 
comprehensive due to the full coverage of the whole state, which has a relatively stable 
population. This study also has some potential limitations. First, the TCR was established in 
1978. Some cancers classified as a “first diagnosis” in the early 1980s might be SPCs, thus 
resulting in miscoding of first cancer deaths in the early 1980s. Second, a lack of treatment 
data in the TCR records precluded evaluation of different treatment regimens on patients’ 
outcome.  
In conclusion, our study observed an increased risk of SPC deaths for individuals with a first 
cancer diagnosis in the 1990s, while the risk of first cancer and non-cancer deaths generally 
decreased from 1980-2009. The increased risk of SPC deaths in the 1990s possibly reflects 
greater detection of some non-fatal cancers that were registered as first cancers, or the 
adverse late effects of cancer treatment. Wider application of competing risk analysis in 
studies of mortality after cancer may help to alert clinicians, policy-makers and patients to 
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Chapter 6: Cardiovascular and other competing causes of 
death among cancer patients, 2006-2015: An Australian 
population-based study 
6.1 Abstract 
Background: With improved cancer survivorship, cardiovascular disease (CVD) and other 
non-cancer events compete with cancer as the underlying cause of death but mortality risks in 
competing risk settings have not been well characterized. 
Methods: We identified 21,637 individuals with a first cancer registered between 2006-2013, 
with follow-up to 2015, in the population-based Tasmanian Cancer Registry, Australia. 
Cumulative incidences of deaths due to specific competing events were assessed in 
competing risk settings. Standardized mortality ratios (SMRs) and absolute excess risks 
(AERs) for non-cancer deaths were calculated for comparison with the general population.   
Results: Overall, 8,844 deaths were observed with 1,946 (22.0%) from competing events. 
The cumulative incidence of CVD deaths increased significantly with age at first cancer 
diagnosis and exceeded other competing events at age 65 years or older. The risk of CVD 
deaths was more common than expected in the first follow-up year (SMR, 1.44; 95%CI 1.26-
1.64; AER, 36.8/10,000 person-years). The SMR and AER for CVD deaths varied by first 
cancer site showing increased risks after a first diagnosis of lung cancer, haematological 
malignancies and urinary tract cancers. For other non-cancer events, the SMRs significantly 
increased for infectious disease and respiratory disease and were highest in the first follow-up 
year. 
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Conclusion: CVD was the leading cause of competing mortality among Tasmanian cancer 
patients diagnosed from 2006-2013. The higher than expected occurrence of death due to 
CVD and other non-cancer events during the first year after a cancer diagnosis highlights the 
importance of early preventive interventions.   
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6.2 Introduction  
The number of people living with a history of cancer has continued to increase over recent 
decades in most developed countries 1. In 2012, nearly one million Australians were living 
with a history of cancer diagnosed since 1982, and in 2016, more than 15.5 million 
Americans had a history of cancer 2. With successful cancer treatment, patients are less likely 
to die from cancer and cancer mortality rates have continued to fall 2, 3. Patients are also more 
likely to live with cancers that are not life-threatening because more sensitive screening tests 
have increased the chance of detecting slow- or non-progressive cancers 4. 
Previous studies suggest that non-cancer events are playing an important role as the cause of 
death among individuals with specific cancers 5-8 and among patients with all types of cancers 
combined 9, 10. Patients may experience devastating non-cancer events related to their cancer 
treatment (e.g. chemotherapy–related cardiac dysfunction) or as a result of a deterioration of 
pre-existing or new non-cancer disease 11.  
Cardiovascular disease (CVD) was the leading cause of death worldwide from 2006-2016 12 
and a number of studies have assessed CVD mortality in cancer survivors 13-17. However, 
studies of mortality due to other non-cancer events are outdated 9 or only report on death due 
to specific causes such as suicide 14, 15 and respiratory disease 7, 17. To the best of our 
knowledge, only one recent study from the United States reported the risk of death due to 
specific non-cancer events among patients with all cancers combined 10. However, it did not 
consider follow-up time nor the presence of competing risks, which may have biased the 
comparison of cancer mortality with non-cancer mortality within the cohort. Our previous 
study identified an increasing risk of death from non-cancer events among cancer patients 
with longer survival time but data on specific non-cancer events was limited 18. This study 
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aimed to assess specific non-cancer mortality among all individuals with a cancer diagnosis 
in Tasmania over an 8-year period in the presence of competing risks. We also compared the 
risk of death due to specific non-cancer events with that expected in the general population. 
6.3 Methods   
6.3.1 Study population 
We identified individuals registered with a first cancer diagnosed at age 15 years or older in 
the Tasmanian Cancer Registry (TCR), Australia, between January 2006 and December 2013. 
Follow-up of the cohort ended on December 31, 2015. The TCR was established in 1977 as a 
population-based registry covering the entire state. We obtained ethics approval for the study 
from the Tasmanian Health and Medical Human Research Ethics Committee.  
6.3.2 Ascertainment of cause of death 
The TCR routinely received notifications of deaths from the Tasmanian Registry of Births, 
Deaths and Marriages. Each death subsequently recorded in the TCR dataset included up to 
five causes of death, up to eight antecedent causes of death and up to two other significant 
conditions noted at time of death. The TCR’s coders determined whether the cause of death 
was related to a notifiable cancer and coded it using International Classification of Diseases 
for Oncology, Third Edition (ICD-O3) codes. Deaths from non-cancer causes were all given 
a single non-cancer code. To obtain the specific cause of death due to non-cancer causes, the 
TCR database was linked to the national Cause of Death Unit Record File (COD-URF). The 
COD-URF is a dataset including information on causes of death relating to all deaths 
registered in Australia. The Australian Bureau of Statistics (ABS) codes and categorizes the 
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underlying cause of death and other contributing causes using the 10th revision of the 
International Classification of Diseases (ICD-10) coding rules.  
We compared the records of the underlying cause of death in the TCR dataset with the COD-
URF. If there were any differences between the recorded causes between the two sources, we 
reviewed the details in the death records, and where possible the digital medical records 
stored in the public hospital system, and then assigned the underlying cause of death in 
consultation with a medical advisor and experienced cancer coder.  
Underlying causes of death due to cancer were classified as causes due to the first recorded 
primary cancer or, if applicable, a subsequent primary cancer (SPC). Underlying causes of 
death due to non-cancer causes were grouped according to the ICD-10 classification of 
disease. Deaths due to non-cancer causes were then allocated to one of nine categories by 
ICD-10 code: deaths due to infectious disease (A00-B99), endocrine, nutritional and 
metabolic diseases (E00-E90), mental and behavioural disorders (F00-F99), disease of the 
nervous system (G00-G99), CVD (I00-I99), respiratory disease (J00-J99), digestive disease 
(K00-K93), genitourinary disease (N00-N99) and other non-cancer events (D50-D89, H00-
H95, L00-L99, M00-M99, O00-O99, P00-P99, Q00-Q99, R00-R99, S00-T98, V01-Y98, 
Z00-Z99, U00-U89). Patients without a death record before the end of follow-up (December 
2015) were deemed to be still living.  
6.3.3 Statistical analysis 
6.3.3.1 Internal comparison within the cohort 
The cumulative incidence function (CIF) was used to estimate deaths due to non-cancer 
events in the presence of competing risks 19. This is preferred to the traditional Kaplan-Meier 
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method which usually overestimates the absolute risk in cause-specific survival 20. Estimates 
for cumulative incidence of death at 1-, 5-, and 9-years post primary cancer diagnosis were 
presented by sex, age grouping (15-64, 65-74, 75-84 and ≥85 years), and first cancer type.  
6.3.3.2 Comparison with the general population 
Standardized mortality ratios (SMRs) and absolute excess risks (AERs) were computed for 
each underlying cause of death due to non-cancer events using the standard person-years 
approach 21, 22. Person-years at risk (PYR) started at the date of the first cancer diagnosis and 
ended at the date of death, or the end of follow-up (December 31, 2015), whichever came 
first. The SMR was calculated as the ratio of observed to expected deaths. Expected deaths 
were calculated using PYR for all specific sex, 5-year age group and 1-year calendar period 
strata multiplied by the corresponding mortality rate for the Tasmanian population. The AER 
was calculated by subtracting the expected number of deaths from the observed number and 
then dividing by 10,000 person-years. The SMRs and AERs for each non-cancer event were 
then stratified by sex, age at first cancer diagnosis (15-64, 65-74, 75-84 and ≥85 years), 
follow-up interval (<1 year, 1-4 years, 5-9 years) and first cancer type. The 95% confidence 
intervals (CIs) of the SMRs and AERs were derived from Poisson regression models. 
Statistical analyses were conducted using R project for statistical computing (version 3.3.2, 
package ‘cmprsk’ and ‘survival’) and Stata software (version 15; StataCorp LLC, College 
Station, Texas).  
6.4 Results 
Overall, 8,844 deaths were observed among 21,637 eligible cancer patients who accumulated 
88,722 PYR during 2006-2015. There was a 4.2% discrepancy (352 of a total 8,844 death 
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records) between the TCR recorded cause of death and the COD-URF due to differences 
between the TCR and ABS cause of death coding guidelines. 174 deaths were registered as 
non-cancer causes in the TCR but as cancer causes in the COD-URF, and 178 deaths were 
registered as cancer causes in the TCR but non-cancer causes in the COD-URF. Following 
review, 127 of the 352 underlying causes of death were assigned using ABS codes and the 
remainder had a TCR allocated code.  
Patient characteristics are presented in Table 6.1. Underlying causes of death were 
ascertained among 8,756 of 8,844 deaths (99.0 %). There were 1,946 deaths due to 
competing events (332 from SPCs, 741 from CVD and 873 from other non-cancer events). 
The mean age of patients at the first cancer diagnosis was 65.8 years (median 66.5 years; 
25th-75th percentiles, 57.4-75.7 years). The mean follow-up was 4.1 years (median 3.8 years; 
25th-75th percentiles, 1.6-6.5 years). According to absolute numbers, the most common 
cause of non-cancer deaths was CVD (n=741), followed by respiratory disease (n=271), 
endocrine, nutritional and metabolic diseases (n=124) and mental and behavioural disorders 
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Overall 21,637 (100.0) 
Sex   
   Male 12,156 (56.2) 
   Female 9,481 (43.8) 
Age at diagnosis   
   15-64 9,790 (45.2) 
   65-74 6,065 (28.0) 
   75-84 4,274 (19.8) 
   85+ 1,508 (7.0) 
Follow-up intervals   
   < 1 y 4,437 (20.5) 
   1-4 y 8,907 (41.2) 
   5-9 y 8,293 (38.3) 
First cancer sites   
   Head and neck 892 (4.1) 
   Digestive, except colorectal 1,605 (7.4) 
   Colorectal 3,102 (14.3) 
   Lung 2,050 (9.5) 
   Hematological 1,006 (4.7) 
   Skin 2,196 (10.2) 
   Breast 2,649 (12.2) 
   Female organs 843 (3.9) 
   Prostate 3,967 (18.3) 
   Urinary tract 1,164 (5.4) 
   Lymphoma 668 (3.1) 
   Others 1,495 (6.9) 
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Table 6.2: Characteristics of non-cancer deaths among cancer patients during 2006-2015 
 CVD* Infection Endocrine Mental Nervous Respiratory Digestive Genitourinary Others Total 
Overall 741 39 111 124 62 271 79 52 135 1,614 
Sex           
Male 447 27 65 67 35 168 44 34 90 977 
Female 294 12 46 57 27 103 35 18 45 637 
Age at diagnosis           
15-64 74 10 12 5 9 30 21 2 31 194 
65-74 160 6 34 14 14 76 13 9 34 360 
75-84 302 16 49 58 25 111 27 21 42 651 
85+ 205 7 16 47 14 54 18 20 28 409 
Follow-up intervals          
< 1 y 228 15 36 15 11 69 24 14 37 449 
1-4 y 354 15 55 74 34 144 38 29 64 807 
5-9 y 159 9 20 35 17 58 17 9 34 358 
First cancer sites           
Head and neck 30 1 2 8 3 14 8 0 11 77 
Digestive, except 
colorectal 28 4 3 4 1 9 8 5 4 66 
Colorectal 151 8 26 20 8 40 16 4 19 292 
Lung 48 3 6 0 2 40 3 3 11 116 
Haematological 53 2 8 6 3 25 2 8 12 119 
skin 78 4 12 26 10 23 4 5 15 177 
Breast 61 2 9 16 11 20 6 3 11 139 
Female organs 13 2 5 2 1 4 8 1 2 38 
Prostate 161 6 20 28 13 54 14 13 30 339 
Urinary tract 71 5 9 8 6 21 6 6 10 142 
Lymphoma 21 1 7 4 3 10 2 3 7 58 
Others 26 1 4 2 1 11 2 1 3 51 
*CVD: Cardiovascular disease. 
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6.4.1 Cumulative incidence of cause-specific deaths 
For individuals with all cancers combined, CVD was the leading cause of competing 
mortality in both male and female cancer patients (Figure 6.1). The cumulative incidence of 
deaths due to CVD exceeded other competing events for those first diagnosed with cancer at 
age 65 years or older and was greatest for individuals with a first cancer diagnosis at age 85 
or above (Figure 6.2). The 5-year cumulative incidence of deaths due to CVD increased from 
0.7% at age 15-64y to 2.1% at age 65-74y, 6.0% at age 75-84y and 13.1% at age 85 or older 
respectively (Table 6.3). For all causes of death, first cancer was the leading cause of death 
among individuals with a cancer diagnosis between 2006-2013 (Figure 6.3).   
Table 6.3 also illustrates the cumulative incidence of deaths due to all non-cancer events and 
specific non-cancer events by first cancer types. Individuals whose first cancer was a 
haematological malignancy had a higher 1-year cumulative incidence of non-cancer deaths 
than those with other first cancer types. At 5 years and 9 years following a first diagnosis, 
individuals with a first cancer of the urinary tract were more likely to experience non-cancer 
deaths compared to other cancer types.  
The 1-year cumulative incidence of CVD deaths was greatest among patients whose first 
cancer was a haematological malignancy (1.9%). The 5-year and 9-year cumulative incidence 
of CVD deaths were highest among patients with a first cancer of the urinary tract (5.9% and 
8.1%, respectively). The cumulative incidences of other non-cancer events were consistently 
lower than for CVD. 
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Figure 6.1: Cumulative incidence function curves for deaths due to subsequent primary cancers (SPCs) and non-cancer events by sex. 
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Figure 6.2: Cumulative incidence function curves for deaths due to subsequent primary cancers (SPCs) and non-cancer events by age at 
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Table 6.3: Cumulative incidence (%) of death due to non-cancer events, by sex, age at first cancer diagnosis and first cancer sites 
 All non-cancer events  CVD*  Infection  Endocrine  Mental 
 1 5 9  1 5 9  1 5 9  1 5 9  1 5 9 
Overall 2.1 6.4 11.0  1.1 3.0 4.9  0.1 0.1 0.3  0.2 0.5 0.7  0.1 0.5 1.0 
Sex                    
Male 2.3 6.9 11.9  1.2 3.2 5.3  0.1 0.2 0.3  0.2 0.5 0.7  0.1 0.5 1.0 
Female 1.8 5.9 9.9  0.9 2.7 4.5  0.1 0.1 0.2  0.1 0.5 0.6  0.1 0.5 1.1 
Age at diagnosis                    
15-64 0.6 1.7 2.9  0.2 0.7 1.1  0.1 0.1 0.1  0.0 0.1 0.2  <0.1 0.1 0.1 
65-74 1.5 4.8 9.6  0.7 2.1 4.2  <0.1 0.1 0.1  0.2 0.6 0.7  <0.1 0.2 0.6 
75-84 3.9 12.5 22.6  2.1 6.0 9.9  0.1 0.3 0.6  0.4 0.9 1.4  0.1 1.0 2.5 
85+ 9.0 26.7 35.3  5.0 13.1 18.1  0.1 0.4 0.7  0.3 1.0 1.3  0.5 2.9 4.4 
First cancer sites                    
Head and neck 1.5 6.4 14.8  0.3 2.5 6.6  <0.1 0.1 0.1  <0.1 0.1 0.4  0.2 0.6 1.3 
Digestive, except 
colorectal 2.2 3.9 5.3  0.9 1.7 2.3  0.1 0.2 0.2  0.1 0.1 0.3  0.1 0.3 0.3 
Colorectal 2.7 8.1 15.1  1.6 4.3 7.4  0.1 0.3 0.3  0.3 0.8 1.1  <0.1 0.4 1.7 
Lung 3.2 5.8 6.9  1.3 2.3 2.9  0.1 0.1 0.1  0.2 0.3 0.3  <0.1 <0.1 <0.1 
Haematological 4.0 10.9 16.2  1.9 4.6 7.6  0.1 0.2 0.2  0.1 0.8 1.1  0.3 0.7 0.7 
skin 1.7 7.1 12.0  0.9 3.2 4.8  <0.1 0.2 0.2  0.1 0.5 0.7  0.1 1.0 1.9 
Breast 0.7 4.5 8.1  0.4 1.9 3.4  <0.1 <0.1 0.1  <0.1 0.4 0.4  <0.1 0.7 1.0 
Female organs 0.9 3.6 6.4  0.6 1.5 1.9  <0.1 <0.1 0.7  0.1 0.4 0.6  <0.1 0.2 0.5 
Prostate 1.5 6.4 13.5  0.9 3.1 6.1  <0.1 0.1 0.2  0.2 0.4 0.6  0.1 0.6 1.2 
Urinary tract 2.9 11.3 16.4  1.7 5.9 8.1  0.2 0.3 0.8  0.2 0.7 1.1  0.1 0.7 0.8 
Other 2.2 3.7 4.7  0.9 1.3 1.7  0.1 0.1 0.1  0.3 0.4 0.6  <0.1 0.2 0.5 
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Continued 
 Nervous  Respiratory  Digestive  Genitourinary  Others 
 1 5 9  1 5 9  1 5 9  1 5 9  1 5 9 
Overall 0.1 0.2 0.5  0.3 1.1 1.9  0.1 0.3 0.5  0.1 0.2 0.3  0.2 0.5 1.0 
Sex                    
Male 0.1 0.2 0.4  0.3 1.2 2.1  0.1 0.3 0.5  0.1 0.2 0.4  0.2 0.6 1.1 
Female <0.1 0.2 0.5  0.4 1.0 1.6  0.1 0.3 0.5  0.1 0.2 0.2  0.1 0.4 0.7 
Age at diagnosis                    
15-64 <0.1 0.1 0.2  0.1 0.2 0.5  0.1 0.2 0.3  <0.1 <0.1 <0.1  0.1 0.3 0.4 
65-74 0.1 0.2 0.3  0.2 1.0 2.2  0.1 0.2 0.4  <0.1 0.2 0.2  0.1 0.4 0.8 
75-84 <0.1 0.4 1.1  0.7 2.3 3.7  0.1 0.5 0.8  0.1 0.3 0.9  0.3 0.7 1.8 
85+ 0.1 1.0 1.1  1.3 3.8 4.8  0.4 1.2 1.4  0.5 1.4 1.5  0.7 1.8 2.1 
First cancer sites                    
Head and neck <0.1 0.2 0.4  0.3 1.4 2.3  0.3 0.9 1.1  <0.1 <0.1 <0.1  0.2 0.6 2.4 
Digestive, except 
colorectal 0.1 0.1 0.1  0.4 0.5 0.7  0.3 0.5 0.5  0.1 0.2 0.6  0.1 0.2 0.2 
Colorectal <0.1 0.2 0.7  0.3 1.1 2.0  0.2 0.5 0.8  <0.1 0.1 0.3  0.2 0.6 0.8 
Lung <0.1 0.2 0.2  1.0 2.0 2.4  <0.1 0.2 0.2  <0.1 0.2 0.2  0.3 0.6 0.6 
Haematological <0.1 0.2 0.4  0.9 2.3 3.7  <0.1 0.1 0.3  0.2 0.7 0.9  0.5 1.2 1.4 
skin 0.2 0.4 0.7  0.1 0.9 1.8  <0.1 0.2 0.2  <0.1 0.2 0.5  0.2 0.5 1.1 
Breast 0.2 0.3 0.7  0.2 0.6 1.4  <0.1 0.2 0.3  <0.1 0.1 0.1  0.1 0.2 0.7 
Female organs <0.1 0.1 0.1  <0.1 0.4 0.7  0.1 0.7 1.6  0.1 0.1 0.1  <0.1 0.3 0.3 
Prostate 0.1 0.3 0.5  0.1 1.0 2.3  0.0 0.2 0.6  0.1 0.3 0.4  0.1 0.6 1.5 
Urinary tract <0.1 0.3 0.8  0.3 1.7 2.1  0.2 0.6 0.6  0.1 0.5 0.7  0.2 0.7 1.5 
Other 0.2 0.2 0.2  0.3 0.7 0.7  0.1 0.1 0.1  0.1 0.2 0.2  0.2 0.4 0.7 
Lymphoma <0.1 0.1 0.1  0.6 1.3 2.9  0.1 0.3 0.3  0.1 0.1 0.1  0.1 0.5 0.5 
*CVD: Cardiovascular disease. 
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6.4.2 SMRs and AERs for non-cancer events 
For cause of death due to CVD, the overall mortality risk was no greater than expected in the 
general population (SMR, 0.97; 95%CI 0.90-1.04) (Table 6.4). The SMRs for CVD was 
significantly lower than expected for individuals with a first cancer diagnosis at age 75-84 
years (SMR, 0.82; 95%CI 0.74-0.92). For the oldest cancer patients (age 85+ years at first 
cancer diagnosis), although the CVD mortality was not significantly higher than in the 
general population (SMR, 1.09; 95%CI 0.95-1.25), the AER was greatest in this age group 
(AER, 57.1/10,000 PYR). The SMR and AER for CVD declined with increasing duration of 
follow-up but were significantly increased within one year of a cancer diagnosis (SMR, 1.44; 
95%CI 1.26-1.64; AER, 36.8/10,000 PYR). The SMR and AER for CVD varied by first 
cancer site showing an increased risk after a first diagnosis of lung cancer (SMR, 1.84; 
95%CI 1.39-2.44; AER, 77.4/10,000 PYR), haematological malignancies (SMR, 1.53; 
95%CI 1.17-2.00; AER, 49.4/10,000 PYR) and urinary tract cancers (SMR, 1.31; 95%CI 
1.04-1.65; AER, 34.1/10,000 PYR).  
For cause of death due to other non-cancer events, the SMRs were significantly increased for 
infectious disease (SMR, 1.56; 95%CI 1.11-2.14) and respiratory disease (SMR, 1.17; 95%CI 
1.04-1.32). The SMRs for infectious disease, respiratory disease and digestive disease were 
significantly elevated for younger cancer patients (those with a first cancer diagnosis at 15-64 
years). Within one year from cancer diagnosis, cancer patients had a significantly higher risk 
of death due to infectious disease, endocrine disease, respiratory disease and digestive 
disease. For patients with specific cancer types, the SMR for respiratory disease was greatest 
among individuals with a first diagnosis of lung cancer (SMR, 5.00; 95%CI 3.67-6.82), 
generating an AER of 112.8/10000 PYR. For other increased SMRs by first cancer types, the 
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observed number of deaths were generally small (less than 10) and the increase may have 
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Table 6.4: Standardized mortality ratios (SMRs) and absolute excess risks (AERs) for specific non-cancer disease by sex, age at first cancer 
diagnosis, follow-up intervals and first cancer sites 
   CVD*    Infection    Endocrine    Mental  
  Obs SMR (95% CI) AER  Obs SMR (95% CI) AER  Obs SMR (95% CI) AER  Obs SMR (95% CI) AER 
Overall  741 0.97 
(0.90 to 1.04) 
-2.7 
(-8.7 to 3.3) 
 39 1.56 
(1.11 to 2.14) 
1.6 
(0.2 to 3.0) 
 111 0.90 
(0.74 to 1.08) 
-1.4 
(-3.7 to 0.9) 
 124 0.75 
(0.63 to 0.90) 
-4.6 
(-7.0 to -2.1) 
Sex                 
Male  447 0.93 
(0.85 to 1.02) 
-6.6 
(-14.8 to 1.6) 
 27 1.79 
(1.22 to 2.60) 
2.3 
(0.3 to 4.4) 
 65 0.84  
(0.66 to 1.07) 
-2.4 
(-5.6 to 0.7) 
 67 0.74  
(0.58 to 0.94) 
-4.7 
(-7.9 to -1.5) 
Female  294 1.03 
(0.92 to 1.16) 
2.5 
(-6.3 to 11.3) 
 12 1.22 
(0.69 to 2.15) 
0.6 
(-1.2 to 2.4) 
 46 1.00  
(0.75 to 1.33) 
0.0 
(-3.5 to 3.5) 
 57 0.77  
(0.60 to 1.00) 
-4.4 
(-8.2 to -0.5) 
Age at diagnosis                 
15-64  74 1.23 
(0.98 to 1.54) 
2.9 
(-0.7 to 6.5) 
 10 2.87 
(1.55 to 5.34) 
1.4 
(0.1 to 2.7) 
 12 0.90  
(0.51 to 1.59) 
-0.3 
(-1.7 to 1.2) 
 5 1.09  
(0.45 to 2.61) 
0.1 
(-0.8 to 1.0) 
65-74  160 1.07 
(0.92 to 1.25) 
4.2 
(-5.7 to 14.0) 
 6 1.06 
(0.48 to 2.37) 
0.1 
(-1.8 to 2.1) 
 34 1.07  
(0.76 to 1.50) 
0.9 
(-3.7 to 5.4) 
 14 0.62  
(0.37 to 1.04) 
-3.4 
(-6.3 to -0.5) 
75-84  302 0.82 
(0.74 to 0.92) 
-47.2 
(-72.0 to -22.3) 
 16 1.46 
(0.89 to 2.38) 
3.7 
(-2.0 to 9.4) 
 49 0.88  
(0.66 to 1.16) 
-5.0 
(-15.0 to 5.0) 
 58 0.65  
(0.51 to 0.85) 
-22.4 
(-33.3 to -11.5) 
85+  205 1.09 
(0.95 to 1.25) 
57.1 
(-37.4 to 151.6) 
 7 1.44 
(0.69 to 3.02) 
7.2 
(-10.3 to 24.7) 
 16 0.72  
(0.44 to 1.17) 
-21.4 
(-47.8 to 5.0) 
 47 0.97  
(0.73 to 1.29) 
-4.7 
(-49.9 to 40.6) 
Follow-up group                 
< 1 y  228 1.44 
(1.26 to 1.64) 
36.8 
(21.1 to 52.5) 
 15 3.38 
(2.04 to 5.60) 
5.6 
(1.6 to 9.6) 
 36 1.43  
(1.03 to 1.98) 
5.8 
(-0.5 to 12.0) 
 15 0.51  
(0.31 to 0.84) 
-7.8 
(-11.8 to -3.7) 
1-4 y  354 0.83 
(0.75 to 0.92) 
-14.0 
(-21.2 to -6.8) 
 15 1.08 
(0.65 to 1.78) 
0.2 
(-1.3 to 1.7) 
 55 0.79  
(0.60 to 1.02) 
-2.9 
(-5.8 to -0.1) 
 74 0.80  
(0.64 to 1.01) 
-3.5 
(-6.8 to -0.2) 
5-9 y  159 0.88 
(0.76 to 1.03) 
-11.4 
(-24.7 to 1.9) 
 9 1.37 
(0.71 to 2.64) 
1.3 
(-1.8 to 4.5) 
 20 0.71  
(0.46 to 1.10) 
-4.4 
(-9.1 to 0.3) 
 35 0.82  
(0.59 to 1.14) 
-4.2 
(-10.4 to 2.1) 
First cancer sites                 
Head and neck  30 0.94 
(0.66 to 1.35) 
-4.7 
(-31.6 to 22.2) 
 1 0.95 
(0.13 to 6.74) 
-0.1 
(-5.0 to 4.8) 
 2 0.40  
(0.10 to 1.58) 
-7.6 
(-14.6 to -0.7) 
 8 1.18  
(0.59 to 2.36) 
3.0 
(-10.9 to 16.9) 
Digestive, except 
colorectal 
 28 1.07 
(0.74 to 1.55) 
7.2 
(-34.6 to 49.0) 
 4 4.88 
(1.83 to 13.01) 
12.8 
(-3.0 to 28.6) 
 3 0.72  
(0.23 to 2.24) 
-4.7 
(-18.3 to 9.0) 
 4 0.71  
(0.27 to 1.89) 
-6.6 
(-22.4 to 9.2) 
Colorectal  151 1.03 
(0.88 to 1.21) 
3.2 
(-15.6 to 22.0) 
 8 1.69 
(0.84 to 3.38) 
2.5 
(-1.8 to 6.9) 
 26 1.12  
(0.76 to 1.65) 
2.2 
(-5.6 to 10.0) 
 20 0.59  
(0.38 to 0.91) 
-11.0 
(-17.9 to -4.2) 
Lung  48 1.84 
(1.39 to 2.44) 
77.4 
(29.5 to 125.2) 
 3 3.69 
(1.19 to 11.44) 
7.7 
(-4.3 to 19.7) 
 6 1.39  
(0.62 to 3.09) 
5.9 
(-11.0 to 22.8) 
 0 - -18.9 
 
Hematological  53 1.53 
(1.17 to 2.00) 
49.1 
(10.8 to 87.4) 
 2 1.78 
(0.45 to 7.13) 
2.4 
(-5.1 to 9.8) 
 8 1.44  
(0.72 to 2.88) 
6.6 
(-8.3 to 21.5) 
 6 0.79  
(0.36 to 1.76) 
-4.2 
(-17.1 to 8.7) 
Skin  78 0.82 
(0.66 to 1.02) 
-15.4 
(-30.9 to 0.1) 
 4 1.31 
(0.49 to 3.48) 
0.8 
(-2.7 to 4.3) 
 12 0.82  
(0.47 to 1.45) 
-2.3 
(-8.4 to 3.7) 
 26 1.21  
(0.82 to 1.78) 
4.0 
(-4.9 to 13.0) 
Breast  61 0.89 
(0.69 to 1.14) 
-5.7 
(-16.8 to 5.5) 
 2 0.79 
(0.20 to 3.18) 
-0.4 
(-2.4 to 1.6) 
 9 0.77  
(0.40 to 1.47) 
-2.0 
(-6.3 to 2.3) 
 16 0.94  
(0.57 to 1.53) 
-0.8 
(-6.5 to 4.9) 
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Female organs  13 0.71 
(0.41 to 1.23) 
-15.0 
(-35.1 to 5.2) 
 2 3.04 
(0.76 to 12.14) 
3.8 
(-4.1 to 11.7) 
 5 1.53  
(0.64 to 3.68) 
4.9 
(-7.5 to 17.4) 
 2 0.45  
(0.11 to 1.80) 
-6.9 
(-14.8 to 1.0) 
Prostate  161 0.73 
(0.62 to 0.85) 
-27.4 
(-38.7 to -16.0) 
 6 0.85 
(0.38 to 1.90) 
-0.5 
(-2.7 to 1.7) 
 20 0.55  
(0.36 to 0.86) 
-7.3 
(-11.3 to -3.4) 
 28 0.68  
(0.47 to 0.98) 
-6.1 
(-10.8 to -1.4) 
Urinary tract  71 1.31 
(1.04 to 1.65) 
34.1 
(0.7 to 67.5) 
 5 2.97 
(1.24 to 7.14) 
6.7 
(-2.2 to 15.6) 
 9 1.06  
(0.55 to 2.04) 
1.1 
(-10.8 to 13.0) 
 8 0.69  
(0.35 to 1.39) 
-7.2 
(-18.4 to 4.0) 
Lymphoma  26 1.27 
(0.86 to 1.86) 
18.0 
(-14.7 to 50.8) 
 1 1.42 
(0.19 to 9.75) 
1.0 
(-5.4 to 7.4) 
 4 1.17  
(0.44 to 3.13) 
1.9 
(-10.9 to 14.8) 
 2 0.45  
(0.11 to 1.80) 
-8.0 
(-17.0 to 1.1) 
Others  21 1.00 
(0.65 to 1.54) 
0.1 
(-20.0 to 20.1) 
 1 1.37 
(0.20 to 10.10) 
0.6 
(-3.8 to 5.0) 
 7 2.02  
(0.96 to 4.24) 
7.9 
(-3.7 to 19.4) 
 4 0.88  
(0.33 to 2.34) 
-1.2 
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Continued 
   Nervous    Respiratory    Digestive    Genitourinary  
  Obs SMR (95% CI) AER  Obs SMR (95% CI) AER  Obs SMR (95% CI) AER  Obs SMR (95% CI) AER 
Overall  62 0.59 
(0.45 to 0.76) 
-4.8 
(-6.5 to -3.1) 
 271 1.17  
(1.04 to 1.32) 
4.5 
(0.8 to 8.1) 
 79 0.99  
(0.78 to 1.23) 
-0.1 
(-2.1 to 1.9) 
 52 0.98  
(0.73 to 1.29) 
-0.1 
(-1.7 to 1.5) 
Sex                 
Male  35 0.54 
(0.39 to 0.76) 
-5.8 
(-8.1 to -3.5) 
 168 1.09  
(0.94 to 1.27) 
2.8 
(-2.2 to 7.8) 
 44 0.93  
(0.69 to 1.24) 
-0.7 
(-3.3 to 1.9) 
 34 1.09  
(0.78 to 1.52) 
0.5 
(-1.7 to 2.8) 
Female  27 0.67 
(0.46 to 0.98) 
-3.4 
(-6.1 to -0.8) 
 103 1.33  
(1.10 to 1.61) 
6.7 
(1.5 to 11.9) 
 35 1.08  
(0.78 to 1.51) 
0.7 
(-2.3 to 3.7) 
 18 0.83  
(0.52 to 1.32) 
-1.0 
(-3.1 to 1.2) 
Age at diagnosis                 
15-64  9 0.78  
(0.41 to 1.50) 
-0.5 
(-1.8 to 0.7) 
 30 1.45  
(1.01 to 2.07) 
2.0 
(-0.3 to 4.3) 
 21 1.78  
(1.16 to 2.73) 
2.0 
(0.1 to 3.9) 
 2 0.91  
(0.23 to 3.65) 
0.0 
(-0.6 to 0.6) 
65-74  14 0.57  
(0.34 to 0.96) 
-4.2 
(-7.1 to -1.3) 
 76 1.24  
(0.99 to 1.55) 
5.8 
(-1.0 to 12.6) 
 13 0.71  
(0.41 to 1.22) 
-2.1 
(-4.9 to 0.7) 
 9 1.03  
(0.54 to 1.98) 
0.1 
(-2.2 to 2.4) 
75-84  25 0.51  
(0.35 to 0.76) 
-17.3 
(-24.4 to -10.1) 
 111 1.04  
(0.86 to 1.25) 
3.0 
(-12.1 to 18.0) 
 27 0.79  
(0.54 to 1.16) 
-5.1 
(-12.6 to 2.3) 
 21 0.76  
(0.50 to 1.17) 
-4.8 
(-11.4 to 1.7) 
85+  14 0.71  
(0.42 to 1.20) 
-19.3 
(-44.0 to 5.4) 
 54 1.28  
(0.98 to 41.67) 
39.7 
(-8.8 to 88.2) 
 18 1.15  
(0.72 to 1.82) 
7.8 
(-20.2 to 35.8) 
 20 1.39  
(0.90 to 2.15) 
18.8 
(-10.7 to 48.4) 
Follow-up group                 
< 1 y  11 0.57  
(0.31 to 1.02) 
-4.5 
(-7.9 to -1.0) 
 69 1.54  
(1.22 to 1.95) 
12.9 
(4.2 to 21.5) 
 24 1.51  
(1.01 to 2.25) 
4.3 
(-0.8 to 9.4) 
 14 1.33  
(0.79 to 2.25) 
1.8 
(-2.0 to 5.7) 
1-4 y  34 0.59  
(0.42 to 0.83) 
-4.6 
(-6.8 to -2.4) 
 144 1.11  
(0.95 to 1.31) 
2.9 
(-1.7 to 7.5) 
 38 0.85  
(0.62 to 1.17) 
-1.3 
(-3.7 to 1.0) 
 29 0.99  
(0.69 to 1.43) 
0.0 
(-2.1 to 2.0) 
5-9 y  17 0.62  
(0.38 to 0.99) 
-5.7 
(-10.0 to -1.3) 
 58 1.01  
(0.78 to 1.31) 
0.4 
(-7.6 to 8.4) 
 17 0.88  
(0.55 to 1.42) 
-1.2 
(-5.6 to 3.1) 
 9 0.68  
(0.36 to 1.31) 
-2.2 
(-5.4 to 0.9) 
First cancer sites                 
Head and neck  3 0.69  
(0.22 to 2.15) 
-3.3 
(-11.8 to 5.2) 
 14 1.47  
(0.87 to 2.48) 
11.2 
(-7.1 to 29.6) 
 8 2.39  
(1.20 to 4.78) 
11.7 
(-2.2 to 25.5) 
 0 - -5.4 
Digestive, except 
colorectal 
 1 0.29  
(0.04 to 2.05) 
-9.9 
(-17.8 to -2.0) 
 9 1.19  
(0.62 to 2.29) 
5.8 
(-17.9 to 29.5) 
 8 3.00  
(1.50 to 5.99) 
21.5 
(-0.9 to 43.8) 
 5 2.72  
(1.13 to 6.53) 
12.7 
(-4.9 to 30.4) 
Colorectal  8 0.41  
(0.20 to 0.81) 
-9.2 
(-13.5 to -4.8) 
 40 0.95  
(0.69 to 1.29) 
-1.8 
(-11.5 to 7.9) 
 16 1.06  
(0.65 to 1.74) 
0.7 
(-5.4 to 6.9) 
 4 0.38  
(0.14 to 1.01) 
-5.1 
(-8.2 to -2.0) 
Lung  2 0.57  
(0.14 to 2.29) 
-5.3 
(-15.1 to 4.5) 
 40 5.00  
(3.67 to 6.82) 
112.8 
(69.1 to 156.5) 
 3 1.11  
(0.36 to 3.43) 
1.0 
(-11.0 to 13.0) 
 3 1.63  
(0.53 to 5.06) 
4.1 
(-7.9 to 16.1) 
Hematological  3 0.64  
(0.21 to 1.99) 
-4.5 
(-13.6 to 4.6) 
 25 2.44  
(1.65 to 3.61) 
39.6 
(13.3 to 65.9) 
 2 0.55 (0.14-2.20) -4.4 
(-11.8 to 3.0) 
 8 3.32  
(1.66 to 6.63) 
15.0 
(0.1 to 29.9) 
Skin  10 0.79  
(0.42 to 1.46) 
-2.4 
(-8.0 to 3.1) 
 23 0.84  
(0.56 to 1.27) 
-3.9 
(-12.3 to 4.5) 
 4 0.41  
(0.15 to 1.10) 
-5.1 
(-8.6 to -1.6) 
 5 0.74  
(0.31 to 1.78) 
-1.6 
(-5.5 to 2.4) 
Breast  11 1.05  
(0.58 to 1.90) 
0.4 
(-4.3 to 5.1) 
 20 0.97  
(0.63 to 1.51) 
-0.4 
(-6.8 to 6.0) 
 6 0.72  
(0.32 to 1.60) 
-1.7 
(-5.2 to 1.8) 
 3 0.57  
(0.19 to 1.78) 
-1.6 
(-4.1 to 0.9) 
Female organs  1 0.35  
(0.05 to 2.50) 
-5.2 
(-10.8 to 0.4) 
 4 0.70  
(0.26 to 1.88) 
-4.8 
(-16.0 to 6.4) 
 8 3.57  
(1.78 to 7.14) 
16.4 
(0.6 to 32.2) 
 1 0.72  
(0.10 to 5.11) 
-1.1 
(-6.7 to 4.5) 
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Prostate  13 0.43  
(0.25 to 0.75) 
-7.7 
(-10.9 to -4.5) 
 54 0.75  
(0.58 to 0.98) 
-8.1 
(-14.6 to -1.5) 
 14 0.63  
(0.38 to 1.07) 
-3.7 
(-7.0 to -0.3) 
 13 0.91  
(0.53 to 1.58) 
-0.6 
(-3.8 to 2.7) 
Urinary tract  6 0.84  
(0.38 to 1.87) 
-2.3 
(-12.0 to 7.4) 
 21 1.31  
(0.85 to 2.01) 
10.0 
(-8.1 to 28.2) 
 6 1.10  
(0.50 to 2.46) 
1.2 
(-8.6 to 10.9) 
 6 1.61  
(0.72 to 3.57) 
4.6 
(-5.1 to 14.3) 
Lymphoma  1 0.35  
(0.05 to 2.46) 
-6.2 
(-12.6 to 0.2) 
 11 1.77  
(0.98 to 3.19) 
15.6 
(-5.7 to 36.9) 
 2 0.89  
(0.22 to 3.56) 
-0.8 
(-9.9 to 8.3) 
 1 0.71  
(0.10 to 5.05) 
-1.3 
(-7.7 to 5.1) 
Others  3 1.02  
(0.33 to 3.15) 
0.1 
(-7.5 to 7.7) 
 10 1.66  
(0.89 to 3.08) 
8.9 
(-5.0 to 22.7) 
 2 0.83  
(0.21 to 3.34) 
-0.9 
(-7.1 to 5.3) 
 3 2.08  
(0.67 to 6.46) 
3.5 
(-4.1 to 11.0) 
*CVD: Cardiovascular disease. Bold numbers indicated statistically significance. 
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6.5 Discussion 
This population-based study identified that CVD was the leading cause of competing 
mortality among Tasmanian cancer patients diagnosed from 2006 to 2013. CVD mortality 
exceeded mortality due to SPCs and other non-cancer events for individuals with a first 
cancer diagnosis at age 65 years or older and was greatest for those aged 85 or above. For the 
whole follow-up period, CVD mortality risk among cancer patients were as expected for the 
general population but significantly higher than expected in the first year of diagnosis. For 
other non-cancer events, cancer patients were significantly more likely to die from infectious 
disease and respiratory disease than the general population, particularly those with a younger 
age at diagnosis and in the first year of follow-up.  
The high CVD mortality among patients with a cancer diagnosis at age 65 years or older is 
consistent with general population mortality rates. However, for individuals with a cancer 
diagnosis at the oldest ages (85 years or older), a greater excess CVD mortality burden was 
observed than in other age groups. A slight increase in the SMR can produce a large increase 
in the AER when the expected mortality burden in the general population is high (e.g. high 
CVD mortality in an older population) 23. In our cohort, the proportion of deaths due to heart 
failure increased from 1.4% of all CVD deaths for age 15-64 years to 11.7% of all CVD 
deaths for those aged 85 years or older at cancer diagnosis (Table 6.5). Other common causes 
of CVD deaths for age 85+ years include deaths due to chronic ischemic heart disease 
(22.9%), stroke (17.1%) and acute myocardial infarction (14.6%). The great excess burdens 
of CVD deaths were observed among colorectal, hematologic and urinary tract cancer 
patients but not for other cancer types. In the absence of treatment data in this population-
based cancer registry, it is unclear whether cardiotoxicity caused by anticancer treatment 
played a role, but the literature has demonstrated connections between conventional 
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anticancer drugs (e.g. anthracyclines, cyclophosphamide and fluoropyrimidines), novel 
targeted cancer therapies (e.g. kinase inhibitors) and cardiac dysfunction including heart 
failure, vascular thrombosis and cardiac ischemia 11, 24, 25. Opportunities for better 
cardioprotective interventions might be considered for the oldest cancer patients and for 
patients with a first diagnosis of colorectal, hematologic and urinary tract cancer. 
Our finding of a significantly increased risk of CVD death within one year of a cancer 
diagnosis is consistent with previous studies from Sweden 14 and the United States for any 
cancer diagnosed from 1973-2012 or for prostate cancer diagnosed from 1979-2004 10, 15. 
Psychological stress is associated with adverse cardiovascular pathophysiological changes 26. 
A cancer diagnosis might be an important stressor that triggers CVD death in the short term 
14, 15.  
For the whole follow-up period, the CVD mortality risk among cancer patients was as 
expected for the general population. This is in contrast to a previous Australian study that 
observed the risk of CVD deaths to be higher than expected in the state of Queensland 
following cancers diagnosed between 1982 and 2002 9. Recent advances in cardiovascular 
imaging, improved treatment and cardioprotective therapy for cancer patients might explain 
why we did not see an excess CVD mortality risk for cancer diagnosed during 2006-2013, 
other than in the first year after cancer diagnosis. 
For other non-cancer events, the increased SMR for infectious disease is likely attributable to 
sepsis after cancer diagnosis. In our study, the number of deaths due to sepsis accounted for 
more than half of all deaths due to infection, and all deaths due to infection in lung cancer 
patients. These deaths mostly occurred within one year after cancer diagnosis. Although 
clinical guidelines provide recommendations on sepsis prevention and management in 
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patients with cancer, more efforts should be made to reduce this preventable cause of death 
during the first year of follow-up 27, 28, especially for lung cancer patients. The increased 
SMR for respiratory disease is likely because of a high incidence of chronic obstructive 
pulmonary disease (COPD) among cancer patients, especially for lung cancer patients (67.5% 
of respiratory deaths were due to COPD, Table 6.6). The pronounced excess mortality due to 
respiratory disease, particularly COPD, among lung cancer patients may reflect the strong 
association between lung cancer and other smoking-related diseases 29. The effects of 
smoking may also be reflected in the high excess CVD mortality among lung cancer patients. 
Smoking cessation is therefore essential as the core prevention activity to reduce tobacco-
related deaths. However, the capacity to reduce CVD deaths in lung cancer patients may be 
limited given their short median survival time. 
Our finding of a lower risk of CVD deaths among prostate cancer patients than in the general 
population is consistent with a previous finding from the Swedish national prostate cancer 
registry 30. This apparent decreased risk may be partially explained by self-selection of 
relatively health-conscious men undergoing Prostate Specific Antigen (PSA) testing with a 
subsequent diagnosis of prostate cancer. 
It is interesting to note that there was no increase in deaths from mental disorders or nervous 
system diseases among cancer patients when compared to the general population. This 
finding is consistent with previous findings using data from the World Mental Health Surveys 
between 2001-2011 31 which showed similar rates of common mental disorders among cancer 
survivors and cancer-free respondents. 
A major strength of our study was the focus on non-cancer mortality in a recent population-
based cohort with a combination of internal comparisons considering the presence of 
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competing risks, and external comparisons with the general population. To the best of our 
knowledge, only one other study has reported non-cancer mortality due to a variety of causes 
among cancer patients in recent times. The authors concluded that the risk of non-cancer 
deaths now exceeds the risk of cancer deaths, but did not account for follow-up time nor the 
presence of competing risks 10. In our study in Tasmania, first cancers were still the leading 
cause of death among individuals with cancer diagnosis between 2006-2013. Careful 
interpretation is needed when comparing cancer mortality risk with non-cancer mortality risk, 
especially in cohorts with high competing risks 20. Limitations of our study include the 
relatively short follow-up time, the lack of data on cancer treatment and history of other 
diseases prior to and/or after cancer diagnosis, which prohibited examination of long-term 
cause-specific mortality and the possible adverse effects of cancer treatments. 
In conclusion, CVD was the most likely competing cause of death among Tasmanian cancer 
patients in recent years, particularly for individuals diagnosed with cancer at age 65 or above. 
Although CVD mortality among cancer patients was no greater than expected from the 
general population overall, interventions to reduce the risk of CVD deaths within the first 
year after cancer diagnosis should be considered. The increased risk of death due to 
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Table 6.5: Number of CVD deaths among cancer patients with all first cancer sites combined, by age at first cancer diagnosis 
Age at first cancer diagnosis 15-64y 
 
Age at first cancer diagnosis 65-74y 




Cause of death ICD10 code No. Percent 
Total  74 100.0%  Total  160 100.0% 
Hypertensive heart disease I11 1 1.4% 
 
Essential (primary) hypertension I10 2 1.3% 
Acute myocardial infarction I21 15 20.3% 
 
Hypertensive renal disease I12 1 0.6% 
Other acute ischemic heart diseases I24 2 2.7% 
 
Hypertensive heart and renal disease I13 2 1.3% 
Chronic ischemic heart disease I25 21 28.4% 
 
Acute myocardial infarction I21 28 17.5% 
Other diseases of pericardium I31 2 2.7% 
 
Chronic ischemic heart disease I25 40 25.0% 
Nonrheumatic aortic valve disorders I35 1 1.4% 
 
Pulmonary embolism I26 2 1.3% 
Cardiomyopathy I42 6 8.1% 
 
Other pulmonary heart diseases I27 1 0.6% 
Atrial fibrillation and flutter I48 2 2.7% 
 
Nonrheumatic aortic valve disorders I35 3 1.9% 
Other cardiac arrhythmias I49 1 1.4% 
 
Endocarditis, valve unspecified I38 2 1.3% 
Heart failure I50 1 1.4% 
 
Cardiomyopathy I42 6 3.8% 
Subarachnoid hemorrhage I60 4 5.4% 
 
Cardiac arrest I46 1 0.6% 
Intracerebral hemorrhage I61 2 2.7% 
 
Atrial fibrillation and flutter I48 1 0.6% 
Other nontraumatic intracranial hemorrhage I62 2 2.7% 
 
Other cardiac arrhythmias I49 2 1.3% 
Cerebral infarction I63 2 2.7% 
 
Heart failure I50 12 7.5% 
Stroke, not specified as hemorrhage or infarction I64 4 5.4% 
 
Complications and ill-defined descriptions of heart 
disease 
I51 7 4.4% 
Aortic aneurysm and dissection I71 2 2.7% 
 
Subarachnoid hemorrhage I60 1 0.6% 
Other peripheral vascular diseases I73 2 2.7% 
 
Intracerebral hemorrhage I61 4 2.5% 
Phlebitis and thrombophlebitis I80 2 2.7% 
 
Other nontraumatic intracranial hemorrhage I62 3 1.9% 
Varicose veins of lower extremities I83 1 1.4% 
 
Cerebral infarction I63 6 3.8% 
Other disorders of veins I87 1 1.4% 
 
Stroke, not specified as hemorrhage or infarction I64 21 13.1%      
Other cerebrovascular diseases I67 1 0.6%      
Sequelae of cerebrovascular disease I69 4 2.5%      
Aortic aneurysm and dissection I71 7 4.4%      
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Continued 
Age at first cancer diagnosis 75-84y 
 
Age at first cancer diagnosis 85+ y 
Cause of death ICD10 code No. Percent 
 
Cause of death ICD10 code No. Percent 
Total  302 100.0%  Total  205 100.0% 
Rheumatic mitral valve diseases I05 3 1.0% 
 
Rheumatic tricuspid valve diseases I07 1 0.5% 
Essential (primary) hypertension I10 4 1.3% 
 
Essential (primary) hypertension I10 7 3.4% 
Hypertensive heart disease I11 6 2.0% 
 
Hypertensive heart disease I11 5 2.4% 
Hypertensive renal disease I12 3 1.0% 
 
Hypertensive renal disease I12 1 0.5% 
Hypertensive heart and renal disease I13 2 0.7% 
 
Hypertensive heart and renal disease I13 1 0.5% 
Angina pectoris I20 2 0.7% 
 
Angina pectoris I20 1 0.5% 
Acute myocardial infarction I21 48 15.9% 
 
Acute myocardial infarction I21 30 14.6% 
Other acute ischemic heart diseases I24 7 2.3% 
 
Other acute ischemic heart diseases I24 2 1.0% 
Chronic ischemic heart disease I25 88 29.1% 
 
Chronic ischemic heart disease I25 47 22.9% 
Pulmonary embolism I26 3 1.0% 
 
Pulmonary embolism I26 3 1.5% 
Other pulmonary heart diseases I27 3 1.0% 
 
Other pulmonary heart diseases I27 6 2.9% 
Acute and subacute endocarditis I33 2 0.7% 
 
Acute and subacute endocarditis I33 1 0.5% 
Nonrheumatic mitral valve disorders I34 1 0.3% 
 
Nonrheumatic aortic valve disorders I35 7 3.4% 
Nonrheumatic aortic valve disorders I35 5 1.7% 
 
Endocarditis, valve unspecified I38 1 0.5% 
Endocarditis, valve unspecified I38 2 0.7% 
 
Cardiomyopathy I42 2 1.0% 
Cardiomyopathy I42 8 2.6% 
 
Other conduction disorders I45 1 0.5% 
Atrial fibrillation and flutter I48 11 3.6% 
 
Cardiac arrest I46 1 0.5% 
Other cardiac arrhythmias I49 3 1.0% 
 
Atrial fibrillation and flutter I48 2 1.0% 
Heart failure I50 19 6.3% 
 
Heart failure I50 24 11.7% 
Complications and ill-defined descriptions of 
heart disease 
I51 2 0.7% 
 
Complications and ill-defined descriptions of heart 
disease 
I51 8 3.9% 
Subarachnoid hemorrhage I60 1 0.3% 
 
Intracerebral hemorrhage I61 2 1.0% 
Intracerebral hemorrhage I61 7 2.3% 
 
Other nontraumatic intracranial hemorrhage I62 1 0.5% 
Other nontraumatic intracranial hemorrhage I62 3 1.0% 
 
Cerebral infarction I63 1 0.5% 
Cerebral infarction I63 5 1.7% 
 
Stroke, not specified as hemorrhage or infarction I64 35 17.1% 
Stroke, not specified as hemorrhage or infarction I64 41 13.6% 
 
Sequelae of cerebrovascular disease I69 6 2.9% 
Other cerebrovascular diseases I67 1 0.3% 
 
Atherosclerosis I70 1 0.5% 
Sequelae of cerebrovascular disease I69 5 1.7% 
 
Aortic aneurysm and dissection I71 4 2.0% 
Atherosclerosis I70 2 0.7% 
 
Other peripheral vascular diseases I73 1 0.5% 
Aortic aneurysm and dissection I71 10 3.3% 
 
Arterial embolism and thrombosis I74 1 0.5% 
Other peripheral vascular diseases I73 4 1.3% 
 
Phlebitis and thrombophlebitis I80 1 0.5% 
Other venous embolism and thrombosis I82 1 0.3% 
 
Varicose veins of lower extremities I83 1 0.5% 
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Table 6.6: Number of respiratory deaths among lung cancer patients 
Cause of death ICD10 code No.  Percent 
Total  40 100.0% 
Influenza due to identified zoonotic or pandemic influenza 
virus 
J09 1 2.5% 
Influenza due to identified seasonal influenza virus J10 1 2.5% 
Pneumonia, organism unspecified J18 5 12.5% 
Emphysema J43 2 5.0% 
Chronic obstructive pulmonary disease J44 27 67.5% 
Respiratory conditions due to other external agents J70 1 2.5% 
Other interstitial pulmonary diseases J84 2 5.0% 
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Chapter 7: Discussion 
7.1 Background   
A growing number of individuals are living with a history of cancer in Australia due to 
increases in cancer incidence and improved cancer survival 1. In 2012, there were nearly 1 
million cancer survivors, representing 4.3% of the Australian population. With the aging 
population and improved cancer survival, one of the potentially most life-threatening events 
among these cancer survivors is facing cancer again - the development of MPCs. A research 
focus on temporal trends in the risk of developing MPCs can provide valuable information to 
indicate potential changes in factors that relate to MPC development, help predict future rates 
of MPC occurrence and help guide MPC management planning.  
Cancer patients can also experience non-cancer events such as fatal cardiovascular events 
after a first cancer diagnosis. MPCs and non-cancer events compete with the first cancer as 
the cause of death. In this era of personalized cancer therapy, monitoring mortality from 
MPCs and non-cancer events contributes to knowledge of patient outcomes after a first 
cancer diagnosis, may help to guide individualized treatments, and optimise follow-up care. 
Using a systematic review and original data from the TCR, this thesis aimed to add to the 
current literature on temporal trends in the risk of MPCs and competing mortality among 
patients with adult-onset cancer, through four studies with the following aims: 
1. Study 1: To conduct a systematic review of the scientific literature to determine 
whether the risk of MPCs has increased over recent decades (Chapter 3).   
2. Study 2: To investigate trends in the risk of second primary cancer among adult 
cancer survivors in Tasmania during 1980-2013 (Chapter 4). 
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3. Study 3: To assess subsequent primary cancer mortality among Tasmanian adult-onset 
cancer patients in competing risk models and to investigate their patterns since 1980 
(Chapter 5). 
4. Study 4: To assess the risk of non-cancer deaths among Tasmanian cancer patients in 
competing risk models during 2006-2015 (Chapter 6). 
The following sections provide a summary of the key findings in this thesis, their public 
health and clinical implications, the limitations of the current studies and future directions.   
7.2 Summary of findings 
Epidemiological research indicated changing trends in medical investigations, treatment 
protocols for cancer and environmental and lifestyle factors associated with cancer during 
recent decades 1-5. However, whether the risk of MPCs have changed during this period 
remained unknown. Chapter 3 presented a systematic review of the scientific literature and 
identified an increasing trend in the risk of developing MPCs from the 1980s to 2000 in the 
USA and Australia, for all first cancer sites combined. However, evidence of the trend in 
overall MPC risk since 2000 was limited as described in the systematic review. Chapter 4 
extends and progresses findings from the systematic review using original data from the TCR 
for the period 1980 to 2013. In Tasmania, nearly 10% of adult-onset cancer survivors were 
diagnosed with MPCs during the past three decades. The risk of second primary cancers 
increased significantly with periods of first cancer diagnosis from 1980 to 2009.  
Traditional survival analyses overestimate mortality risk due to a specific cause, because of 
the failure to consider the presence of competing risks. To date, there has been limited 
assessment of mortality from MPCs and non-cancer events in the presence of competing 
risks. Chapter 5 described temporal trends in MPC mortality since 1980 among adult-onset 
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cancer patients in competing risk models. The risk of first cancer mortality gradually 
decreased from 1980-2009, whereas the risk of MPC mortality increased in later time periods 
relative to 1980-1984, and was highest for individuals with a first cancer diagnosis in the 
1990s. Chapter 6 identified that CVD was the leading cause of competing mortality among 
Tasmanian cancer patients diagnosed from 2006-2013. The risks of death due to specific non-
cancer events were higher than expected during the first year after a cancer diagnosis. 
7.3 Implications of Research 
The implementation of cancer screening programs and increased use of medical imaging has 
promoted the early diagnosis of cancer, but also contributed to the detection of cancers that 
are slow- or even non-progressive, and potential overdiagnosis in cancer 6. Overdiagnosis due 
to population-based cancer screening in the general population has been well recognised 6-11. 
Our finding of an increasing trend in the risk of developing MPCs from the 1980s to 2000 in 
the USA and Australia may reflect an increase in the use of medical investigations among 
cancer survivors over this period. In Tasmania, site-specific time trends in the risk of MPCs 
were generally consistent with changing patterns of cancer screening interventions, 
particularly PSA testing and use of medical imaging for specific cancer types. Patient anxiety 
after a first cancer diagnosis may result in overestimation of the benefits and underestimation 
of the potential harms of cancer screening in the case of overdiagnosis. In addition, frequent 
medical imaging during post-treatment surveillance may increase the chance of detecting 
indolent MPCs. Our long-term surveillance on the risk of MPCs over time provides valuable 
information for predicting future MPC occurrence rates, and supports the need for future 
investigation into the mode of MPC diagnosis. Although some international evidence has 
found that cancer patients were more likely to participate in cancer screening than the general 
population 12, 13, this is unknown for Australia given the lack of information on mode of MPC 
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ascertainment. Assessing the mode of MPC diagnosis will help to delineate whether 
overdiagnosis has occurred in the detection of MPCs. The increased risk of smoking related 
MPCs in recent periods also supports the potential of MPC prevention strategies. Cessation of 
cigarette smoking may help to reduce the risk of developing smoking-related MPCs. 
However, there are no known data quantifying the effect size of smoking cessation after the 
diagnosis of a first cancer on reducing the risk of smoking-related MPCs. Studies that 
specifically examine the effect of smoking cessation on MPC prevention are therefore 
recommended. 
The increased risk of MPC mortality for a first cancer diagnosed in the 1990s may reflect a 
combination of greater detection of non-fatal first cancers during this period and/or adverse 
late effects of cancer treatment. The detection of prostate cancer increased dramatically in 
Tasmania in the 1990s, strongly influenced by intensive use of PSA testing. However, PSA-
based screening may be associated with a high risk of overdiagnosis 7, 9, 11. If a large number 
of ‘first cancers’ were overdiagnosed, a life-threatening MPC will be registered as a 
‘subsequent cancer’. Therefore, an increase in the mortality related to MPCs will 
consequently occur. In the case of greater detection of non-fatal first cancers, another concern 
arises from the adverse late effects of cancer treatment, which may induce life-threatening 
MPCs. Monitoring time trends in competing mortality from MPCs could help inform 
clinicians, policy-makers and patients about the potential harms of increased detection of 
non-fatal first cancers and the potential risk of treatment-related MPCs. 
With the aging population in Australia, the burden of chronic disease, especially CVD will 
increase among older cancer patients. Our finding of an excess burden of CVD among 
individuals with a cancer diagnosis at age ≥ 85 years suggests that treating clinicians might 
consider advising on CVD prevention strategies for this population. The increased mortality 
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risk due to specific non-cancer disease during the first year of follow-up helped to identify 
diseases that require prevention, early detection, and/or more effective treatment after a 
cancer diagnosis. Current evidence-based cancer guidelines generally focused on cancer-
associated disease, cancer treatment-induced disease or cancer-related symptoms 14. Our 
research on current non-cancer mortality among cancer patients contributes to the evidence 
base to optimise current follow-up guidelines and thereby inform clinicians of how to 
improve the management of non-cancer events among cancer patients. 
7.4 Limitations in current studies  
The major limitations of the studies presented in this thesis are the lack of data on the mode 
of MPC ascertainment and treatment information of the first primary cancer, which prevented 
a more precise interpretation of the results. The TCR is a population-based cancer registry 
that collects demographic data and basic histopathological characteristics such as cancer site 
and morphology. Detailed histopathological data such as tumour stage, tumour grade were 
not available for all cancer types, nor are tumour biomarkers and tumour genetics collected, 
which prohibited complete analyses for risk stratification. Lack of treatment information 
precluded the evaluation of treatment effect on patient outcomes. These limitations, however, 
can be at least partially overcome through future projects linking the TCR database with 
Tasmanian public hospital administrative data.   
Other limitations relate to the underascertainment of MPCs due to out-migration of the 
Tasmanian cancer patients. The Australian Cancer Database (ACD) is managed by the 
Australian Institute of Health and Welfare (AIHW) and includes data for all cancers 
diagnosed in Australia since 1982 (excluding basal and squamous cell carcinomas of the 
skin). Some states and territories provide borderline, uncertain and in-situ neoplasms for 
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certain topographies as part of annual data submissions, however the routine reporting of data 
by the AIHW focuses on invasive tumours only. On an annual basis, the AIHW undertakes a 
process of data-deduplication where it applies probabilistic data linkage techniques to 
identify potential duplicate records across jurisdictions to limit the risk of duplicate reporting.  
The TCR does not undertake any routine matching of Tasmanian cases to other Australian 
state and territory cancer records stored in the ACD, but does update its records where it 
becomes aware of the existence of duplicate tumour registrations in other states of territories.  
However, we determined that in our study period the proportion of all Tasmanian cancer 
cases with MPCs registered in another Australian jurisdiction was very small (0.34%, 
personal communication, Manager, Australian Cancer Database). The relatively small 
Tasmanian population limits statistical power for less common cancer types. However, less 
common cancer types were never specifically investigated in this thesis. The TCR data has a 
particular advantage due to the relative stable population (less out-migration) of the 
Tasmanian population. Further, given similar characteristics to populations in other 
Australian jurisdictions, the findings were considered generalisable. 
7.5 Future directions 
In this thesis, we have presented a systematic review of the time trends in the risk of 
developing MPCs worldwide, and several novel findings of the temporal trends in the risk of 
MPCs, competing mortality due to MPCs, and competing mortality due to non-cancer events 
among adult-onset cancer patients in the state of Tasmania, Australia. On the basis of this 
research, it is identified that further research is necessary with regard to mode of MPC 
diagnosis and management of patient outcomes after first cancer diagnosis, including MPCs 
and non-cancer events to improve the prognosis of cancer patients. Directions for future 
research could include the following:   
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• Identify the mode of MPC diagnosis. Chapters 3 and 4 reported an increasing trend in 
the risk of MPCs over time. As cancer patients may receive more frequent medical 
examination than the general population, it is necessary to identify how the 
subsequent primary cancer is diagnosed, by the patient as a result of symptoms, by 
cancer screening, or through a routine follow-up examination. The mode of MPC 
diagnosis helps to indicate if the subsequent primary cancer is delayed diagnosis, i.e. 
diagnosed at an advanced stage, diagnosed at an early stage, or overdiagnosed 
respectively.  
• Identify and quantify any overdiagnosis of MPCs among cancer survivors, and thus 
assess whether there is potential for optimizing follow-up guidelines. This concern 
arises because screening tests and medical imaging for some cancer types in the 
general population were associated with overdiagnosis, thus it is equally important to 
determine whether the mode of MPC diagnosis is associated with overdiagnosis in 
cancer survivors. It should also be noted that while overdiagnosis may be easily 
identifiable at the population level based on review of population data, in the clinical 
situation, overdiagnosis at the individual patient level would be difficult to ascertain. 
This situation reflects a tension between system level and individual needs. 
• Chapters 4 and 5 indicated that increased incidence and mortality risk of MPCs 
following specific first cancers might also be an adverse late effect of the treatment of 
first cancer. Previous studies have reported the risk of MPCs following specific 
treatments of different first cancers. However, the risks varied across countries and 
evidence from Australian data is limited. In addition, treatment for cancer is rapidly 
evolving, thus findings from historical data may not be generalizable to individuals 
with more recent cancer diagnoses. Current treatment data (procedures and dosage) is 
therefore needed to assess associations between treatment and the development of 
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MPCs in Australians with a first cancer diagnosis. Data linkage between the TCR 
database and Tasmanian public hospital radiation oncology database could advance 
our understanding of these associations between first cancer treatment and the 
development of MPCs and corresponding mortality.  
• Given the finding of increased mortality risks due to specific non-cancer events in 
Chapter 6, it is important to assess the relationship between cancer treatment and 
development of fatal non-cancer events, and/or if cancer treatment aggravates pre-
existing non-cancer disease. These findings will help optimise follow-up guidelines 
for cancer and otherwise improve supportive care after a cancer diagnosis.  
• Findings in this thesis have indicated that cancer patients are now facing a higher and 
increasing risk of developing MPCs, and are at risk of death from their MPCs. 
Further, with improved cancer survivorship and the aging population, there will be an 
increasing number of individuals living with MPCs. Individuals with one cancer 
diagnosis may experience a number of psychological problems 15, thus individuals 
with MPCs could be expected to have more severe psychological impacts. A recent 
systematic review identified only five studies that have reported psychological 
distress among MPC survivors 16, revealing a striking paucity of research on this 
topic. Future studies are required to enable firm conclusions to be drawn on the 
comparative impacts of psychological distress among MPC survivors, and to identify 
psychosocial needs in this population. 
7.6 Conclusion  
The series of studies presented in this thesis have together revealed that the risk of developing 
MPCs has increased since the 1980s, and that the mortality risk due to MPCs became 
elevated during a period in which there was an increased detection of non-fatal first cancers. 
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CVD was the leading cause of competing mortality among patients with a first cancer 
diagnosed during 2006-2013, with increased mortality risks due to non-cancer events mostly 
observed within one year of cancer diagnosis. These findings add to current literature to 
inform clinicians and cancer patients about the current risk of MPC development, competing 
mortality risks, and provide a robust, unbiased and comprehensive evidence-base to help 
optimise current clinical guidelines for follow-up strategies after a cancer diagnosis. The 
work undertaken in this thesis will be of importance in directing future research on 
investigating the mode of MPC diagnosis, evaluating the benefits and harms of medical 
investigations and cancer treatment, and supporting the necessity of identifying psychosocial 
needs of individuals living with MPCs. 
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